‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻟﻸﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬

‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ‪ ،‬ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪٢٠٠٧‬‬

‫ﺤﺎﻟﺔ ﻫﺫﻩ ﺍﻟﻭﺜﻴﻘﺔ‬

‫ﻫﺫﻩ ﺍﻟﻭﺜﻴﻘﺔ ﻤﺴﺘﻨﺴﺨﺔ ﻤﻥ ﺍﻟﻨﺹ ﺍﻟﻤﻨﺸﻭﺭ ﻓﻲ ﻤﻭﻗﻊ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﺎﺒﻊ ﻟﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﻋﻠﻰ ﺍﻹﻨﺘﺭﻨﺕ‬
‫‪http:/www.who.int/medicines/publications/EML15.pdf‬‬
‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ‬
‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ )ﺘﻡ ﺘﻨﻘﻴﺤﻬﺎ ﻓﻲ ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬
‫ﻤﻼﺤﻅﺎﺕ ﺘﻭﻀﻴﺤﻴﺔ‬

‫ﺘﺩﺭﺝ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻷﺴﺎﺴﻴﺔ ﺍﻟﺤﺩ ﺍﻷﺩﻨﻰ ﻤﻥ ﺍﻻﺤﺘﻴﺎﺠﺎﺕ ﺍﻟﺩﻭﺍﺌﻴﺔ ﺍﻟﻼﺯﻤﺔ ﻷﻱ ﻨﻅﺎﻡ ﻤﻥ ﻨﻅﻡ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﺼﺤﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‪،‬‬
‫ﺤﻴﺙ ﺘﺘﻀﻤﻥ ﺃﻜﺜﺭ ﺍﻷﺩﻭﻴﺔ ﻨﺠﺎﻋﺔ ﻭﻤﺄﻤﻭﻨﻴﺔ ﻭﻤﺭﺩﻭﺩﻴﺔ ﻟﻠﺤﺎﻻﺕ ﺍﻟﻤﺭﻀﻴﺔ ﺫﺍﺕ ﺍﻷﻭﻟﻭﻴﺔ‪ .‬ﻭﻴـﺘﻡ ﺍﻨﺘﻘـﺎﺀ ﺍﻟﺤـﺎﻻﺕ‬
‫ﻼ ﺒﺎﻟﺼﺤﺔ ﺍﻟﻌﻤﻭﻤﻴﺔ‪ ،‬ﻭﺇﻤﻜﺎﻨﻴﺔ ﺍﻟﻌﻼﺝ ﺍﻟﻤﺄﻤﻭﻥ ﺫﻱ‬
‫ﺍﻟﻤﺭﻀﻴﺔ ﺫﺍﺕ ﺍﻷﻭﻟﻭﻴﺔ ﺍﺴﺘﻨﺎﺩﹰﺍ ﺇﻟﻰ ﺼﻠﺘﻬﺎ ﺍﻟﺤﺎﻟﻴﺔ ﻭﺍﻟﻤﻘﺩﺭﺓ ﻤﺴﺘﻘﺒ ﹰ‬
‫ﺍﻟﻤﺭﺩﻭﺩﻴﺔ‪.‬‬
‫ﺃﻤﺎ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ ﻓﺘﺩﺭﺝ ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ ﻟﻸﻤﺭﺍﺽ ﺫﺍﺕ ﺍﻷﻭﻟﻭﻴﺔ ﺍﻟﺘﻲ ﺘـﺴﺘﻠﺯﻡ ﻭﺠـﻭﺩ ﻤﺭﺍﻓـﻕ ﺘﺨﺼـﺼﻴﺔ‬
‫ﻟﻠﺘﺸﺨﻴﺹ ﺃﻭ ﺍﻟﺭﺼﺩ ﻭ‪ /‬ﺃﻭ ﺘﻭﻓﻴﺭ ﺭﻋﺎﻴﺔ ﻁﺒﻴﺔ ﺘﺨﺼﺼﻴﺔ ﻭ‪ /‬ﺃﻭ ﺘﻭﻓﻴﺭ ﺘﺩﺭﻴﺏ ﺘﺨﺼﺼﻲ‪ .‬ﻭﻓﻲ ﺤﺎﻟﺔ ﺍﻟﺸﻙ ﻴﻤﻜـﻥ‬
‫ﺃﻴﻀﹰﺎ ﺇﺩﺭﺍﺝ ﺍﻷﺩﻭﻴﺔ ﻀﻤﻥ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ ﻋﻠﻰ ﺃﺴﺎﺱ ﺍﺭﺘﻔﺎﻉ ﺘﻜﺎﻟﻴﻔﻬﺎ ﺒﻭﺘﻴﺭﺓ ﺜﺎﺒﺘﺔ ﺃﻭ ﻜﻭﻥ ﻤﺭﺩﻭﺩﻴﺘﻬﺎ ﺃﻗل ﺇﻏـﺭﺍ ‪‬ﺀ‬
‫ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﻤﺘﻨﻭﻋﺔ ﻤﻥ ﺍﻟﺒﻴﺌﺎﺕ‪.‬‬
‫ﻭﻴﺭﺩ ﺭﻤﺯ ﺍﻹﻁﺎﺭ ﺍﻟﻤﺭﺒﻊ )…( ﺃﺴﺎﺴﹰﺎ ﻟﻺﺸﺎﺭﺓ ﺇﻟﻰ ﻤﻔﻌﻭل ﺴﺭﻴﺭﻱ ﻤﻤﺎﺜل ﻀﻤﻥ ﻤﺠﻤﻭﻋﺔ ﺩﻭﺍﺌﻴﺔ ﻤﻌﻴﻨﺔ‪ .‬ﻭﻴﻨﺒﻐﻲ ﺃﻥ‬
‫ﻴﻜﻭﻥ ﺍﻟﺩﻭﺍﺀ ﺍﻟﻭﺍﺭﺩ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻤﺜﺎﻻﹰ ﻟﻠﻤﺠﻤﻭﻋﺔ ﻴﺘﻭﺍﻓﺭ ﻟﻪ ﺃﻓﻀل ﺩﻟﻴل ﻋﻠﻰ ﺍﻟﻨﺠﺎﻋﺔ ﻭﺍﻟﻤﺄﻤﻭﻨﻴـﺔ‪ .‬ﻭﻓـﻲ ﺒﻌـﺽ‬
‫ﺍﻟﺤﺎﻻﺕ ﻗﺩ ﻴﻜﻭﻥ ﻫﺫﺍ ﺃﻭل ﺩﻭﺍﺀ ﻤﻥ ﻨﻭﻋﻪ ﺘﻡ ﺍﻟﺘﺭﺨﻴﺹ ﺒﺘﺴﻭﻴﻘﻪ‪ ،‬ﻭﻓﻲ ﺤﺎﻻﺕ ﺃﺨﺭﻯ ﻴﻤﻜﻥ ﺃﻥ ﺘﻜﻭﻥ ﺍﻟﻤﺭﻜﺒـﺎﺕ‬
‫ﺍﻟﺘﻲ ﺘﻡ ﺍﻟﺘﺭﺨﻴﺹ ﺒﻬﺎ ﻓﻴﻤﺎ ﺒﻌﺩ ﺃﻜﺜﺭ ﻤﺄﻤﻭﻨﻴﺔ ﺃﻭ ﻨﺠﺎﻋﺔ‪ .‬ﻭﺤﻴﺜﻤﺎ ﻻ ﺘﻭﺠﺩ ﺃﻴﺔ ﻓﺭﻭﻕ ﻤﻥ ﺤﻴﺙ ﺒﻴﺎﻨـﺎﺕ ﺍﻟﻨﺠﺎﻋـﺔ‬
‫ﻭﺍﻟﻤﺄﻤﻭﻨﻴﺔ ﻴﻨﺒﻐﻲ ﺃﻥ ﻴﻜﻭﻥ ﺍﻟﺩﻭﺍﺀ ﺍﻟﻭﺍﺭﺩ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻫﻭ ﺍﻟﺩﻭﺍﺀ ﺍﻟﻤﺘﺎﺡ ﻋﻤﻭﻤﺎﹰ ﺒﺄﺭﺨﺹ ﺍﻷﺴﻌﺎﺭ‪ ،‬ﺒﺎﻻﺴﺘﻨﺎﺩ ﺇﻟـﻰ‬
‫ﻤﺼﺎﺩﺭ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﺍﻟﺩﻭﻟﻴﺔ ﻷﺴﻌﺎﺭ ﺍﻷﺩﻭﻴﺔ‪.‬‬
‫ﻭﻻ ﻴﺸﺎﺭ ﺇﻟﻰ ﺍﻟﺘﻜﺎﻓﺅ ﺍﻟﻌﻼﺠﻲ ﺇﻻ ﻋﻠﻰ ﺃﺴﺎﺱ ﺍﺴﺘﻌﺭﺍﺽ ﺍﻟﻨﺠﺎﻋﺔ ﻭﺍﻟﻤﺄﻤﻭﻨﻴﺔ‪ ،‬ﻭﻋﻨﺩﻤﺎ ﻴﻜﻭﻥ ﻤﺘﺴﻘﹰﺎ ﻤـﻊ ﺍﻟﻤﺒـﺎﺩﺉ‬
‫ﺍﻟﺘﻭﺠﻴﻬﻴﺔ ﺍﻟﺴﺭﻴﺭﻴﺔ ﻟﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ‪ .‬ﻭﻻ ﻴﻨﺒﻐﻲ ﺃﻥ ‪‬ﻴﺴﺘﺨﺩﻡ ﻓﻲ ﺍﻟﻘﻭﺍﺌﻡ ﺍﻟﻭﻁﻨﻴﺔ ﺭﻤﺯ ﻤﻤﺎﺜـل‪ ،‬ﻭﻴﻨﺒﻐـﻲ ﺃﻥ‬
‫ﺘﻜﻭﻥ ﺍﻟﻘﻭﺍﺌﻡ ﺍﻟﻭﻁﻨﻴﺔ ﻤﺤﺩﺩﺓ ﻓﻲ ﺍﻨﺘﻘﺎﺌﻬﺎ ﺍﻟﻨﻬﺎﺌﻲ‪ ،‬ﺍﻟﺫﻱ ﻴﻌﺘﻤﺩ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻓﺭ ﻤﺤﻠﻴﹰﺎ ﻭﺍﻟﺴﻌﺭ ﻋﻠﻰ ﺍﻟﺼﻌﻴﺩ ﺍﻟﻤﺤﻠﻲ‪ .‬ﻭﻴﺭﺩ‬
‫ﺘﺭﺘﻴﺏ ﺍﻷﺩﻭﻴﺔ ﻀﻤﻥ ﺃﻗﺴﺎﻡ ﺍﻟﻘﺎﺌﻤﺔ ﺤﺴﺏ ﺍﻟﺘﺭﺘﻴﺏ ﺍﻷﺒﺠﺩﻱ ﺍﻹﻨﻜﻠﻴﺯﻱ‪.‬‬
‫ﻭﻻ ﻴﻌﻨﻲ ﻭﺭﻭﺩ ﺃﻱ ﺒﻨﺩ ﻓﻲ ﻗﺎﺌﻤﺔ ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ ﻭﺠﻭﺩ ﺃﻱ ﻨﻭﻉ ﻤﻥ ﺍﻟﻀﻤﺎﻨﺎﺕ ﻓﻴﻤﺎ ﻴﺘﻌﻠـﻕ ﺒـﺎﻟﺠﻭﺩﺓ ﺍﻟﺩﻭﺍﺌﻴـﺔ‪.‬‬
‫ﻭﺘﺘﺤﻤل ﻜل ﺴﻠﻁﺔ ﺘﻨﻅﻴﻤﻴﺔ ﻤﺤﻠﻴﺔ ﺍﻟﻤﺴﺅﻭﻟﻴﺔ ﻋﻥ ﻀﻤﺎﻥ ﺘﻤﺘﻊ ﻜل ﻋﻼﻤﺔ ﺘﺠﺎﺭﻴﺔ ﺒﺎﻟﺠﻭﺩﺓ ﺍﻟﺩﻭﺍﺌﻴﺔ ﺍﻟﻤﻼﺌﻤﺔ )ﺒﻤﺎ ﻓﻲ‬
‫ﺫﻟﻙ ﺍﻟﺜﺒﺎﺕ(‪ ،‬ﻭﻋﻥ ﻀﻤﺎﻥ ﺇﻤﻜﺎﻨﻴﺔ ﺃﻥ ﺘﺤل ﺍﻟﻌﻼﻤﺎﺕ ﺍﻟﺘﺠﺎﺭﻴﺔ ﺍﻟﻤﺨﺘﻠﻔﺔ ﻤﺤل ﺒﻌﻀﻬﺎ ﺍﻟﺒﻌﺽ‪ ،‬ﺤﺴﺏ ﺍﻻﻗﺘﻀﺎﺀ‪.‬‬
‫ﻭﺘﺭﺩ ﺃﺸﻜﺎل ﺠﺭﻋﺎﺕ ﺍﻷﺩﻭﻴﺔ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﺒﺎﻟﺘﺭﺘﻴﺏ ﺍﻷﺒﺠﺩﻱ ﺍﻹﻨﻜﻠﻴﺯﻱ‪ ،‬ﺩﻭﻥ ﺘﻔﻀﻴل ﺃﻱ ﻤﻥ ﺍﻷﺸﻜﺎل ﻋﻠﻰ ﺍﻵﺨـﺭ‪.‬‬
‫ﻭﻴﻨﺒﻐﻲ ﺍﻟﺭﺠﻭﻉ ﺇﻟﻰ ﺍﻟﻤﺒﺎﺩﺉ ﺍﻟﺘﻭﺠﻴﻬﻴﺔ ﺍﻟﻌﻼﺠﻴﺔ ﺍﻟﻤﻭﺤﺩﺓ ﻟﻼﻁﻼﻉ ﻋﻠﻰ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﺍﻟﺨﺎﺼـﺔ ﺒﺄﺸـﻜﺎل ﺍﻟﺠﺭﻋـﺎﺕ‬
‫ﺍﻟﻤﻼﺌﻤﺔ‪.‬‬
‫ﻭﺍﻟﻬﺩﻑ ﻤﻥ ﺍﻟﺒﻨﻭﺩ ﺍﻟﻤﻨﺩﺭﺠﺔ ﻀﻤﻥ ﻨﻤﻁ ﺍﻟﺸﺭﺍﺏ ﻫﻭ ﺍﻟﺴﻤﺎﺡ ﺒﺄﻱ ﻤﺤﻠﻭل ﺃﻭ ﻤﺴﺘﻌﻠﻕ ﺃﻭ ﺃﻱ ﺸﻜل ﺁﺨﺭ ﻤﻥ ﺃﺸـﻜﺎل‬
‫ﻼ ﻟﻸﺸﺭﺒﺔ ﻭﺘﻜﻭﻥ ﻤﻴﺯﺍﺘﻬﺎ ﻋﺎﺩﺓ ﻓﻲ ﺸﻜل ﺍﻟﺜﺒﺎﺕ ﺍﻷﻓﻀل‬ ‫ﺍﻟﺴﻭﺍﺌل‪ .‬ﻭﻴﻤﻜﻥ ﺃﻥ ﺘﺸﻜل ﺤﺒﻴﺒﺎﺕ ﺍﻻﺴﺘﻨﺸﺎﺀ ﻜﺸﺭﺍﺏ ﺒﺩﻴ ﹰ‬
‫ﻭﺍﻨﺨﻔﺎﺽ ﺘﻜﺎﻟﻴﻑ ﺍﻟﻨﻘل‪ .‬ﻭﺇﺫﺍ ﺃﺘﻴﺢ ﺃﻜﺜﺭ ﻤﻥ ﻨﻤﻁ ﻭﺍﺤﺩ ﻤﻥ ﺍﻷﺸﺭﺒﺔ ﻓﻲ ﺍﻟﺴﻭﻕ ﻨﻔﺴﻬﺎ )ﻤﺜل ﺍﻟﻤﺤﻠﻭل ﺃﻭ ﺍﻟﻤﺴﺘﻌﻠﻕ ﺃﻭ‬
‫ﺤﺒﻴﺒﺎﺕ ﺍﻻﺴﺘﻨﺸﺎﺀ( ﻓﻴﻤﻜﻥ ﺃﻥ ﺘﺤل ﻤﺤل ﺒﻌﻀﻬﺎ ﺍﻟﺒﻌﺽ‪ ،‬ﻭﻓﻲ ﻫﺫﻩ ﺍﻟﺤﺎﻻﺕ ﻴﻨﺒﻐﻲ ﺃﻥ ﺘﻜـﻭﻥ ﻤﺘﻜﺎﻓﺌـﺔ ﺒﻴﻭﻟﻭﺠﻴـﹰﺎ‪.‬‬
‫ﻭﻴﻔﻀل ﺃﻻ ﺘﺤﺘﻭﻱ ﺍﻷﺸﺭﺒﺔ ﻋﻠﻰ ﺍﻟﺴﻜﺭ‪ ،‬ﻭﺃﻻ ﺘﺤﺘﻭﻱ ﺍﻟﻤﺤﺎﻟﻴل ﺍﻟﺨﺎﺼﺔ ﺒﺎﻷﻁﻔﺎل ﻋﻠﻰ ﺍﻟﻜﺤﻭل‪.‬‬
‫ﻭﺍﻟﻬﺩﻑ ﻤﻥ ﺍﻟﺒﻨﻭﺩ ﺍﻟﻤﻨﺩﺭﺠﺔ ﻀﻤﻥ ﻨﻤﻁ ﺍﻷﻗﺭﺍﺹ ﻫﻭ ﺍﻟﺴﻤﺎﺡ ﺒﺄﺸﻜﺎل ﻤﺨﺘﻠﻔﺔ ﻤﻥ ﺃﻗﺭﺍﺹ ﺍﻟﺘﺴﺭﻴﺏ ﺍﻟﻔﻭﺭﻱ‪ ،‬ﻤﺜـل‬
‫ﺍﻷﻗﺭﺍﺹ ﻏﻴﺭ ﺍﻟﻤﻐﻠﻔﺔ ﻭﺍﻷﻗﺭﺍﺹ ﺍﻟﻤﻐﻠﻔﺔ ﺒﻐﺸﺎﺀ ﻭﺃﻗﺭﺍﺹ ﺍﻟﺴﺤﻕ ﻭﺃﻗﺭﺍﺹ ﺍﻟﻤﻀﻎ ﻭﺍﻷﻗﺭﺍﺹ ﺍﻻﻨﺘـﺸﺎﺭﻴﺔ‪ .‬ﻭﻤـﻥ‬
‫ﺍﻟﻨﺎﺤﻴﺔ ﺍﻷﺨﺭﻯ ﻓﺈﻥ ﺍﻟﺘﻐﻠﻴﻑ ﺍﻟﻤﻌﻭﻱ ﻴﻐﻴﺭ ﺘﺴﺭﻴﺏ ﺍﻟﺩﻭﺍﺀ‪ ،‬ﻭﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻟﻤﻐﻠﻔﺔ ﺍﻟﻤﻌﻭﻴﺔ ﻫﻲ ﺸﻜل ﻤﻥ ﺍﻟﺠﺭﻋﺎﺕ‬
‫ﺫﺍﺕ ﺍﻟﺘﺴﺭﻴﺏ ﺍﻟﻤﻌﺩل‪ .‬ﻭﺭﺒﻤﺎ ﻴﺴﻬل ﺇﻋﻁﺎﺀ ﺃﻗﺭﺍﺹ ﺍﻟﺴﺤﻕ ﻭﺃﻗﺭﺍﺹ ﺍﻟﻤـﻀﻎ ﻭﺍﻷﻗـﺭﺍﺹ ﺍﻻﻨﺘـﺸﺎﺭﻴﺔ ﻟﻸﻁﻔـﺎل‬
‫ﻭﺍﻟﻤﺴﻨﻴﻥ‪.‬‬
‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -١‬ﺍﻟﻤﺒﻨﺠﺎﺕ‬
‫‪ ١-١‬ﺍﻟﻤﺒﻨﺠﺎﺕ ﺍﻟﻌﺎﻤﺔ ﻭﺍﻷﻭﻜﺴﺠﻴﻥ‬
‫ﺍﺴﺘﻨﺸﺎﻕ‪.‬‬ ‫… ﺍﻟﻬﺎﻟﻭﺜﺎﻥ‬
‫ﺤﻘﻨﺔ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪١٠‬‬ ‫ﺍﻟﻜﻴﺘﺎﻤﻴﻥ‬
‫ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺍﺴﺘﻨﺸﺎﻕ‪.‬‬ ‫ﺃﻜﺴﻴﺩ ﺍﻟﻨﺘﺭﻭﺯ‬
‫ﺍﺴﺘﻨﺸﺎﻕ )ﻏﺎﺯ ﺩﻭﺍﺌﻲ(‪.‬‬ ‫ﺃﻭﻜﺴﺠﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٠‚٥ :‬ﻍ‪ ١‚٠ ،‬ﻍ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ‪.‬‬ ‫… ﺜﻴﻭﺒﻨﺘﺎل‬
‫‪ ٢-١‬ﺍﻟﻤﺒﻨﹼﺠﺎﺕ ﺍﻟﻤﻭﻀﻌﻴﺔ‬
‫ﺤﻘﻨﺔ‪) ٪٠‚٥ ،٪٠‚٢٥ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺤﻘﻨﺔ ﻟﻠﺘﺒﻨﻴﺞ ﺍﻟﻨﺨﺎﻋﻲ‪) ٪٠‚٥ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓـﻲ ﺃﻤﺒﻭﻟـﺔ ﺴـﻌﺔ ‪٤‬‬ ‫… ﺒﻭﺒﻴﻔﺎﻜﺎﻴﻴﻥ‬
‫ﻤﻴﻠﻴﻠﺘﺭ ﺘﻤﺯﺝ ﻤﻊ ﻤﺤﻠﻭل ﺍﻟﻐﻠﻭﻜﻭﺯ ‪.٪٧‚٥‬‬
‫ﺤﻘﻨﺔ‪) ٪٢ ،٪١ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺤﻘﻨﺔ ﻟﻠﺘﺒﻨﻴﺞ ﺍﻟﻨﺨﺎﻋﻲ‪) ٪٥ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‬
‫… ﻟﻴﺩﻭﻜﺎﻴﻴﻥ‬
‫ﺘﻤﺯﺝ ﻤﻊ ﻤﺤﻠﻭل ﺍﻟﻐﻠﻭﻜﻭﺯ ‪.٪٧‚٥‬‬
‫ﺃﺸﻜﺎل ﻤﻭﻀﻌﻴﺔ‪) ٪٤-٢ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺨﺭﻁﻭﺸﺔ ﺴﻨﻴﺔ‪) ٪٢ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ‪ +‬ﺇﺒﻴﻨﻴﻔﺭﻴﻥ ‪.٨٠ ٠٠٠ :١‬‬
‫ﻟﻴﺩﻭﻜﺎﻴﻴﻥ ‪ +‬ﺇﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ(‬
‫ﺤﻘﻨﺔ‪) ٪٢ ،٪١ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ‪ +‬ﺇﺒﻴﻨﻴﻔﺭﻴﻥ ‪ ٢٠٠ ٠٠٠ :١‬ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٣٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺇﻴﻔﻴﺩﺭﻴﻥ‬
‫)ﻴﺴﺘﺨﺩﻡ ﻓﻲ ﺍﻟﺘﺒﻨﻴﺞ ﺍﻟﻨﺨﺎﻋﻲ ﺇﺒﺎﻥ ﺍﻟﻭﻻﺩﺓ‪ ،‬ﻟﻤﻨﻊ ﻨﻘﺹ ﻀﻐﻁ ﺍﻟﺩﻡ(‪.‬‬
‫‪ ٣-١‬ﺍﻟﻤﺩﺍﻭﺍﺓ ﻭﺍﻟﺘﻬﺩﺌﺔ ﻗﺒل ﺍﻟﺠﺭﺍﺤﺔ ﻟﻺﺠﺭﺍﺀﺍﺕ ﺍﻟﻘﺼﻴﺭﺓ ﺍﻷﻤﺩ‬
‫ﺤﻘﻨﺔ‪ ١ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺃﺘﺭﻭﺒﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ٥ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫… ﺩﻴﺎﺯﻴﺒﺎﻡ‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ ﺃﻭ ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓـﻲ ﺃﻤﺒﻭﻟـﺔ ﺴـﻌﺔ ‪١‬‬ ‫ﻤﻭﺭﻓﻴﻥ‬
‫ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺒﺭﻭﻤﻴﺜﺎﺯﻴﻥ‬

‫‪EML 15‬‬ ‫‪page - 1‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﻜﻨﺔ ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺤﻤﻰ‪ ،‬ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺏ ﻏﻴﺭ ﺍﻟـﺴﺘﻴﺭﻴﻭﺩﻴﺔ‪،‬‬
‫ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﻋﻼﺝ ﺍﻟﻨﻘﺭﺱ ﻭﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﻌﺩﻟـﺔ ﻟﻸﻤـﺭﺍﺽ ﻓـﻲ ﺍﻻﻀـﻁﺭﺍﺒﺎﺕ‬
‫ﺍﻟﺭﻭﻤﺎﺘﻴﺩﻴﺔ‬
‫‪ ١-٢‬ﺍﻷﺩﻭﻴﺔ ﻏﻴﺭ ﺍﻷﻓﻴﻭﻨﻴﺔ ﺍﻟﻤﻔﻌﻭل ﻭﻏﻴﺭ ﺍﻟﺴﺘﻴﺭﻴﻭﺩﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺏ‬
‫ﺘﺤﺎﻤﻴل‪ ١٥٠-٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻤﺽ ﺃﺴﻴﺘﻴل ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠-١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٤٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺇﻴﺒﻭﺒﺭﻭﻓﻴﻥ‬
‫ﺸﺭﺍﺏ‪ ١٢٥ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺘﺤﺎﻤﻴل‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠-١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﺎﺭﺍﺴﻴﺘﺎﻤﻭل*‬
‫* ﻻ ﻴﻭﺼﻰ ﺒﺎﺴﺘﻌﻤﺎﻟﻪ ﻜﻤﻀﺎﺩ ﻟﻼﻟﺘﻬﺎﺏ ﻨﻅﺭﹰﺍ ﻟﻌﺩﻡ ﺜﺒﻭﺕ ﻓﺎﺌﺩﺘﻪ ﻟﻬـﺫﺍ‬
‫ﺍﻟﻐﺭﺽ‪.‬‬
‫‪ ٢-٢‬ﻤﺴﻜﻨﺎﺕ ﺃﻓﻴﻭﻨﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠ :‬ﻤﻠﻐﻡ )ﻓﻭﺴﻔﺎﺕ(‪.‬‬ ‫ﻜﻭﺩﻴﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ ﺍﻟﻤﻭﺭﻓﻴﻥ ﺃﻭ ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻤﻭﺭﻓﻴﻥ( ﻓـﻲ‬
‫ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ ﺍﻟﻤﻭﺭﻓﻴﻥ ﺃﻭ ﻜﺒﺭﻴﺘـﺎﺕ ﺍﻟﻤـﻭﺭﻓﻴﻥ(‪/‬‬
‫‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻤﻭﺭﻓﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻤﻭﺭﻓﻴﻥ(‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻤﻤﺘﺩﺓ ﺍﻟﺘﺴﺭﻴﺏ(‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٣٠ ،‬ﻤﻠﻐﻡ‪ ٦٠ ،‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘـﺎﺕ‬
‫ﺍﻟﻤﻭﺭﻓﻴﻥ(‪.‬‬
‫‪ ٣-٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻟﻌﻼﺝ ﺍﻟﻨﻘﺭﺱ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﻟﻭﺒﻭﺭﻴﻨﻭل‬
‫‪ ٤-٢‬ﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﻌﺩﻟﺔ ﻟﻸﻤﺭﺍﺽ ﻓﻲ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﺭﻭﻤﺎﺘﻴﺩﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ١٥٠ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻓﻭﺴﻔﺎﺕ ﺃﻭ ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬ ‫ﻜﻠﻭﺭﻭﻜﻴﻥ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﺯﺍﺜﻴﻭﺒﺭﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٢‚٥ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬ ‫ﻤﻴﺜﻭﺘﺭﻴﻜﺴﺎﺕ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﻴﻨﻴﺴﻴﻼﻤﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺴﻭﻟﻔﺎﺯﺍﻻﺯﻴﻥ‬

‫‪EML 15‬‬ ‫‪page - 2‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﺭﺠﻴﺔ ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﻋﻼﺝ ﺍﻟﺘﺄﻕ‬

‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻤﺎﻟﻴﺎﺕ ﺍﻟﻬﻴﺩﺭﻭﺠﻴﻥ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫… ﻜﻠﻭﺭﻓﻴﻨﺎﻤﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٤ :‬ﻤﻠﻐﻡ )ﻤﺎﻟﻴﺎﺕ ﺍﻟﻬﻴﺩﺭﻭﺠﻴﻥ(‪.‬‬
‫ﺤﻘﻨﺔ‪ ٤ :‬ﻤﻠﻐﻡ ﻓﻭﺴﻔﺎﺕ ﺩﻴﻜـﺴﺎﻤﻴﺜﺎﺯﻭﻥ )ﻋﻠـﻰ ﺸـﻜل ﻤﻠـﺢ ﺜﻨـﺎﺌﻲ‬
‫ﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ‬
‫ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ ﺃﻭ ﻁﺭﻁﺭﺍﺕ ﺍﻟﻬﻴـﺩﺭﻭﺠﻴﻥ(‬ ‫ﺇﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ(‬
‫ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺴﻜﺴﻴﻨﺎﺕ ﺍﻟـﺼﻭﺩﻴﻭﻡ( ﻓـﻲ‬
‫ﻫﻴﺩﺭﻭﻜﻭﺭﺘﻴﺯﻭﻥ‬
‫ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪ ٢٥ ،‬ﻤﻠﻐﻡ‪.‬‬
‫* ﻻ ﻴﻭﺠﺩ ﺃﻱ ﺩﻟﻴل ﻋﻠﻰ ﺍﻟﺘﻤﺎﺜل ﺍﻟﺴﺭﻴﺭﻱ ﺍﻟﺘﺎﻡ ﺒـﻴﻥ ﺍﻟﺒﺭﻴـﺩﻨﻴﺯﻭﻟﻭﻥ‬ ‫… ﺒﺭﻴﺩﻨﻴﺯﻭﻟﻭﻥ*‬
‫ﻭﺍﻟﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ ﻋﻨﺩ ﺇﻋﻁﺎﺌﻬﻤﺎ ﺒﺠﺭﻋﺎﺕ ﻜﺒﻴﺭﺓ‪.‬‬
‫‪ -٤‬ﺍﻟﺩﺭﻴﺎﻗﺎﺕ ﻭﺍﻟﻤﻭﺍﺩ ﺍﻷﺨﺭﻯ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻟﻌﻼﺝ ﺍﻟﺘﺴﻤﻡ‬
‫‪ ١-٤‬ﻏﻴﺭ ﺍﻟﻨﻭﻋﻴﺔ‬
‫ﻤﺴﺤﻭﻕ‪.‬‬ ‫ﺍﻟﻔﺤﻡ‪ ،‬ﺍﻟﻤﻨﺸﻁ‬
‫‪ ٢-٤‬ﺍﻟﻨﻭﻋﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺃﺴﻴﺘﻴل ﺴﻴﺴﺘﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ١ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺃﺘﺭﻭﺒﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻏﻠﻭﻜﻭﻨﺎﺕ ﺍﻟﻜﺎﻟﺴﻴﻭﻡ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠٠ :‬ﻤﻠﻐﻡ )ﻤﺴﻴﻼﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺩﻴﻔﻴﺭﻭﻜﺴﺎﻤﻴﻥ‬
‫ﺤﻘﻨﺔ ﻓﻲ ﺯﻴﺕ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺩﻴﻤﻴﺭﻜﺎﺒﺭﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺩل ‪ -‬ﻤﻴﺜﻴﻭﻨﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﻤﻴﺘﻴﻠﻴﻭﻨﻴﻨﻴﻭﻡ )ﺃﺯﺭﻕ ﺍﻟﻤﻴﺘﻴل(‬
‫ﺤﻘﻨﺔ‪ ٤٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻨﺎﻟﻭﻜﺴﻭﻥ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﻴﻨﻴﺴﻴﻼﻤﻴﻥ‬
‫ﻓﺭ‪‬ﻴﻙ ﺍﻟﺒﻭﺘﺎﺴـﻴﻭﻡ ﻫﻜـﺴﺎﺴﻴﺎﻨﻭﻓﻴﺭﻴﺕ‬
‫ﻤﺴﺤﻭﻕ ﻴﺅﺨﺫ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ‪.‬‬
‫‪) (II)-2H2O‬ﺃﺯﺭﻕ ﺒﺭﻭﺴﻲ(‬
‫ﺤﻘﻨﺔ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺇﻴﺩﻴﺘﺎﺕ ﻜﺎﻟﺴﻴﻭﻡ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﺤﻘﻨﺔ‪ ٣٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻨﺘﺭﻴﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﺤﻘﻨﺔ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺜﻴﻭﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ‬

‫‪EML 15‬‬ ‫‪page - 3‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -٥‬ﻤﻀﺎﺩﺍﺕ ﺍﻻﺨﺘﻼﺝ‪ /‬ﻤﻀﺎﺩﺍﺕ ﺍﻟﺼﺭﻉ‬

‫ﺸﺭﺍﺏ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﻤﻀﻎ(‪١٠٠ :‬ﻤﻠﻐﻡ‪ ٢٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻜﺎﺭﺒﺎﻤﺎﺯﻴﺒﻴﻥ‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭ‪‬ﺯﺓ(‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٢٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ )ﻓﻲ ﺍﻟﻭﺭﻴﺩ ﺃﻭ ﻓـﻲ‬
‫… ﺩﻴﺎﺯﻴﺒﺎﻡ‬
‫ﺍﻟﻤﺴﺘﻘﻴﻡ(‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘـﺭ؛ ‪ ٥٠٠‬ﻤﻠﻐـﻡ‪/‬‬
‫ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫* ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﻋﻼﺝ ﺍﻀﻁﺭﺍﺒﺎﺕ ﺍﻻﺭﺘﻌﺎﺝ ﻭﺍﻀﻁﺭﺍﺒﺎﺕ ﻤـﺎ ﻗﺒـل‬ ‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻤﻐﻨﻴﺯﻴﻭﻡ*‬
‫ﺍﻻﺭﺘﻌﺎﺝ ﺍﻟﺤﺎﺩﺓ ﻭﻻ ﻴﺴﺘﻌﻤل ﻓﻲ ﻋﻼﺝ ﺃﻴـﺔ ﺍﻀـﻁﺭﺍﺒﺎﺕ ﺍﺨﺘﻼﺠﻴـﺔ‬
‫ﺃﺨﺭﻯ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ )ﺼﻭﺩﻴﻭﻡ ﺍﻟﻔﻴﻨﻭﺒﺎﺭﺒﻴﺘﺎل(‪.‬‬
‫ﺸﺭﺍﺏ‪ ١٥ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ )ﻓﻴﻨﻭﺒﺎﺭﺒﻴﺘﺎل( ﺃﻭ ‪ ٥‬ﻤﻴﻠﻴﻠﺘـﺭ )ﺼـﻭﺩﻴﻭﻡ‬
‫ﻓﻴﻨﻭﺒﺎﺭﺒﻴﺘﺎل‬
‫ﺍﻟﻔﻴﻨﻭﺒﺎﺭﺒﻴﺘﺎل(‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠-١٥ :‬ﻤﻠﻐﻡ )ﻓﻴﻨﻭﺒﺎﺭﺒﻴﺘﺎل(‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥ :‬ﻤﻠﻐﻡ‪ ٥٠ ،‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬
‫ﺸﺭﺍﺏ‪ ٣٠-٢٥ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪*.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ‪ ٥٠ ،‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬ ‫ﻓﻴﻨﻴﺘﻭﻴﻥ‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﻤﻀﻎ(‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﻤﻥ ﺸﺄﻥ ﺘﻭﺍﻓﺭ ﻗﻭﺓ ﺍﻟﺠﺭﻋﺔ ‪ ٢٥‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ ﻭﻗﻭﺓ ﺍﻟﺠﺭﻋﺔ ‪٣٠‬‬
‫ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺍﻟﺴﻭﻕ ﺫﺍﺘﻬﺎ ﺃﻥ ﻴﺴﺒﺏ ﺨﻠﻁﹰﺎ ﻓﻲ ﻭﺼـﻑ ﺍﻟـﺩﻭﺍﺀ‬
‫ﻭﺼﺭﻓﻪ‪ ،‬ﻭﻫﺫﺍ ﺃﻤﺭ ﻴﻨﺒﻐﻲ ﺘﻼﻓﻴﻪ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﺴﺤﻕ(‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻤﺽ ﺍﻟﻔﺎﻟﺒﺭﻭﻴﻙ‬
‫ﺃﻗﺭﺍﺹ )ﻤﻌﻭﻴـﺔ ﻤﻐﻠﻔـﺔ(‪ ٢٠٠ :‬ﻤﻠﻐـﻡ‪ ٥٠٠ ،‬ﻤﻠﻐـﻡ )ﻓـﺎﻟﺒﺭﻭﺍﺕ‬
‫ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺇﻴﺜﻭﺴﻭﻜﺴﻴﻤﻴﺩ‬
‫ﺸﺭﺍﺏ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 4‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻌﺩﻭﻯ‬

‫‪ ١-٦‬ﻁﺎﺭﺩﺍﺕ ﺍﻟﺩﻴﺩﺍﻥ‬
‫‪ ١-١-٦‬ﻁﺎﺭﺩﺍﺕ ﺍﻟﺩﻴﺩﺍﻥ ﺍﻟﻤﻌﻭﻴﺔ‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﻤﻀﻎ(‪ ٤٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﻟﺒﻴﻨﺩﺍﺯﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ؛ ‪ ١٥٠‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﻟﻴﻔﺎﻤﻴﺴﻭل‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﻤﻀﻎ(‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٥٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﻤﻴﺒﻴﻨﺩﺍﺯﻭل‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﻤﻀﻎ(‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﺩﻭﺍﺀ ﻨﻴﻜﻠﻭﺯﺍﻤﻴﺩ ﻤﺩﺭﺝ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﺤﺎﻟﺔ ﺇﺨﻔﺎﻕ ﺍﻟﻌﻼﺝ‬ ‫ﻨﻴﻜﻠﻭﺯﺍﻤﻴﺩ*‬
‫ﺒﺩﻭﺍﺀ ﺒﺭﺍﺯﻴﻜﻭﺍﻨﺘﻴل‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪ ٦٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﺭﺍﺯﻴﻜﻭﺍﻨﺘﻴل‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺇﻤﺒﻭﻨﺎﺕ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺒﻴﺭﺍﻨﺘﻴل‬
‫ﺃﻗﺭﺍﺹ )ﻟﻠﻤﻀﻎ(‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺇﻤﺒﻭﻨﺎﺕ(‪.‬‬
‫‪ ٢-١-٦‬ﻤﻀﺎﺩﺍﺕ ﺍﻟﻔﻴﻼﺭﻴﺎﺕ‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯ‪‬ﺓ(‪ ٣ :‬ﻤﻠﻐﻡ‪ ٦ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺇﻴﻔﺭﻤﻜﺘﻴﻥ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ )ﺴﻴﺘﺭﺍﺕ ﺜﻨﺎﺌﻲ ﺍﻟﻬﻴﺩﺭﻭﺠﻴﻥ(‪.‬‬ ‫ﺜﻨﺎﺌﻲ ﺇﻴﺜﻴل ﻜﺎﺭﺒﺎﻤﺎﺯﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١ :‬ﻍ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺼﻭﺩﻴﻭﻡ ﺍﻟﺴﻭﺭﺍﻤﻴﻥ‬
‫‪ ٣-١-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺒﻠﻬﺎﺭﺴﻴﺎﺕ ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻤﺜﻘﻭﺒﺎﺕ‬
‫ﺃﻗﺭﺍﺹ‪ ٦٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﺭﺍﺯﻴﻜﻭﺍﻨﺘﻴل‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺜﻼﺜﻲ ﻜﻼﺒﻨﺩﺍﺯﻭل‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻭﻜﺴﺎﻤﻨﻴﻜﻴﻥ*‬
‫* ﺩﻭﺍﺀ ﺃﻭﻜﺴﺎﻤﻨﻴﻜﻴﻥ ﻤﺩﺭﺝ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻻﺴﺘﻌﻤﺎﻟﻪ ﻓـﻲ ﺤﺎﻟـﺔ ﺇﺨﻔـﺎﻕ‬
‫ﺍﻟﻌﻼﺝ ﺒﺩﻭﺍﺀ ﺒﺭﺍﺯﻴﻜﻭﺍﻨﺘﻴل‪.‬‬

‫‪EML 15‬‬ ‫‪page - 5‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٢-٦‬ﻤﻀﺎﺩﺍﺕ ﺍﻟﺠﺭﺍﺜﻴﻡ‬
‫‪ ١-٢-٦‬ﺃﺩﻭﻴﺔ ﺍﻟﺒﻴﺘﺎ ﻻﻜﺘﺎﻡ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪ ٥٠٠ ،‬ﻤﻠﻐﻡ )ﻻ ﻤﺎﺌﻴﺔ(‪.‬‬
‫ﺃﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺸﺭﺍﺏ‪ ١٢٥ :‬ﻤﻠﻐﻡ )ﻻ ﻤﺎﺌﻲ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ ‪ ١٢٥ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ ‪ +‬ﺤﻤﺽ ﺍﻟﻜﻼﻓﻭﻻﻨﻴﻙ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪ ١ ،‬ﻍ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟـﺼﻭﺩﻴﻭﻡ( ﻓـﻲ‬
‫ﺃﻤﺒﻴﺴﻴﻠﻴﻥ‬
‫ﻗﻨﻴﻨﺔ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١,٤٤ :‬ﻍ ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ )= ‪ ٢‚٤‬ﻤﻠﻴﻭﻥ ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ(‬
‫ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ ﺍﻟﺒﻨﺯﺍﺜﻴﻥ‬
‫ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤــﺴﺤﻭﻕ ﻟﻠﺤﻘــﻥ‪ ٦٠٠ :‬ﻤﻠﻐــﻡ )= ‪ ١‬ﻤﻠﻴــﻭﻥ ﻭﺤــﺩﺓ ﺩﻭﻟﻴــﺔ(‪،‬‬
‫‪ ٣‬ﻍ )= ‪ ٥‬ﻤﻠﻴﻭﻥ ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ( )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ ﺃﻭ ﻤﻠﺢ ﺍﻟﺒﻭﺘﺎﺴـﻴﻭﻡ(‬ ‫ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ‬
‫ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪١ :‬ﻍ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﻴﻔﺎﺯﻭﻟﻴﻥ*‬
‫* ﻟﻠﺘﻭﻗﻴﺔ ﺍﻟﺠﺭﺍﺤﻴﺔ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٤٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﻤﺩﺭﺝ ﻓﻘﻁ ﻟﻠﻌﻼﺝ ﺍﻟﻭﺤﻴﺩ ﺍﻟﺠﺭﻋﺔ ﻟﻠﺴﻴﻼﻥ ﺍﻟﺘﻨﺎﺴﻠﻲ ﺍﻟﺸﺭﺠﻲ ﻏﻴـﺭ‬ ‫ﺴﻴﻔﻴﻜﺴﻴﻡ*‬
‫ﺍﻟﻤﺼﺤﻭﺏ ﺒﻤﻀﺎﻋﻔﺎﺕ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪١ ،‬ﻍ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫… ﻜﻠﻭﻜﺴﺎﺴﻴﻠﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺸﺭﺍﺏ‪ ١٢٥ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺸﺭﺍﺏ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻓﻴﻨﻭﻜﺴﻴﻤﻴﺜﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ(‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١ :‬ﻍ )= ‪ ١‬ﻤﻠﻴﻭﻥ ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ(‪ ٣ ،‬ﻍ )= ‪ ٣‬ﻤﻠﻴـﻭﻥ‬
‫ﺒﺭﻭﻜﺎﻴﻴﻥ ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ‬
‫ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺒﻨﺘﺎﻫﻴﺩﺭﺍﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﻔﺘﺎﺯﻴﺩﻴﻡ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪١ ،‬ﻍ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟـﺼﻭﺩﻴﻭﻡ( ﻓـﻲ‬
‫… ﺴﻔﺘﺭﻴﺎﻜﺴﻭﻥ‬
‫ﻗﻨﻴﻨﺔ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 6‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻭﻨﻭﻫﻴﺩﺭﺍﺕ( ‪ ٢٥٠ +‬ﻤﻠﻐـﻡ‬

‫)ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪ ٥٠٠ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻭﻨﻭﻫﻴﺩﺭﺍﺕ( ‪+‬‬
‫‪ ٥٠٠‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺇﻴﻤﻴﺒﻴﻨﻴﻡ* ‪ +‬ﺴﻴﻼﺴﺘﺎﺘﻴﻥ*‬
‫* ﻤﺩﺭﺝ ﻓﻘﻁ ﻟﻠﻌﻼﺝ ﻤﻥ ﺤﺎﻻﺕ ﺍﻟﻌﺩﻭﻯ ﺍﻟﺘﻲ ﺘﺤﺩﺙ ﻓﻲ ﺍﻟﻤﺴﺘـﺸﻔﻴﺎﺕ‬
‫ﻭﺘﻬﺩﺩ ﺍﻟﺤﻴﺎﺓ ﻭﺘﻜﻭﻥ ﻨﺎﺠﻤﺔ ﻋﻥ ﺤﺎﻻﺕ ﻋﺩﻭﻯ ﻴﺸﺘﺒﻪ ﻓـﻲ ﻤﻘﺎﻭﻤﺘﻬـﺎ‬
‫ﻟﻸﺩﻭﻴﺔ ﺃﻭ ﺜﺒﺘﺕ ﻤﻘﺎﻭﻤﺘﻬﺎ ﻟﻸﺩﻭﻴﺔ ﺍﻟﻤﺘﻌﺩﺩﺓ‪.‬‬
‫‪ ٢-٢-٦‬ﻤﻀﺎﺩﺍﺕ ﺍﻟﺠﺭﺍﺜﻴﻡ ﺍﻷﺨﺭﻯ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥٠ :‬ﻤﻠﻐﻡ ﺃﻭ ‪ ٥٠٠‬ﻤﻠﻐﻡ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﺯﻴﺜﺭﻭﻤﻴﺴﻴﻥ*‬
‫* ﻤﺩﺭﺝ ﻓﻘﻁ ﻟﻠﻌﻼﺝ ﺍﻟﻭﺤﻴﺩ ﺍﻟﺠﺭﻋـﺔ ﻟﻠﻤﺘـﺩﺜﺭﺓ ﺍﻟﺤﺜﺭﻴـﺔ ﺍﻟﺘﻨﺎﺴـﻠﻴﺔ‬
‫ﻭﺍﻟﺤﺜﺭ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻤﺴﺘﻌﻠﻕ ﺯﻴﺘﻲ ﻟﻠﺤﻘﻥ‪ ٠‚٥ :‬ﻍ )ﻋﻠﻰ ﺸﻜل ﺴﻜـﺴﻴﻨﺎﺕ ﺍﻟـﺼﻭﺩﻴﻭﻡ(‪/‬‬
‫ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻜﻠﻭﺭﺍﻤﻔﻴﻨﻴﻜﻭل‬
‫ﺸﺭﺍﺏ‪ ١٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺒﺎﻟﻤﻴﺘﺎﺕ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١ :‬ﻍ )ﺴﻜﺴﻴﻨﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫… ﺴﻴﺒﺭﻭﻓﻠﻭﻜﺴﺎﻜﻴﻥ*‬
‫* ﻴﻌﺘﻤﺩ ﺍﻻﻨﺘﻘﺎﺀ ﺍﻟﻨﻬﺎﺌﻲ ﻋﻠﻰ ﺩﻭﺍﻋﻲ ﺍﻻﺴﺘﻌﻤﺎل‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺩﻭﻜﺴﻴﺴﻴﻜﻠﻴﻥ*‬
‫* ﻴﻌﺘﻤﺩ ﺍﻻﻨﺘﻘﺎﺀ ﺍﻟﻨﻬﺎﺌﻲ ﻋﻠﻰ ﺩﻭﺍﻋﻲ ﺍﻻﺴﺘﻌﻤﺎل‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺴﺘﻴﺭﺍﺕ ﺃﻭ ﺴﻜـﺴﻴﻨﺎﺕ‬
‫ﺍﻹﻴﺜﻴل(‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻻﻜﺘﻭﺒﻴﻨﺎﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫… ﺇﺭﻴﺜﺭﻭﻤﻴﺴﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺸﺭﺍﺏ‪ ١٢٥ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸـﻜل ﺴـﺘﻴﺭﺍﺕ ﺃﻭ ﺴﻜـﺴﻴﻨﺎﺕ‬
‫ﺍﻹﻴﺜﻴل(‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٤٠ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓـﻲ ﻗﻨﻴﻨـﺔ‬
‫ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﺠﻨﺘﺎﻤﻴﺴﻴﻥ*‬
‫* ﻴﻌﺘﻤﺩ ﺍﻻﻨﺘﻘﺎﺀ ﺍﻟﻨﻬﺎﺌﻲ ﻋﻠﻰ ﺩﻭﺍﻋﻲ ﺍﻻﺴﺘﻌﻤﺎل‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١٠٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺒﻨﺯﻭﺍﺕ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫… ﻤﻴﺘﺭﻭﻨﻴﺩﺍﺯﻭل‬
‫ﺘﺤﻤﻴﻠﺔ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪ ١ ،‬ﻍ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠-٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 7‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻨﻴﺘﺭﻭﻓﻭﺭﺍﻨﺘﻭﻴﻥ‬

‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢ :‬ﻍ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﺒﻜﺘﻴﻨﻭﻤﻴﺴﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ٨٠ :‬ﻤﻠﻐﻡ ‪ ١٦ +‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺘﻴﻥ ﺴـﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘـﺭ‬
‫ﻭ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺴﻠﻔﺎﻤﻴﺜﻭﻜﺴﺎﺯﻭل ‪ +‬ﺘﺭﻴﻤﻴﺜﻭﺒﺭﻴﻡ‬
‫ﺸﺭﺍﺏ‪ ٢٠٠ :‬ﻤﻠﻐﻡ ‪ ٤٠ +‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ ‪ ٢٠ +‬ﻤﻠﻐﻡ‪ ٤٠٠ ،‬ﻤﻠﻐﻡ ‪ ٨٠ +‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٢٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺘﺭﻴﻤﻴﺜﻭﺒﺭﻴﻡ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﻠﻴﻨﺩﺍﻤﻴﺴﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ١٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻓﻭﺴﻔﺎﺕ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٤‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺴﻠﻔﺎﺩﻴﺎﺯﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﻓﺎﻨﻜﻭﻤﻴﺴﻴﻥ‬
‫‪ ٣-٢-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺠﺫﺍﻡ‬
‫ﻻ ﻴﻨﺒﻐﻲ ﻋﻠﻰ ﺍﻹﻁﻼﻕ ﺃﻥ ﺘﺴﺘﺨﺩﻡ ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﻋﻼﺝ ﺍﻟﺠﺫﺍﻡ ﺇﻻ ﻓـﻲ ﺘﻭﻟﻴﻔـﺔ‪ .‬ﻓﺎﻟﻤﻌﺎﻟﺠـﺔ ﺍﻟﺘﻭﻟﻴﻔﻴـﺔ‬
‫ﻀﺭﻭﺭﻴﺔ ﻟﻤﻨﻊ ﻨﺸﻭﺀ ﻤﻘﺎﻭﻤﺔ ﺍﻷﺩﻭﻴﺔ‪ .‬ﻭﻴﻨﺒﻐﻲ ﺍﺴﺘﻌﻤﺎل ﺍﻟﻌﺒﻭﺍﺕ ﺍﻟﻤﻨﻔﻁﺔ ﺍﻟﻤﺭﻤﺯﺓ ﺒﺎﻷﻟﻭﺍﻥ )ﺍﻟﻌﺒـﻭﺍﺕ ﺍﻟﻤﻨﻔﻁـﺔ‬
‫ﻟﻠﻤﻌﺎﻟﺠﺔ ﺍﻟﻤﺘﻌﺩﺩﺓ ﺍﻷﺩﻭﻴﺔ( ﻭﺍﻟﺘﻲ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﺘﻭﻟﻴﻔﺔ ﻤﻌﻴﺎﺭﻴﺔ ﻤﻥ ﺩﻭﺍﺀﻴﻥ )ﻟﻠﺠﺫﺍﻡ ﻗﻠﻴـل ﺍﻟﻌـﺼﻴﺎﺕ( ﺃﻭ ﺘﻭﻟﻴﻔـﺔ‬
‫ﻤﻌﻴﺎﺭﻴﺔ ﻤﻥ ﺜﻼﺜﺔ ﺃﺩﻭﻴﺔ )ﻟﻠﺠﺫﺍﻡ ﻤﺘﻌﺩﺩ ﺍﻟﻌﺼﻴﺎﺕ( ﻟﻌﻼﺝ ﺍﻟﺠﺫﺍﻡ ﻟﺩﻯ ﺍﻟﺒﺎﻟﻐﻴﻥ ﻭﺍﻷﻁﻔﺎل‪ .‬ﻭﻴﻤﻜﻥ ﺘﻭﺭﻴﺩ ﺍﻟﻌﺒـﻭﺍﺕ‬
‫ﺍﻟﻤﻨﻔﻁﺔ ﻟﻠﻤﻌﺎﻟﺠﺔ ﺍﻟﻤﺘﻌﺩﺩﺓ ﺍﻷﺩﻭﻴﺔ‪ ،‬ﻤﺠﺎﻨﹰﺎ ﻋﻥ ﻁﺭﻴﻕ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻜﻠﻭﻓﺎﺯﻴﻤﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ‪ ٥٠ ،‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺩﺍﺒﺴﻭﻥ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪ ٣٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ‬
‫‪ ٤-٢-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴل‬
‫ﺃﻗﺭﺍﺹ‪ ٤٠٠-١٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺇﺜﺎﻤﺒﻭﺘﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠-١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯﺓ(‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ ‪ ٤٠٠ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺇﺜﺎﻤﺒﻭﺘﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٤٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﺍﻨﺘﺸﺎﺭﻴﺔ(‪ ١٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﻴﺭﺍﺯﻴﻨﺎﻤﻴﺩ‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯﺓ(‪ ١٥٠ :‬ﻤﻠﻐﻡ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 8‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪ ٣٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ‬

‫ﺃﻗﺭﺍﺹ‪:‬‬
‫‪ ٦٠‬ﻤﻠﻐﻡ ‪ ٣٠ +‬ﻤﻠﻐﻡ‪ ١٥٠ ،‬ﻤﻠﻐﻡ ‪ ٧٥ +‬ﻤﻠﻐﻡ‪ ٣٠٠ ،‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ‪.‬‬
‫‪ ٦٠‬ﻤﻠﻐﻡ ‪ ٦٠ +‬ﻤﻠﻐﻡ )ﻟﻼﺴﺘﻌﻤﺎل ﺍﻟﻤﺘﻘﻁﻊ ﺜﻼﺙ ﻤﺭﺍﺕ ﻓﻲ ﺍﻷﺴﺒﻭﻉ(‪.‬‬ ‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ‬
‫‪ ١٥٠‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ )ﻟﻼﺴﺘﻌﻤﺎل ﺍﻟﻤﺘﻘﻁـﻊ ﺜـﻼﺙ ﻤـﺭﺍﺕ ﻓـﻲ‬
‫ﺍﻷﺴﺒﻭﻉ(‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ ‪ ٧٥ +‬ﻤﻠﻐﻡ ‪ ٢٧٥ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺇﺜﺎﻤﺒﻭﺘﻭل‬
‫ﺃﻗﺭﺍﺹ‪:‬‬
‫‪ ٦٠‬ﻤﻠﻐﻡ ‪ ٣٠ +‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ؛ ‪ ١٥٠‬ﻤﻠﻐﻡ ‪ ٧٥ +‬ﻤﻠﻐﻡ ‪ ٤٠٠ +‬ﻤﻠﻐﻡ‪.‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺒﻴﺭﺍﺯﻴﻨﺎﻤﻴﺩ‬
‫‪ ١٥٠‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ ‪ ٥٠٠ +‬ﻤﻠﻐﻡ )ﻟﻼﺴﺘﻌﻤﺎل ﺍﻟﻤﺘﻘﻁـﻊ ﺜـﻼﺙ‬
‫ﻤﺭﺍﺕ ﻓﻲ ﺍﻷﺴﺒﻭﻉ(‪.‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺒﻴﺭﺍﺯﻴﻨﺎﻤﻴﺩ‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ ‪ ٧٥ +‬ﻤﻠﻐﻡ ‪ ٤٠٠ +‬ﻤﻠﻐﻡ ‪ ٢٧٥ +‬ﻤﻠﻐﻡ‪.‬‬
‫‪ +‬ﺇﺜﺎﻤﺒﻭﺘﻭل‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١ :‬ﻍ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﺘﺭﺒﺘﻭﻤﻴﺴﻴﻥ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻴﻨﺒﻐﻲ ﺍﺴﺘﻌﻤﺎﻟﻬﺎ ﻓـﻲ‬ ‫)‪(MDR-TB‬‬ ‫ﺃﺩﻭﻴﺔ ﺍﺤﺘﻴﺎﻁﻴﺔ ﻤﻥ ﺍﻟﺨﻁ ﺍﻟﺜﺎﻨﻲ ﻟﻠﻌﻼﺝ ﻤﻥ ﺍﻟﺴل ﺍﻟﻤﻘﺎﻭﻡ ﻟﻸﺩﻭﻴﺔ ﺍﻟﻤﺘﻌﺩﺩﺓ‬
‫ﻤﺭﺍﻜﺯ ﻤﺘﺨﺼﺼﺔ ﺘﻠﺘﺯﻡ ﺒﻤﻌﺎﻴﻴﺭ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﻟﻤﻜﺎﻓﺤﺔ ﺍﻟﺴل‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺃﻤﻴﻜﺎﺴﻴﻥ‬
‫ﺤﺒﻴﺒﺎﺕ‪ ٤ :‬ﻍ ﻓﻲ ﺃﻜﻴﺎﺱ ﺼﻐﻴﺭﺓ‪.‬‬
‫ﺤﻤﺽ ﺍﻟﺒﺎﺭﺍ‪ -‬ﺃﻤﻴﻨﻭﺴﺎﻟﻴﺴﻴﻠﻴﻙ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﻜﺎﺒﺭﻴﻭﻤﻴﺴﻴﻥ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺴﻴﻜﻠﻭﺴﻴﺭﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٢٥ :‬ﻤﻠﻐﻡ‪ ٢٥٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺇﺜﻴﻭﻨﺎﻤﻴﺩ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﻜﺎﻨﺎﻤﻴﺴﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٤٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﻼ ﺤـﺴﺏ ﺍﻟﺘـﻭﺍﻓﺭ‬
‫* ﻴﻤﻜﻥ ﺃﻥ ﻴﻜـﻭﻥ ﺩﻭﺍﺀ ﻟﻴﻔﻭﻓﻠﻭﻜـﺴﺎﺴﻴﻥ ﺒـﺩﻴ ﹰ‬ ‫ﺃﻭﻓﻠﻭﻜﺴﺎﺴﻴﻥ*‬
‫ﻭﺍﻻﻋﺘﺒﺎﺭﺍﺕ ﺍﻟﺨﺎﺼﺔ ﺒﺎﻟﺒﺭﻨﺎﻤﺞ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 9‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٣-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻁﺭﻴﺎﺕ‬

‫ﻜﺭﻴﻡ ﻤﻬﺒﻠﻲ‪.٪١٠ ،٪١ :‬‬
‫ﻜﻠﻭﺘﺭﻴﻤﺎﺯﻭل‬
‫ﺃﻗﺭﺍﺹ ﻤﻬﺒﻠﻴﺔ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٥٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫… ﻓﻠﻭﻜﻭﻨﺎﺯﻭل‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ١٢٥ :‬ﻤﻠﻐﻡ‪ ٢٥٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻏﺭﻴﺯﻴﻭﻓﻭﻟﻔﻴﻥ‬
‫ﺃﻗﺭﺍﺹ ﻟﻠﻤﺹ‪ ١٠٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪.‬‬
‫ﻓﺭﺍﺯﺝ‪ ١٠٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪.‬‬ ‫ﻨﻴﺴﺘﺎﺘﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ ٥٠٠ ٠٠٠ ،‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺃﻤﻔﻭﺘﻴﺭﻴﺴﻴﻥ ﺒﺎﺀ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻓﻠﻭﺴﻴﺘﻭﺴﻴﻥ‬
‫ﻨﻘﻴﻊ‪ ٢‚٥ :‬ﻍ ﻓﻲ ‪ ٢٥٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺤﻠﻭل ﻤﺸﺒﻊ‪.‬‬ ‫ﻴﻭﺩﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ‬
‫‪ ٤-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ‬
‫‪ ١-٤-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻬﺭﺒﺱ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫… ﺃﺴﻴﻜﻠﻭﻓﻴﺭ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫‪ ٢-٤-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ‬
‫ﺒﻨﺎ ‪‬ﺀ ﻋﻠﻰ ﺍﻟﺒﻴ‪‬ﻨﺎﺕ ﺍﻟﺤﺎﻟﻴﺔ ﻭﺨﺒﺭﺓ ﺍﻻﺴﺘﻌﻤﺎل ﺘﺭﺩ ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻨﺩﺭﺠﺔ ﻀﻤﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﺜﻼﺙ ﺍﻟﺘﺎﻟﻴﺔ ﻤﻥ ﺍﻷﺩﻭﻴـﺔ‬
‫ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ ﺒﺎﻋﺘﺒﺎﺭﻫﺎ ﺃﺩﻭﻴﺔ ﺃﺴﺎﺴﻴﺔ ﻟﻠﻌﻼﺝ ﻭﺍﻟﻭﻗﺎﻴﺔ ﻤﻥ ﻓﻴﺭﻭﺱ ﺍﻟﻌـﻭﺯ ﺍﻟﻤﻨـﺎﻋﻲ ﺍﻟﺒـﺸﺭﻱ‬
‫)ﺍﻟﻭﻗﺎﻴﺔ ﻤﻥ ﺍﻨﺘﻘﺎل ﺍﻟﻤﺭﺽ ﻤﻥ ﺍﻷﻡ ﺇﻟﻰ ﺍﻟﻁﻔل ﻭﺍﻟﺘﻭﻗﻴﺔ ﺒﻌﺩ ﺍﻟﺘﻌﺭﺽ(‪ .‬ﻭﺸﺩﺩﺕ ﺍﻟﻠﺠﻨﺔ ﻋﻠﻰ ﺃﻫﻤﻴﺔ ﺍﺴﺘﻌﻤﺎل ﻫﺫﻩ‬
‫ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﻁﺒﻘﹰﺎ ﻟﻠﻤﺒﺎﺩﺉ ﺍﻟﺘﻭﺠﻴﻬﻴﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﻭﺍﻟﻭﻁﻨﻴﺔ‪ .‬ﻭﺘﻭﺼﻲ ﺍﻟﻠﺠﻨﺔ ﺒﺎﺴﺘﻌﻤﺎل ﺍﻟﺘﻭﺍﻟﻴﻑ ﺍﻟﺜﺎﺒﺘـﺔ ﺍﻟﺠﺭﻋـﺔ‬
‫ﻭﺒﺎﺴﺘﺤﺩﺍﺙ ﺘﻭﺍﻟﻴﻑ ﺠﺩﻴﺩﺓ ﺜﺎﺒﺘﺔ ﺍﻟﺠﺭﻋﺔ‪ ،‬ﺒﻤﺎ ﻓﻲ ﺫﻟﻙ ﺃﺸﻜﺎل ﺍﻟﺠﺭﻋﺎﺕ ﺍﻟﻤﻌﺩﻟﺔ ﻭﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﻏﻴـﺭ ﺍﻟﻤﺠﻤـﺩﺓ‬
‫ﻭﺃﺸﻜﺎل ﺍﻟﺠﺭﻋﺎﺕ ﺍﻟﺨﺎﺼﺔ ﺒﺎﻷﻁﻔﺎل‪ ،‬ﺫﺍﺕ ﺍﻟﺠﻭﺩﺓ ﺍﻟﺩﻭﺍﺌﻴﺔ ﺍﻟﻤﻀﻤﻭﻨﺔ‪ ،‬ﻜﻤﺎ ﺘﺅﻴﺩ ﺫﻟﻙ‪.‬‬
‫‪ ١-٢-٤-٦‬ﺍﻟﻤﺜﺒﻁﺎﺕ ﺍﻟﻤﻨﺘﺴﺨﺔ ﺍﻟﻌﻜﺴﻴﺔ ﺍﻟﻨﻭﻜﻠﻴﻭﺯﻴﺩﻴﺔ‪ /‬ﺍﻟﻨﻭﻜﻠﻴﻭﺘﻴﺩﻴﺔ‬
‫ﺸﺭﺍﺏ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﺒﺎﻜﺎﻓﻴﺭ )‪(ABC‬‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬

‫‪EML 15‬‬ ‫‪page - 10‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺴﺤﻭﻕ )ﻤﺩﺭﻭﺀ ﻟﻠﺸﺭﺍﺏ(‪ :‬ﻋﺒﻭﺍﺕ ﺴﻌﺔ ‪ ١٠٠‬ﻤﻠﻐـﻡ‪ ١٦٧ ،‬ﻤﻠﻐـﻡ‪،‬‬

‫‪ ٢٥٠‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ )ﻤﻐﻠﻔﺔ ﻤﻌﻭﻴﺔ ﻏﻴﺭ ﻤـﺩﺭﻭﺀﺓ(‪ ١٢٥ :‬ﻤﻠﻐـﻡ‪ ٢٠٠ ،‬ﻤﻠﻐـﻡ‪،‬‬
‫ﺩﻴﺩﺍﻨﻭﺯﻴﻥ )‪(ddI‬‬
‫‪ ٢٥٠‬ﻤﻠﻐﻡ‪ ٤٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻤـﺩﺭﻭﺀﺓ ﻟﻠﻤـﻀﻎ‪ ،‬ﻭﺍﻨﺘـﺸﺎﺭﻴﺔ(‪ ٢٥ :‬ﻤﻠﻐـﻡ‪ ٥٠ ،‬ﻤﻠﻐـﻡ‪،‬‬
‫‪ ١٠٠‬ﻤﻠﻐﻡ‪ ١٥٠ ،‬ﻤﻠﻐﻡ‪ ٢٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺸﺭﺍﺏ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫* ﻻﻤﻴﻔﻭﺩﻴﻥ ‪ 3TC‬ﺒﺩﻴل ﻤﻘﺒﻭل ﻹﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ )‪ (FTC‬ﺤﺴﺏ ﻤﻌﺭﻓـﺔ‬ ‫ﺇﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ )‪*(FTC‬‬
‫ﻓﺎﺭﻤﺎﻜﻭﻟﻭﺠﻴﺎ ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ ﻭﺃﻨﻤﺎﻁ ﻤﻘﺎﻭﻤﺘﻬـﺎ‬
‫ﻭﺘﺠﺎﺭﺒﻬﺎ ﺍﻟﺴﺭﻴﺭﻴﺔ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻻﻤﻴﻔﻭﺩﻴﻥ )‪(3TC‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ١٥ :‬ﻤﻠﻐﻡ‪ ٢٠ ،‬ﻤﻠﻐﻡ‪ ٣٠ ،‬ﻤﻠﻐﻡ‪ ٤٠ ،‬ﻤﻠﻐﻡ‪*.‬‬
‫* ﺘﺘﻭﻗﻊ ﺍﻟﻠﺠﻨﺔ ﺍﺴﺘﻌﺭﺍﺽ ﻫﺫﺍ ﺍﻟﺸﻜل ﻤﻥ ﺃﺸﻜﺎل ﺍﻟﺠﺭﻋﺎﺕ ﻹﻤﻜﺎﻨﻴـﺔ‬
‫ﺴﺘﺎﻓﻭﺩﻴﻥ )‪(d4T‬‬
‫ﺤﺫﻓﻪ ﻓﻲ ﺍﺠﺘﻤﺎﻋﻬﺎ ﺍﻟﺘﺎﻟﻲ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺸﺭﺍﺏ‪ ٥ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ )ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ﺩﻴﺯﻭﺒﺭﻭﻜﺴﻴل ﻓﻴـﻭﻤﻴﺭﺍﺕ – ﺘﻌـﺎﺩل‬ ‫ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ﺩﻴﺯﻭﺒﺭﻭﻜﺴﻴل‬
‫‪ ٢٤٥‬ﻤﻠﻐﻡ ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ﺩﻴﺯﻭﺒﺭﻭﻜﺴﻴل(‪.‬‬ ‫ﻓﻴﻭﻤﻴﺭﺍﺕ )‪(TDF‬‬

‫ﻜﺒﺴﻭﻻﺕ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٢٥٠ ،‬ﻤﻠﻐﻡ‪.‬‬

‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺤﻠﻭل ﻟﻠﺤﻘﻥ ﺒﺎﻟﺘﺴﺭﻴﺏ ﻓﻲ ﺍﻟﻭﺭﻴﺩ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ‬ ‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ )‪ ZDV‬ﺃﻭ ‪(AZT‬‬
‫‪ ٢٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫‪ ٢-٢-٤-٦‬ﺍﻟﻤﺜﺒﻁﺎﺕ ﺍﻟﻤﻨﺘﺴﺨﺔ ﺍﻟﻌﻜﺴﻴﺔ ﺍﻟﻼﻨﻭﻜﻠﻴﻭﺯﻴﺩﻴﺔ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ‪ ٢٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﺸﺭﺍﺏ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺇﻓﺎﻓﻴﺭﻨﺯ )‪ EFV‬ﺃﻭ ‪(EFZ‬‬
‫ﺃﻗﺭﺍﺹ‪ ٦٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻨﻴﻔﻴﺭﺍﺒﻴﻥ )‪(NVP‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 11‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٣-٢-٤-٦‬ﻤﺜﺒﻁﺎﺕ ﺍﻟﺒﺭﻭﺘﻴﺎﺯ‬
‫ﺴﻴﻠﺯﻡ ﺃﻥ ﻴﻨﺘﻘﻲ ﻜل ﺒﻠﺩ ﻭﺍﺤﺩﹰﺍ ﺃﻭ ﺃﻜﺜﺭ ﻤﻥ ﻤﺜﺒﻁﺎﺕ ﺍﻟﺒﺭﻭﺘﻴﺎﺯ ﻤﻥ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ ﺒﻌﺩ ﺃﺨﺫ ﺍﻟﻤﺒﺎﺩﺉ ﺍﻟﺘﻭﺠﻴﻬﻴـﺔ‬
‫ﻭﺍﻟﺨﺒﺭﺓ ﺍﻟﻌﻼﺠﻴﺔ ﺍﻟﺩﻭﻟﻴﺔ ﻭﺍﻟﻭﻁﻨﻴﺔ ﺒﻌﻴﻥ ﺍﻻﻋﺘﺒﺎﺭ‪ .‬ﻭﻴﻭﺼﻰ ﺒﺎﺴﺘﻌﻤﺎل ﺍﻟﺭﻴﺘﻭﻨﺎﻓﻴﺭ ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﺒﻭﺼﻔﻪ ﻤﺴﺘﺤـﻀﺭﹰﺍ‬
‫ﻤﻌﺯﺯﹰﺍ ﻭﻟﻴﺱ ﺩﻭﺍ ‪‬ﺀ ﻤﻀﺎﺩﹰﺍ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ ﻓﻲ ﺤﺩ ﺫﺍﺘﻪ‪.‬‬
‫ﻭﺴﺘﺴﺘﻌﺭﺽ ﺍﻟﻠﺠﻨﺔ ﻫﺫﺍ ﺍﻟﻔﺭﻉ ﻋﻠﻰ ﺴﺒﻴل ﺍﻷﻭﻟﻭﻴﺔ ﻓﻲ ﺍﺠﺘﻤﺎﻋﻬﺎ ﺍﻟﺘﺎﻟﻲ‪ .‬ﻭﻤﻥ ﺍﻟﻤﺘﻭﻗﻊ ﺘﻘﺩﻴﻡ ﻁﻠـﺏ ﺒﺨـﺼﻭﺹ‬
‫ﺘﺭﻜﻴﺒﺔ ﺃﻗﺭﺍﺹ ﻤﻘﺎﻭﻤﺔ ﻟﺘﻐﻴﺭ ﺍﻟﺤﺭﺍﺭﺓ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ‪ ٥٠/٢٠٠‬ﻤﻠﻐﻡ ﻤﻥ ﻟﻭﺒﻴﻨﺎﻓﻴﺭ ‪ +‬ﺭﻴﺘﻭﻨـﺎﻓﻴﺭ ﻓـﻲ ﺍﻻﺠﺘﻤـﺎﻉ‬
‫ﺍﻟﺘﺎﻟﻲ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٣٣٣ ،‬ﻤﻠﻐﻡ‪ ٤٠٠ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬ ‫ﺇﻨﺩﻴﻨﺎﻓﻴﺭ )‪(IDV‬‬

‫ﻜﺒﺴﻭﻻﺕ‪ ١٣٣,٣ :‬ﻤﻠﻐﻡ ‪ ٣٣‚٣ +‬ﻤﻠﻐﻡ‪.‬‬

‫ﻟﻭﺒﻴﻨﺎﻓﻴﺭ ‪ +‬ﺭﻴﺘﻭﻨﺎﻓﻴﺭ )‪(LPV/r‬‬
‫ﺸﺭﺍﺏ‪ ٤٠٠ :‬ﻤﻠﻐﻡ ‪ ١٠٠ +‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻍ‪.‬‬
‫ﻨﻠﻔﻴﻨﺎﻓﻴﺭ )‪(NFV‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﺴﻴﻼﺕ(‪.‬‬
‫ﺸﺭﺍﺏ‪ ٤٠٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺭﻴﺘﻭﻨﺎﻓﻴﺭ‬
‫ﺸﻜل ﺼﻠﺏ ﻤﻥ ﺃﺸﻜﺎل ﺍﻟﺠﺭﻋﺎﺕ ﺍﻟﻔﻤﻭﻴﺔ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺴﺎﻜﻭﻴﻨﺎﻓﻴﺭ )‪(SQV‬‬

‫ﺍﻟﺘﻭﺍﻟﻴﻑ ﺍﻟﺜﺎﺒﺘﺔ ﺍﻟﺠﺭﻋﺔ‬

‫ﺃﻗﺭﺍﺹ‪ ٦٠٠ :‬ﻤﻠﻐﻡ ‪ ٢٠٠ +‬ﻤﻠﻐﻡ ‪ ٣٠٠ +‬ﻤﻠﻐﻡ‪.‬‬
‫* ‪ 3TC‬ﺒﺩﻴل ﻤﻘﺒﻭل ﻟـ ‪ FTC‬ﺤﺴﺏ ﻤﻌﺭﻓﺔ ﻓﺎﺭﻤﺎﻜﻭﻟﻭﺠﻴـﺎ ﺍﻷﺩﻭﻴـﺔ‬ ‫ﺇﻓﺎﻓﻴﺭﻨﺯ ‪ +‬ﺇﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ*‪ +‬ﺘﻴﻨﻭﻓﻭﻓﻴﺭ‬
‫ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ ﻭﺃﻨﻤﺎﻁ ﻤﻘﺎﻭﻤﺘﻬﺎ ﻭﺘﺠﺎﺭﺒﻬﺎ ﺍﻟﺴﺭﻴﺭﻴﺔ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ ‪ ٣٠٠ +‬ﻤﻠﻐﻡ‪.‬‬
‫* ‪ 3TC‬ﺒﺩﻴل ﻤﻘﺒﻭل ﻟـ ‪ FTC‬ﺤﺴﺏ ﻤﻌﺭﻓﺔ ﻓﺎﺭﻤﺎﻜﻭﻟﻭﺠﻴـﺎ ﺍﻷﺩﻭﻴـﺔ‬ ‫ﺇﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ*‪ +‬ﺘﻴﻨﻭﻓﻭﻓﻴﺭ‬
‫ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ ﻭﺃﻨﻤﺎﻁ ﻤﻘﺎﻭﻤﺘﻬﺎ ﻭﺘﺠﺎﺭﺒﻬﺎ ﺍﻟﺴﺭﻴﺭﻴﺔ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠ :‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ ‪ ٢٠٠ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺴﺘﺎﻓﻭﺩﻴﻥ ‪ +‬ﻻﻤﻴﻔﻭﺩﻴﻥ ‪ +‬ﻨﻴﻔﻴﺭﺍﺒﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ ‪ +‬ﻻﻤﻴﻔﻭﺩﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ ‪ ١٥٠ +‬ﻤﻠﻐﻡ ‪ ٢٠٠ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ ‪ +‬ﻻﻤﻴﻔﻭﺩﻴﻥ ‪ +‬ﻨﻴﻔﻴﺭﺍﺒﻴﻥ‬
‫‪ ٣-٤-٦‬ﺃﺩﻭﻴﺔ ﺃﺨﺭﻯ ﻤﻀﺎﺩﺓ ﻟﻠﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﻘﻬﻘﺭﻴﺔ‬
‫ﺤﻘﻨﺔ ﺘﻌﻁﻰ ﻓﻲ ﺍﻟﻭﺭﻴﺩ‪ ١٠٠٠ :‬ﻤﻠﻐﻡ ﻭ‪ ٨٠٠‬ﻤﻠﻐﻡ ﻓـﻲ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘـﺭ‬
‫ﻤﺤﻠﻭل ﻓﻭﺴﻔﺎﺘﻲ ﺩﺍﺭﺉ‪.‬‬
‫ﺭﻴﺒﺎﻓﻴﺭﻴﻥ‬
‫ﺸﻜل ﺼﻠﺏ ﻤﻥ ﺃﺸﻜﺎل ﺍﻟﺠﺭﻋﺎﺕ ﺍﻟﻔﻤﻭﻴﺔ‪ ٢٠٠ :‬ﻤﻠﻐـﻡ‪ ٤٠٠ ،‬ﻤﻠﻐـﻡ‪،‬‬
‫‪ ٦٠٠‬ﻤﻠﻐﻡ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 12‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٥-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻭﺍﻟﻲ‬

‫‪ ١-٥-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻤﻴﺒﺔ ﻭﺍﻟﻤﻀﺎﺩﺓ ﻟﺩﺍﺀ ﺍﻟﺠﻴﺎﺭﺩﻴ‪‬ﺎﺕ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ )ﻓﻴﻭﺭﻭﺍﺕ(‪.‬‬ ‫ﺩﻴﻠﻭﻜﺴﺎﻨﻴﺩ‬
‫ﺤﻘﻨﺔ‪ ٥٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١٠٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺒﻨﺯﻭﺍﺕ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﻤﺘﺭﻭﻨﻴﺩﺍﺯﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠-٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫‪ ٢-٥-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﺩﺍﺀ ﺍﻟﻠﻴﺸﻤﺎﻨﻴﺎﺕ‬
‫ﺤﻘﻨﺔ‪ ،٪٣٠ :‬ﺘﻜﺎﻓﺊ ﻤﺎ ﻴﻘﺎﺭﺏ ‪ ٪٨,١‬ﻤﻥ ﺍﻷﻨﺘﻴﻤﻭﻥ‪ ،‬ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴـﻌﺔ‬
‫… ﻤﻐﻠﻭﻤﻴﻥ ﺃﻨﺘﻴﻤﻭﻨﻴﺎﺕ‬
‫‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺤﻠﻭل ﻟﻠﺤﻘﻥ ﻓﻲ ﺍﻟﻌـﻀل‪ ٧٥٠ :‬ﻤﻠﻐـﻡ‪ ٢/‬ﻤﻴﻠﻴﻠﺘـﺭ )ﻋﻠـﻰ ﺸـﻜل‬ ‫ﺒﺎﺭﻭﻤﻭﻤﻴﺴﻴﻥ‬
‫ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺃﻤﻔﻭﺘﻴﺭﻴﺴﻴﻥ ﺒﺎﺀ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٣٠٠ ،‬ﻤﻠﻐﻡ )ﺇﻴﺯﻴﺘﻴﻭﻨﺎﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺒﻨﺘﺎﻤﻴﺩﻴﻥ‬
‫‪ ٣-٥-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻤﻼﺭﻴﺎ‬
‫‪ ١-٣-٥-٦‬ﻤﻥ ﺃﺠل ﺍﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﺸﺎﻓﻴﺔ‬
‫ﻴﻨﺒﻐﻲ ﺃﻥ ﺘﹸﺴﺘﻌﻤل ﺃﺩﻭﻴﺔ ﺍﻟﻌﻼﺝ ﻤﻥ ﻤﻼﺭﻴﺎ ﺍﻟﻤﺘﺼﻭﺭﺍﺕ ﺍﻟﻤﻨﺠﻠﻴﺔ ﻓﻲ ﺘﻭﻟﻴﻔﺎﺕ‪ .‬ﻭﺘﻭﺼﻲ ﺍﻟﻘﺎﺌﻤﺔ ﺤﺎﻟﻴﹰﺎ ﺒﺎﻟﺘﻭﻟﻴﻔـﺎﺕ‬
‫ﻁﺒﻘﹰﺎ ﻟﻠﻤﺒﺎﺩﺉ ﺍﻟﺘﻭﺠﻴﻬﻴﺔ ﺍﻟﻌﻼﺠﻴﺔ‪ .‬ﻭﺘﻘﺭ ﺍﻟﻠﺠﻨﺔ ﺒﺄﻥ ﻫﺫﻩ ﺍﻟﺘﻭﺍﻟﻴﻑ ﺍﻟﺜﺎﺒﺘﺔ ﺍﻟﺠﺭﻋﺔ ﻟﻴﺴﺕ ﻤﺘﺎﺤﺔ ﻜﻠﻬﺎ‪ ،‬ﻭﺘﺸﺠﻊ ﻋﻠﻰ‬
‫ﺘﻁﻭﻴﺭﻫﺎ ﻭﺇﺨﻀﺎﻋﻬﺎ ﻻﺨﺘﺒﺎﺭﺍﺕ ﺼﺎﺭﻤﺔ‪ .‬ﻭﺘﺸﺠﻊ ﺍﻟﻠﺠﻨﺔ ﺃﻴﻀﹰﺎ ﻋﻠﻰ ﺘﻁﻭﻴﺭ ﻭﺍﺨﺘﺒﺎﺭ ﺘﺭﻜﻴﺒﺎﺕ ﺍﻟﺠﺭﻋـﺎﺕ ﺍﻟﺘـﻲ‬
‫ﺘﻌﻁﻰ ﻓﻲ ﺍﻟﻤﺴﺘﻘﻴﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٣ :‬ﻤﻠﻐﻡ ﺃﻭ ‪ ٢٠٠‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫* ﻴ‪‬ﺴﺘﻌﻤل )ﺃ( ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ‪ ٥٠‬ﻤﻠﻐﻡ ﻤـﻥ ﺍﻷﺭﺘﻴـﺴﻭﻨﺎﺕ ﺃﻭ )ﺏ(‬ ‫ﺃﻤﻭﺩﻴﺎﻜﻴﻥ*‬
‫ﻴﻤﻜﻥ ﺃﻥ ﻴ‪‬ﺴﺘﻌﻤل ﻭﺤﺩﻩ ﻟﻌﻼﺝ ﺤﺎﻻﺕ ﺍﻟﻌﺩﻭﻯ ﺒﺎﻟﻤﺘﺼﻭﺭﺓ ﺍﻟﻨـﺸﻴﻁﺔ‬
‫ﻭﺍﻟﻤﺘﺼﻭﺭﺓ ﺍﻟﺒﻴﻀﺎﻭﻴﺔ ﻭﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﺘﺼﻭﺭﺓ‪.‬‬
‫ﺤﻘﻨﺔ ﺯﻴﺘﻴﺔ‪ ٨٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﺭﺘﻤﻴﺜﺭ‬
‫ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﺍﻟﺘﺩﺒﻴﺭ ﺍﻟﻌﻼﺠﻲ ﻟﻠﻤﻼﺭﻴﺎ ﺍﻟﺸﺩﻴﺩﺓ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠ :‬ﻤﻠﻐﻡ ‪ ١٢٠ +‬ﻤﻠﻐﻡ‪.‬‬
‫* ﻻ ﻴﻭﺼﻰ ﺒﺎﺴﺘﻌﻤﺎﻟﻪ ﻓﻲ ﻓﺘﺭﺓ ﺍﻷﺸﻬﺭ ﺍﻟﺜﻼﺜﺔ ﺍﻷﻭﻟﻰ ﻤـﻥ ﺍﻟﺤﻤـل‬ ‫ﺃﺭﺘﻤﻴﺜﺭ ‪ +‬ﻟﻭﻤﻴﻔﺎﻨﺘﺭﻴﻥ*‬
‫ﻭﻻ ﻟﺩﻯ ﺍﻷﻁﻔﺎل ﺍﻟﺫﻴﻥ ﻴﻘل ﻭﺯﻨﻬﻡ ﻋﻥ ‪ ٥‬ﻜﻴﻠﻭﻏﺭﺍﻤﺎﺕ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 13‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺤﻘﻨﺔ‪ :‬ﺃﻤﺒﻭﻻﺕ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ‪ ٦٠‬ﻤﻠﻐـﻡ ﻤـﻥ ﺤﻤـﺽ ﺍﻷﺭﺘﻴـﺴﻭﻨﻴﻙ‬

‫ﺍﻟﻼﻤﺎﺌﻲ ﻤﻊ ﺃﻤﺒﻭﻟﺔ ﻤﻨﻔﺼﻠﺔ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ‪ ٪٥‬ﻤﻥ ﻤﺤﻠﻭل ﺒﻴﻜﺭﺒﻭﻨـﺎﺕ‬
‫ﺍﻟﺼﻭﺩﻴﻭﻡ‪.‬‬
‫ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﺍﻟﺘﺩﺒﻴﺭ ﺍﻟﻌﻼﺠﻲ ﻟﻠﻤﻼﺭﻴﺎ ﺍﻟﺸﺩﻴﺩﺓ‪.‬‬ ‫ﺃﺭﺘﻴﺴﻭﻨﺎﺕ*‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ﺃﻤﻭﺩﻴﺎﻜﻴﻥ ﺃﻭ ﻤﻔﻠﻭﻜﻴﻥ ﺃﻭ ﺴﻠﻔﺎﺩﻭﻜـﺴﻴﻥ ‪+‬‬
‫ﺒﻴﺭﻴﻤﻴﺜﺎﻤﻴﻥ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻓﻭﺴﻔﺎﺕ ﺃﻭ ﻜﺒﺭﻴﺘﺎﺕ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ١٥٠ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻓﻭﺴﻔﺎﺕ ﺃﻭ ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬ ‫ﻜﻠﻭﺭﻭﻜﻴﻥ*‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﻋﻼﺝ ﺍﻟﻌﺩﻭﻯ ﺒﺎﻟﻤﺘﺼﻭﺭﺓ ﺍﻟﻨﺸﻴﻁﺔ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﺍﻨﺘﺸﺎﺭﻴﺔ(‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻓﻲ ﺸﻜل ﺃﺤﺎﺩﻱ ﺍﻹﻤﺎﻫﺔ(‪.‬‬ ‫ﺩﻭﻜﺴﻴﺴﻴﻜﻠﻴﻥ*‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ﺍﻟﻜﻴﻨﻴﻥ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﻤﻔﻠﻭﻜﻴﻥ*‬
‫* ﻴﺴﺘﻌﻤل ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ‪ ٥٠‬ﻤﻠﻐﻡ ﻤﻥ ﺍﻷﺭﺘﻴﺴﻭﻨﺎﺕ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٧,٥ :‬ﻤﻠﻐﻡ‪ ١٥ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺜﻨﺎﺌﻲ ﺍﻟﻔﻭﺴﻔﺎﺕ(‪.‬‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻟﻠﺸﻔﺎﺀ ﺍﻟﺠﺫﺭﻱ ﻤﻥ ﺍﻟﻌﺩﻭﻯ ﺒﺎﻟﻤﺘـﺼﻭﺭﺓ ﺍﻟﻨـﺸﻴﻁﺔ‬ ‫ﺒﺭﻴﻤﺎﻜﻴﻥ*‬
‫ﻭﺍﻟﻤﺘﺼﻭﺭﺓ ﺍﻟﺒﻴﻀﺎﻭﻴﺔ ﻭﺍﻟﺫﻱ ﻴﻌﻁﻰ ﻟﻤﺩﺓ ‪ ١٤‬ﻴﻭﻤﹰﺎ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٣٠٠ :‬ﻤﻠﻐﻡ ﻤﻥ ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ ﺍﻟﻜﻴﻨﻴﻥ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴـﻌﺔ‬
‫‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻜﻴﻨﻴﻥ( ﺃﻭ ‪ ٣٠٠‬ﻤﻠﻐﻡ )ﺜﻨﺎﺌﻲ ﻜﺒﺭﻴﺘﺎﺕ‬
‫ﻜﻴﻨﻴﻥ*‬
‫ﺍﻟﻜﻴﻨﻴﻥ(‪.‬‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﺍﻟﺘﺩﺒﻴﺭ ﺍﻟﻌﻼﺠﻲ ﻟﻠﻤﻼﺭﻴﺎ ﺍﻟـﺸﺩﻴﺩﺓ‪ ،‬ﻭﻴﻨﺒﻐـﻲ ﺃﻥ‬
‫ﻴ‪‬ﺴﺘﻌﻤل ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ﺩﻭﻜﺴﻴﺴﻴﻜﻠﻴﻥ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ ‪ ٢٥ +‬ﻤﻠﻐﻡ‪.‬‬
‫ﺴﻠﻔﺎﺩﻭﻜﺴﻴﻥ ‪ +‬ﺒﻴﺭﻴﻤﻴﺜﺎﻤﻴﻥ*‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ‪ ٥٠‬ﻤﻠﻐﻡ ﻤﻥ ﺍﻷﺭﺘﻴﺴﻭﻨﺎﺕ‪.‬‬
‫‪ ٢-٣-٥-٦‬ﻟﻼﺘﻘﺎﺀ‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻓﻭﺴﻔﺎﺕ ﺃﻭ ﻜﺒﺭﻴﺘﺎﺕ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻓﻭﺴﻔﺎﺕ ﺃﻭ ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬
‫ﻜﻠﻭﺭﻭﻜﻴﻥ*‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﻤﻨﺎﻁﻕ ﺃﻤﺭﻴﻜﺎ ﺍﻟﻭﺴﻁﻰ ﻭﻟﻠﻌﻼﺝ ﻤﻥ ﺍﻟﻤﺘـﺼﻭﺭﺓ‬
‫ﺍﻟﻨﺸﻴﻁﺔ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺩﻭﻜﺴﻴﺴﻴﻜﻠﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﻤﻔﻠﻭﻜﻴﻥ‬

‫‪EML 15‬‬ ‫‪page - 14‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬

‫ﺒﺭﻭﻏﺎﻨﻴل*‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﺘﻭﻟﻴﻔﺔ ﻤﻊ ﺍﻟﻜﻠﻭﺭﻭﻜﻴﻥ‪.‬‬
‫‪ ٤-٥-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﺩﺍﺀ ﺍﻟﻤﺘﻜﻴ‪‬ﺴﺎﺕ ﺍﻟﺭﺌﻭﻴﺔ ﻭﺍﻟﻤﻀﺎﺩﺓ ﻟﺩﺍﺀ ﺍﻟﻤﻘﻭ‪‬ﺴﺎﺕ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﻴﺭﻴﻤﻴﺜﺎﻤﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ٨٠ :‬ﻤﻠﻐﻡ ‪ ١٦ +‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟـﺔ ﺴـﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘـﺭ‪،‬‬
‫ﺴﻠﻔﺎﻤﻴﺜﻭﻜﺴﺎﺯﻭل ‪ +‬ﺘﺭﻴﻤﻴﺜﻭﺒﺭﻴﻡ‬
‫‪ ٨٠‬ﻤﻠﻐﻡ ‪ ١٦ +‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ ٣٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﻨﺘﺎﻤﻴﺩﻴﻥ‬
‫‪ ٥-٥-٦‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻤﺜﻘﺒﻴﺎﺕ‬
‫‪ ١-٥-٥-٦‬ﺩﺍﺀ ﺍﻟﻤﺜﻘﺒﻴﺎﺕ ﺍﻷﻓﺭﻴﻘﻲ‬
‫ﺃﺩﻭﻴﺔ ﺍﻟﻌﻼﺝ ﻓﻲ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻷﻭﻟﻰ ﻤﻥ ﺩﺍﺀ ﺍﻟﻤﺜﻘﺒﻴﺎﺕ ﺍﻷﻓﺭﻴﻘﻲ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٠٠ :‬ﻤﻠﻐﻡ )ﺇﺴﻴﺘﻴﻭﻨﺎﺕ ﺍﻟﺒﻨﺘﺎﻤﻴﺩﻴﻥ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺒﻨﺘﺎﻤﻴﺩﻴﻥ*‬
‫* ﻴﺴﺘﻌﻤل ﻟﻠﻌﻼﺝ ﻤﻥ ﺍﻟﻌﺩﻭﻯ ﺒﺎﻟﻤﺜﻘﺒﻴﺎﺕ ﺍﻟﺒﺭﻭﺴﻴﺔ ﺍﻟﻐﺎﻤﺒﻴﺔ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١ :‬ﻍ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫* ﻻ ﻴﺴﺘﻌﻤل ﺇﻻ ﻓﻲ ﺍﻟﻌﻼﺝ ﻤﻥ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻷﻭﻟﻴﺔ ﻤﻥ ﺍﻟﻌﺩﻭﻯ ﺒﺎﻟﻤﺜﻘﺒﻴﺎﺕ‬ ‫ﺼﻭﺩﻴﻭﻡ ﺍﻟﺴﻭﺭﺍﻤﻴﻥ*‬
‫ﺍﻟﺒﺭﻭﺴﻴﺔ ﺍﻟﺭﻭﺩﻴﺴﻴﺔ‪.‬‬
‫ﺃﺩﻭﻴﺔ ﺍﻟﻌﻼﺝ ﻓﻲ ﺍﻟﻤﺭﺤﻠﺔ ﺍﻟﺜﺎﻨﻴﺔ ﻤﻥ ﺩﺍﺀ ﺍﻟﻤﺜﻘﺒﻴﺎﺕ ﺍﻷﻓﺭﻴﻘﻲ‬
‫ﺤﻘﻨﺔ‪ ٢٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗـﺎﺭﻭﺭﺓ ﺴـﻌﺔ ‪١٠٠‬‬
‫ﺇﻓﻠﻭﺭﻨﻴﺜﻴﻥ‬
‫ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ :‬ﻤﺤﻠﻭل ‪ ،٪٣,٦‬ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘـﺭ )‪ ١٨٠‬ﻤﻠﻐـﻡ ﻤـﻥ‬
‫ﻤﻴﻼﺭﺴﻭﺒﺭﻭل‬
‫ﺍﻟﻤﺭﻜﺏ ﺍﻟﻔﻌﺎل(‪.‬‬
‫‪ ٢-٥-٥-٦‬ﺩﺍﺀ ﺍﻟﻤﺜﻘﺒﻴﺎﺕ ﺍﻷﻤﺭﻴﻜﻲ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﻨﺯﻨﻴﺩﺍﺯﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠ :‬ﻤﻠﻐﻡ‪ ١٢٠ ،‬ﻤﻠﻐﻡ‪ ٢٥٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻨﻴﻔﻭﺭﺘﻴﻤﻭﻜﺱ‬
‫‪ -٧‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺸﻘﻴﻘﻪ )ﺍﻟﺼﺩﺍﻉ ﺍﻟﻨﺼﻔﻲ(‬
‫‪ ١-٧‬ﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻨﻭﺒﺎﺕ ﺍﻟﺤﺎﺩﺓ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠-٣٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺤﻤﺽ ﺃﺴﻴﺘﻴل ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠-٣٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺒﺎﺭﺍﺴﻴﺘﺎﻤﻭل‬

‫‪EML 15‬‬ ‫‪page - 15‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٢-٧‬ﻟﻼﺘﻘﺎﺀ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠ :‬ﻤﻠﻐﻡ‪ ٤٠ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫… ﺒﺭﻭﺒﺭﺍﻨﻭﻟﻭل‬
‫‪ -٨‬ﻤﻀﺎﺩﺍﺕ ﺍﻷﻭﺭﺍﻡ‪ ،‬ﻭﻜﺎﺒﺘﺎﺕ ﺍﻟﻤﻨﺎﻋﺔ‪ ،‬ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﻤﻠﻁﹼﻔﺔ‬
‫‪ ١-٨‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻜﺎﺒﺘﺔ ﻟﻠﻤﻨﺎﻋﺔ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺃﺯﺍﺜﻴﻭﺒﺭﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺭﻜﺎﺯﺓ ﻟﻠﺤﻘﻥ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘـﺭ ﻟـﺯﺭﻉ‬ ‫ﺴﻴﻜﻠﻭﺴﺒﻭﺭﻴﻥ‬
‫ﺍﻷﻋﻀﺎﺀ‪.‬‬
‫‪ ٢-٨‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﺴﺎﻤﺔ ﻟﻠﺨﻼﻴﺎ‬
‫ﻤﻥ ﺍﻟﻤﻨﺘﻅﺭ ﺍﺴﺘﻌﺭﺍﺽ ﻫﺫﺍ ﺍﻟﻔﺭﻉ ﻓﻲ ﺍﻻﺠﺘﻤﺎﻉ ﺍﻟﻘﺎﺩﻡ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺃﺴﺒﺎﺭﺍﺠﻴﻨﺎﺯ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٥ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺒﻠﻴﻭﻤﻴﺴﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ٣ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻓﻭﻟﻴﻨﺎﺕ ﺍﻟﻜﺎﻟﺴﻴﻭﻡ‬
‫ﺃﻗﺭﺍﺹ‪ ١٥ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻜﻠﻭﺭﺍﻤﺒﻭﺴﻴل‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٥٠ ،‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﻴﺴﺒﻼﺘﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺴﻴﻜﻠﻭﻓﻭﺴﻔﺎﻤﻴﺩ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﻴﺘﺎﺭﺍﺒﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺩﺍﻜﺎﺭﺒﺎﺯﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺩﺍﻜﺘﻴﻨﻭﻤﻴﺴﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺩﺍﻭﻨﻭﺭﻭﺒﻴﺴﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٥٠ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺩﻭﻜﺴﻭﺭﻭﺒﻴﺴﻴﻥ‬

‫‪EML 15‬‬ ‫‪page - 16‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻜﺒﺴﻭﻻﺕ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬

‫ﺇﻴﺘﻭﺒﻭﺴﻴﺩ‬
‫ﺤﻘﻨﺔ‪ ٢٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻓﻠﻭﺭﻭﻴﻭﺭﺍﺴﻴل‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻤﻴﺭﻜﺎﺒﺘﻭﺒﻭﺭﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﻤﻴﺜﻭﺘﺭﻜﺴﺎﺕ‬
‫ﺃﻗﺭﺍﺹ‪ ٢‚٥ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺒﺭﻭﻜﺎﺭﺒﺎﺯﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﻓﻴﻨﺒﻼﺴﺘﻴﻥ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١ :‬ﻤﻠﻐﻡ‪ ٥ ،‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﻓﻴﻨﻜﺭﻴﺴﺘﻴﻥ‬
‫‪ ٣-٨‬ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﻭﻤﻀﺎﺩﺍﺕ ﺍﻟﻬﺭﻤﻭﻨﺎﺕ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٤ :‬ﻤﻠﻐﻡ ﻤﻥ ﻓﻭﺴﻔﺎﺕ ﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ )ﻋﻠﻰ ﺸـﻜل ﻤﻠـﺢ ﺜﻨـﺎﺌﻲ‬
‫ﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ‬
‫ﺍﻟﺼﻭﺩﻴﻭﻡ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺴﻜﺴﻴﻨﺎﺕ ﺍﻟـﺼﻭﺩﻴﻭﻡ( ﻓـﻲ‬
‫ﻫﻴﺩﺭﻭﻜﻭﺭﺘﻴﺯﻭﻥ‬
‫ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪ ٢٥ ،‬ﻤﻠﻐﻡ‪.‬‬
‫* ﻻ ﻴﻭﺠﺩ ﺃﻱ ﺩﻟﻴل ﻋﻠﻰ ﺍﻟﺘﻤﺎﺜل ﺍﻟﺴﺭﻴﺭﻱ ﺍﻟﺘﺎﻡ ﺒـﻴﻥ ﺍﻟﺒﺭﻴـﺩﻨﻴﺯﻭﻟﻭﻥ‬ ‫… ﺒﺭﻴﺩﻨﻴﺯﻭﻟﻭﻥ*‬
‫ﻭﺍﻟﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ ﻋﻨﺩ ﺇﻋﻁﺎﺌﻬﻤﺎ ﺒﺠﺭﻋﺎﺕ ﻜﺒﻴﺭﺓ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٢٠ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﺴﻴﺘﺭﺍﺕ(‪.‬‬ ‫ﺘﺎﻤﻭﻜﺴﻴﻔﻴﻥ‬
‫‪ ٤-٨‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﻤﻠﻁﹼﻔﺔ‬
‫ﺘﻘﺭ ﻟﺠﻨﺔ ﺍﻟﺨﺒﺭﺍﺀ ﺍﻟﺘﺎﺒﻌﺔ ﻟﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺒﺄﻫﻤﻴﺔ ﺇﺩﺭﺍﺝ ﺃﺩﻭﻴﺔ ﻤﺤﺩﺩﺓ ﻓﻲ ﺍﻟﻔـﺭﻉ ﺍﻟﺨـﺎﺹ ﺒﺎﻟﺭﻋﺎﻴـﺔ‬
‫ﺍﻟﻤﻠﻁﻔﺔ‪ .‬ﻭﺒﻌﺽ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﺘﹸﺴﺘﻌﻤل ﺤﺎﻟﻴﺎﹰ ﻓﻲ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﻤﻠﻁﻔﺔ ﻤﺩﺭﺝ ﺒﺎﻟﻔﻌل ﻓﻲ ﺍﻟﻔﺭﻭﻉ ﺫﺍﺕ ﺍﻟـﺼﻠﺔ ﻤـﻥ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‪ ،‬ﺤﺴﺏ ﺍﺴﺘﻌﻤﺎﻟﻬﺎ ﺍﻟﻌﻼﺠﻲ‪ ،‬ﻤﺜل ﺍﻟﻤﺴﻜﻨﺎﺕ‪ .‬ﻭﻴﻠﺯﻡ ﺘﺤﺩﻴﺙ ﺍﻟﻤﺒـﺎﺩﺉ ﺍﻟﺘﻭﺠﻴﻬﻴـﺔ ﺍﻟﺨﺎﺼـﺔ‬
‫ﺒﺎﻟﺭﻋﺎﻴﺔ ﺍﻟﻤﻠﻁﻔﺔ ﺍﻟﻤﺸﺎﺭ ﺇﻟﻴﻬﺎ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺴﺎﺒﻘﺔ‪ .‬ﻭﺘﺘﻭﻗﻊ ﺍﻟﻠﺠﻨﺔ ﺘﻘﺩﻴﻡ ﻁﻠﺒﺎﺕ ﺒﺨﺼﻭﺹ ﺍﻷﺩﻭﻴﺔ ﺍﻟﻼﺯﻤﺔ ﻤـﻥ‬
‫ﺃﺠل ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﻤﻠﻁﻔﺔ ﻻﺠﺘﻤﺎﻋﻬﺎ ﺍﻟﻘﺎﺩﻡ‪.‬‬
‫‪ -٩‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺒﺎﺭﻜﻴﻨﺴﻭﻨﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٥ :‬ﻤﻠﻐﻡ )ﻻﻜﺘﺎﺕ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺒﻴﺒﻴﺭﺩﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٢ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ ‪ ١٠ +‬ﻤﻠﻐﻡ‪ ٢٥٠ ،‬ﻤﻠﻐﻡ ‪ ٢٥ +‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻟﻴﻔﻭﺩﻭﺒﺎ ‪ … +‬ﻜﺎﺭﺒﻴﺩﻭﺒﺎ‬

‫‪EML 15‬‬ ‫‪page - 17‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -١٠‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﺘﺅﺜﺭ ﻋﻠﻰ ﺍﻟﺩﻡ‬

‫‪ ١-١٠‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻔﻘﺭ ﺍﻟﺩﻡ‬
‫ﺸﺭﺍﺏ‪ :‬ﻤﻜﺎﻓﺊ ﻟـ ‪ ٢٥‬ﻤﻠﻐﻡ ﻤﻥ ﺍﻟﺤﺩﻴﺩ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﻠﺢ ﺍﻟﺤﺩﻴﺩﻭﺯ‬
‫ﺃﻗﺭﺍﺹ‪ :‬ﻤﻜﺎﻓﺌﺔ ﻟـ ‪ ٦٠‬ﻤﻠﻐﻡ ﻤﻥ ﺍﻟﺤﺩﻴﺩ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ :‬ﻤﻜﺎﻓﺌﺔ ﻟـ ‪ ٦٠‬ﻤﻠﻐـﻡ ﻤـﻥ ﺍﻟﺤﺩﻴـﺩ ‪ ٤٠٠ +‬ﻤﻴﻜﺭﻭﻏـﺭﺍﻡ‬
‫ﻤﻠﺢ ﺍﻟﺤﺩﻴﺩﻭﺯ ‪ +‬ﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ‬
‫ﻤﻥ ﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ ) ﺘﻜﻤﻠﺔ ﺘﻐﺫﻭﻴﺔ ﺘﺴﺘﻌﻤل ﺃﺜﻨﺎﺀ ﺍﻟﺤﻤل(‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ١ :‬ﻤﻠﻐﻡ‪ ٥ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ‬
‫ﺤﻘﻨﺔ‪ ١ :‬ﻤﻠﻐﻡ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻫﻴﺩﺭﻭﻜﺴﻭﻜﻭﺒﺎﻻﻤﻴﻥ‬
‫‪ ٢-١٠‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﺘﺅﺜﺭ ﻋﻠﻰ ﺍﻟﺘﺨﺜﹼﺭ‬
‫ﺤﻘﻨﺔ‪ ١٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪ ٥٠٠٠ ،‬ﻭﺤﺩﺓ ﺩﻭﻟﻴـﺔ‪ /‬ﻤﻴﻠﻴﻠﺘـﺭ‪،‬‬
‫ﺼﻭﺩﻴﻭﻡ ﺍﻟﻬﻴﺒﺎﺭﻴﻥ‬
‫‪ ٢٠ ٠٠٠‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻓﻴﺘﻭﻤﻴﻨﺎﺩﻴﻭﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺒﺭﻭﺘﺎﻤﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١ :‬ﻤﻠﻐﻡ‪ ٢ ،‬ﻤﻠﻐﻡ‪ ٥ ،‬ﻤﻠﻐﻡ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬ ‫… ﻭﺍﺭﻓﺎﺭﻴﻥ‬
‫‪ -١١‬ﻤﻨﺘﺠﺎﺕ ﺍﻟﺩﻡ ﻭﺃﺒﺩﺍل ﺍﻟﺒﻼﺯﻤﺎ‬
‫‪ ١-١١‬ﺃﺒﺩﺍل ﺍﻟﺒﻼﺯﻤﺎ‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪.٪٦ :‬‬
‫* ﻴ‪‬ﻌﺘﺒﺭ ﺩﻭﺍﺀ ﺒﻭﻟﻴﺠﻴﻠﻴﻥ‪ ،‬ﻋﻠﻰ ﺸﻜل ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪ ٪٣,٥ ،‬ﻤﻜﺎﻓﺌﹰﺎ‬ ‫… ﺩﻜﺴﺘﺭﺍﻥ ‪*٧٠‬‬
‫ﻟﻪ‪.‬‬
‫‪ ٢-١١‬ﺃﺠﺯﺍﺀ ﺍﻟﺒﻼﺯﻤﺎ ﻻﺴﺘﻌﻤﺎﻻﺕ ﻤﺤﺩﺩﺓ‬
‫ﻴﺘﻌﻴﻥ ﺃﻥ ﺘﻔﻲ ﻜل ﺃﺠﺯﺍﺀ ﺍﻟﺒﻼﺯﻤﺎ ﺒﺎﺸﺘﺭﺍﻁﺎﺕ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﻟﺘﺠﻤﻴﻊ‪ ،‬ﻭﺘﺠﻬﻴﺯ ﻭﻤﺭﺍﻗﺒـﺔ ﺠـﻭﺩﺓ ﺍﻟـﺩﻡ‪،‬‬
‫ﻭﻤﻜﻭﻨﺎﺕ ﺍﻟﺩﻡ‪ ،‬ﻭﻤﺸﺘﻘﺎﺕ ﺍﻟﺒﻼﺯﻤﺎ )ﺍﻟﻨﺴﺨﺔ ﺍﻟﻤﻨﻘﺤﺔ ﻋﺎﻡ ‪) .(١٩٩٢‬ﺴﻠﺴﻠﺔ ﺍﻟﺘﻘـﺎﺭﻴﺭ ﺍﻟﺘﻘﻨﻴـﺔ ﻟﻤﻨﻅﻤـﺔ ﺍﻟـﺼﺤﺔ‬
‫ﺍﻟﻌﺎﻟﻤﻴﺔ‪ ،‬ﺭﻗﻡ ‪ ،١٩٩٤ ،٨٤٠‬ﺍﻟﻤﻠﺤﻕ ‪.(٢‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻓﻲ ﺍﻟﻌﻀل‪ :‬ﻤﺤﻠﻭل ﺒﺭﻭﺘﻴﻨﻲ ‪.٪١٦‬‬
‫ﻏﻠﻭﺒﻭﻟﻴﻥ ﻤﻨﺎﻋﻲ ﻋﺎﺩﻱ ﺒﺸﺭﻱ‬
‫ﻓﻲ ﺍﻟﻭﺭﻴﺩ‪ :‬ﻤﺤﻠﻭل ﺒﺭﻭﺘﻴﻨﻲ ‪.٪١٠ ،٪٥‬‬

‫‪EML 15‬‬ ‫‪page - 18‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺠﻔﻔﺔ‪.‬‬ ‫… ﺭﻜﺎﺯﺓ ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ‬

‫… ﺭﻜﺎﺯﺓ ﻤﺭﻜﺏ ﺍﻟﻌﺎﻤل ﺍﻟﺘﺎﺴﻊ‬
‫)ﻋﻭﺍﻤــل ﺍﻟﺘﺨﺜــﺭ‪ ،‬ﺍﻟﺜــﺎﻨﻲ ﻤﺠﻔﻔﺔ‪.‬‬
‫ﻭﺍﻟﺴﺎﺒﻊ ﻭﺍﻟﺘﺎﺴﻊ ﻭﺍﻟﻌﺎﺸﺭ(‬
‫‪ -١٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﺍﻟﻭﻋﺎﺌﻴﺔ‬
‫‪ ١-١٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺫﺒﺤﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺃﺘﻴﻨﻭﻟﻭل‬
‫ﺃﻗﺭﺍﺹ )ﺘﺤﺕ ﺍﻟﻠﺴﺎﻥ(‪ ٥٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬ ‫ﺜﻼﺜﻲ ﻨﺘﺭﺍﺕ ﺍﻟﻐﻠﻴﺴﻴﺭﻴل‬
‫ﺃﻗﺭﺍﺹ )ﺘﺤﺕ ﺍﻟﻠﺴﺎﻥ(‪ ٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺜﻨﺎﺌﻲ ﻨﺘﺭﺍﺕ ﺍﻷﻴﺯﻭﺴﻭﺭﺒﻴﺩ‬
‫ﺃﻗﺭﺍﺹ‪ ٤٠ :‬ﻤﻠﻐﻡ‪ ٨٠ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﻓﻴﺭﺍﺒﺎﻤﻴل‬
‫‪ ٢-١٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻻﻀﻁﺭﺍﺏ ﺍﻟﻨﻅﻡ‬
‫ﺴﻴﺠﺭﻱ ﺍﺴﺘﻌﺭﺍﺽ ﻫﺫﺍ ﺍﻟﻘﺴﻡ ﺍﻟﻔﺭﻋﻲ ﻓﻲ ﺍﻻﺠﺘﻤﺎﻉ ﺍﻟﻘﺎﺩﻡ ﻟﻠﺠﻨﺔ ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺃﺘﻴﻨﻭﻟﻭل‬
‫ﺤﻘﻨﺔ‪ ٢٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺩﻴﻐﻭﻜﺴﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٦٢‚٥ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ ٢٥٠ ،‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ )ﻋﻠﻰ ﺸﻜل ﻁﺭﻁﺭﺍﺕ ﺤﻤـﻀﻴﺔ ﺃﻭ‬
‫ﺇﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ(‬
‫ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﻭﺭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻟﻴﺩﻭﻜﺎﻴﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ٢‚٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻓﻴﺭﺍﺒﺎﻤﻴل‬
‫ﺃﻗﺭﺍﺹ‪ ٤٠ :‬ﻤﻠﻐﻡ‪ ٨٠ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘـﺭ ﻓـﻲ ﺃﻤﺒﻭﻟـﺔ ﺴـﻌﺔ ‪١٠‬‬ ‫ﺒﺭﻭﻜﺎﻴﻨﺎﻤﻴﺩ‬ ‫…‬

‫ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ )ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬ ‫… ﻜﻴﻨﻴﺩﻴﻥ‬
‫‪ ٣-١٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻔﺭﻁ ﻀﻐﻁ ﺍﻟﺩﻡ‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﻤﻠﻭﺩﻴﺒﻴﻥ‬ ‫…‬

‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪ ١٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺃﺘﻴﻨﻭﻟﻭل‬

‫ﺃﻗﺭﺍﺹ‪ ٢‚٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺇﻴﻨﺎﻻﺒﺭﻴل‬

‫‪EML 15‬‬ ‫‪page - 19‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ٢٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ‪.‬‬

‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ‪ ٥٠ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫* ﺍﻟﻬﻴﺩﺭﺍﻻﺯﻴﻥ ﻤﺩﺭﺝ ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﺍﻟﺘﺩﺒﻴﺭ ﺍﻟﻌﻼﺠﻲ ﺍﻟﺤـﺎﺩ ﻟﻔـﺭﻁ‬ ‫ﻫﻴﺩﺭﺍﻻﺯﻴﻥ*‬
‫ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﻭﺨﻴﻡ ﺍﻟﻨﺎﺠﻡ ﻋﻥ ﺍﻟﺤﻤل ﻓﻘﻁ‪ .‬ﻭﻻ ﻴﻭﺼﻰ ﺒﺎﺴﺘﻌﻤﺎﻟﻪ ﻓـﻲ‬
‫ﻋﻼﺝ ﻓﺭﻁ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻷﺴﺎﺴﻲ‪ ،‬ﻭﺫﻟﻙ ﻨﻅﺭﹰﺍ ﻟﺘﻭﺍﻓﺭ ﺃﺩﻟﺔ ﺃﻜﺜﺭ ﻋﻠـﻰ‬
‫ﻨﺠﺎﻋﺔ ﻭﻤﺄﻤﻭﻨﻴﺔ ﺃﺩﻭﻴﺔ ﺃﺨﺭﻯ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯﺓ(‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻭﺜﻴﺎﺯﻴﺩ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﺩﻭﺍﺀ ﻤﻴﺜﻴل ﺩﻭﺒﺎ ﻤﺩﺭﺝ ﻟﻼﺴﺘﻌﻤﺎل ﻓﻲ ﺍﻟﺘﺩﺒﻴﺭ ﺍﻟﻌﻼﺠﻲ ﻟﻔﺭﻁ ﻀﻐﻁ‬
‫ﺍﻟﺩﻡ ﺍﻟﻨﺎﺠﻡ ﻋﻥ ﺍﻟﺤﻤل ﻓﻘﻁ‪ .‬ﻭﻻ ﻴﻭﺼﻰ ﺒﺎﺴﺘﻌﻤﺎﻟﻪ ﻓﻲ ﻤﻌﺎﻟﺠـﺔ ﻓـﺭﻁ‬ ‫ﻤﻴﺜﻴل ﺩﻭﺒﺎ*‬
‫ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻷﺴﺎﺴﻲ‪ ،‬ﻭﺫﻟﻙ ﻨﻅﺭﹰﺍ ﻟﺘﻭﺍﻓﺭ ﺃﺩﻟـﺔ ﺃﻜﺜـﺭ ﻋﻠـﻰ ﻨﺠﺎﻋـﺔ‬
‫ﻭﻤﺄﻤﻭﻨﻴﺔ ﺃﺩﻭﻴﺔ ﺃﺨﺭﻯ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﻨﻘﻊ‪ ٥٠ :‬ﻤﻠﻐﻡ ﻓﻲ ﺃﻤﺒﻭﻟﺔ‪.‬‬ ‫ﻨﺘﺭﻭﺒﺭﻭﺴﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫‪ ٤-١٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻟﻌﻼﺝ ﻗﺼﻭﺭ ﺍﻟﻘﻠﺏ‬
‫ﺴﻴﺠﺭﻱ ﺍﺴﺘﻌﺭﺍﺽ ﻫﺫﺍ ﺍﻟﻘﺴﻡ ﺍﻟﻔﺭﻋﻲ ﻓﻲ ﺍﻻﺠﺘﻤﺎﻉ ﺍﻟﻘﺎﺩﻡ ﻟﻠﺠﻨﺔ ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺩﻴﻐﻭﻜﺴﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٦٢‚٥ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ ٢٥٠ ،‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢‚٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺇﻴﻨﺎﻻﺒﺭﻴل‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻓﻭﺭﻭﺴﻴﻤﻴﺩ‬ ‫…‬
‫ﺃﻗﺭﺍﺹ‪ ٤٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯﺓ(‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻭﺜﻴﺎﺯﻴﺩ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٤٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺩﻭﺒﺎﻤﻴﻥ‬
‫‪ ٥-١٢‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺨﺜﺎﺭ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺤﻤﺽ ﺃﺴﻴﺘﻴل ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ‬

‫‪EML 15‬‬ ‫‪page - 20‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١‚٥ :‬ﻤﻠﻴﻭﻥ ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺴﺘﺭﻴﺒﺘﻭﻜﻴﻨﺎﺯ‬
‫‪ ٦-١٢‬ﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﺨﻔﻀﺔ ﻟﻠﺸﺤﻭﻡ‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪ ١٠ ،‬ﻤﻠﻐﻡ‪ ٢٠ ،‬ﻤﻠﻐﻡ‪ ٤٠ ،‬ﻤﻠﻐﻡ‪.‬‬
‫ﺴﻴﻤﻔﺎﺴﺘﺎﺘﻴﻥ*‬ ‫…‬
‫* ﻴ‪‬ﺴﺘﻌﻤل ﻤﻊ ﺍﻟﻤﺭﻀﻰ ﺍﻟﻤﻌﺭﻀﻴﻥ ﻟﻤﺨﺎﻁﺭ ﺸﺩﻴﺩﺓ‪.‬‬
‫‪ -١٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﺠﻠﺩﻴﺔ )ﻤﻭﻀﻌﻴﺔ(‬
‫‪ ١-١٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻁﺭﻴﺎﺕ‬
‫ﻤﺭﻫﻡ ﺃﻭ ﻜﺭﻴﻡ‪.٪٣ + ٪٦ :‬‬ ‫ﺤﻤﺽ ﺍﻟﺒﻨﺯﻭﻴﻙ ‪ +‬ﺤﻤﺽ ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ‬
‫ﻤﺭﻫﻡ ﺃﻭ ﻜﺭﻴﻡ‪) ٪٢ :‬ﻨﺘﺭﺍﺕ(‪.‬‬ ‫… ﻤﻴﻜﻭﻨﺎﺯﻭل‬
‫ﻤﺤﻠﻭل‪.٪١٥ :‬‬ ‫ﺜﻴﻭﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺴﺘﻌﻠﻕ ﻗﺎﺌﻡ ﻋﻠﻰ ﻤﺎﺩﺓ ﻤﻨﻅﻔﺔ‪.٪٢ :‬‬ ‫ﺴﻠﻔﻴﺩ ﺍﻟﺴﻴﻠﻴﻨﻴﻭﻡ‬
‫‪ ٢-١٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻌﺩﻭﻯ‬
‫… ﻜﻠﻭﺭﻴــﺩ ﺍﻟﻤﻴﺜﻴــل ﺭﻭﺯﺍﻨﻴﻠﻴﻨﻴــﻭﻡ ﻤﺤﻠﻭل ﻤﺎﺌﻲ‪.٪٠‚٥ :‬‬
‫ﺼﺒﻐﺔ ﻜﺤﻭﻟﻴﺔ‪.٪٠‚٥ :‬‬ ‫)ﺒﻨﻔﺴﺠﻲ ﺍﻟﺠﻨﻁﻴﺎﻥ(‬

‫ﻤﺭﻫﻡ‪ ٥ :‬ﻤﻠﻐﻡ ﻤﻥ ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻨﻴﻭﻤﻴﺴﻴﻥ ‪ ٢٥٠ +‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ ﻤﻥ ﺯﻨﻙ‬

‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻨﻴﻭﻤﻴﺴﻴﻥ ‪ … +‬ﺒﺎﺴﻴﺘﺭﺍﺴﻴﻥ‬
‫ﺍﻟﺒﺎﺴﻴﺘﺭﺍﺴﻴﻥ‪ /‬ﻍ‪.‬‬
‫ﻤﺤﻠﻭل ﻤﺎﺌﻲ‪.١٠ ٠٠٠:١ :‬‬ ‫ﺒﺭﻤﻨﻐﻨﺎﺕ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ‬
‫ﻜﺭﻴﻡ‪ ،٪١ :‬ﻓﻲ ﻭﻋﺎﺀ ﺴﻌﺔ ‪ ٥٠٠‬ﻍ‪.‬‬ ‫ﺴﻠﻔﺎﺩﻴﺎﺯﻴﻥ ﺍﻟﻔﻀﺔ‬
‫‪ ٣-١٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺒﺎﺕ ﻭﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺤﻜﺔ‬
‫ﻤﺭﻫﻡ ﺃﻭ ﻜﺭﻴﻡ‪) ٪٠‚١ :‬ﻋﻠﻰ ﺸﻜل ﻓﺎﻟﻴﺭﺍﺕ(‪.‬‬ ‫… ﺒﻴﺘﺎﻤﻴﺜﺎﺯﻭﻥ‬
‫ﻏﺴﻭل‪.‬‬ ‫… ﻏﺴﻭل ﺍﻟﻜﺎﻻﻤﻴﻥ‬
‫ﻤﺭﻫﻡ ﺃﻭ ﻜﺭﻴﻡ‪) ٪١ :‬ﺃﺴﻴﺘﺎﺕ(‪.‬‬ ‫… ﻫﻴﺩﺭﻭﻜﻭﺭﺘﻴﺯﻭﻥ‬
‫‪ ٤-١٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻘﺎﺒﻀﺔ‬
‫ﻤﺤﻠﻭل‪.٪٥ :‬‬ ‫ﺜﺎﻨﻲ ﺃﺴﻴﺘﺎﺕ ﺍﻷﻟﻭﻤﻴﻨﻴﻭﻡ‬
‫‪ ٥-١٣‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺅﺜﺭﺓ ﻋﻠﻰ ﺘﻤﺎﻴﺯ ﻭﺘﻜﺎﺜﺭ ﺍﻷﻨﺴﺠﺔ ﺍﻟﺠﻠﺩﻴﺔ‬
‫ﻏﺴﻭل ﺃﻭ ﻜﺭﻴﻡ‪.٪٥ :‬‬ ‫ﺒﻨﺯﻭﻴل ﺒﺭﻭﻜﺴﺎﻴﺩ‬
‫ﻤﺤﻠﻭل‪.٪٥ :‬‬ ‫ﻗﻁﺭﺍﻥ ﺍﻟﻔﺤﻡ‬

‫‪EML 15‬‬ ‫‪page - 21‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺭﻫﻡ‪.٪٢-٪٠‚١ :‬‬ ‫ﺩﻴﺜﺭﺍﻨﻭل‬

‫ﻤﺭﻫﻡ‪.٪٥ :‬‬ ‫ﻓﻠﻭﺭﻭﺭﺍﺴﻴل‬
‫ﻤﺤﻠﻭل‪.٪٢٥-١٠ :‬‬ ‫… ﺭﺍﺘﻴﻥ ﺠﺫﺭ ﺍﻟﻴﺒﺭﻭﺡ‬
‫ﻤﺤﻠﻭل‪.٪٥ :‬‬ ‫ﺤﻤﺽ ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ‬
‫ﻤﺭﻫﻡ ﺃﻭ ﻜﺭﻴﻡ‪.٪١٠ :‬‬ ‫ﻴﻭﺭﻴﺎ‬
‫‪ ٦-١٣‬ﻤﺒﻴﺩﺍﺕ ﺍﻟﺠﺭﺏ ﻭﻤﺒﻴﺩﺍﺕ ﺍﻟﻘﻤل‬
‫ﻏﺴﻭل‪.٪٢٥ :‬‬ ‫… ﺒﻨﺯﻭﺍﺕ ﺍﻟﺒﻨﺯﻴل‬
‫ﻜﺭﻴﻡ‪.٪٥ :‬‬
‫ﺒﻴﺭﻤﺜﺭﻴﻥ‬
‫ﻏﺴﻭل‪.٪١ :‬‬
‫‪ -١٤‬ﺍﻟﻌﻭﺍﻤل ﺍﻟﺘﺸﺨﻴﺼﻴﺔ‬
‫‪ ١-١٤‬ﺃﺩﻭﻴﺔ ﺍﻟﻌﻴﻥ‬
‫ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ‪) ٪١ :‬ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬ ‫ﻓﻠﻭﺭﻴﺴﻴﻥ‬
‫ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ‪.٪٠‚٥ :‬‬ ‫… ﺘﺭﻭﺒﻴﻜﺎﻤﻴﺩ‬
‫‪ ٢-١٤‬ﻭﺴﺎﺌﻁ ﺘﺒﺎﻴﻥ ﺍﻷﺸﻌﺔ‬
‫ﺤﻘﻨﺔ‪ ٤٢٠-١٤٠ :‬ﻤﻠﻐﻡ ﻤﻥ ﺍﻟﻴﻭﺩ )ﻋﻠﻰ ﺸـﻜل ﺼـﻭﺩﻴﻭﻡ ﺃﻭ ﻤﻠـﺢ‬
‫… ﺃﻤﻴﺩﻭﺘﺭﻴﺯﻭﺍﺕ‬
‫ﺍﻟﻤﻴﻐﻠﻭﻤﻴﻥ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺴﺘﻌﻠﻕ ﻤﺎﺌﻲ‪.‬‬ ‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺒﺎﺭﻴﻭﻡ‬
‫ﺤﻘﻨﺔ‪ ٣٥٠-١٤٠ :‬ﻤﻠﻐﻡ ﻤﻥ ﺍﻟﻴـﻭﺩ‪ /‬ﻤﻴﻠﻴﻠﺘـﺭ ﻓـﻲ ﺃﻤﺒـﻭﻻﺕ ﺴـﻌﺔ‬
‫… ﺃﻴﻭﻫﻴﻜﺴﻭل‬
‫‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪ ١٠ ،‬ﻤﻴﻠﻴﻠﺘﺭ‪ ٢٠ ،‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺤﻠﻭل‪ ٨-٥ :‬ﻍ ﻤﻥ ﺍﻟﻴﻭﺩ ﻓﻲ ‪ ٢٥٠-١٠٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﺃﻴﻭﺘﺭﻭﻜﺴﺎﺕ ﺍﻟﻤﻴﻐﻠﻭﻤﻴﻥ‬
‫‪ -١٥‬ﺍﻟﻤﻁﻬﺭﺍﺕ ﺍﻟﻤﺒﻴﺩﺓ ﻟﻠﺠﺭﺍﺜﻴﻡ ﻭﺍﻟﻤﻁﻬﺭﺍﺕ‬
‫‪ ١-١٥‬ﺍﻟﻤﻁﻬﺭﺍﺕ‬
‫ﻤﺤﻠﻭل‪) ٪٥ :‬ﺜﺎﻨﻲ ﺍﻟﻐﻠﻭﻜﻭﻨﺎﺕ( ﻟﻠﺘﺨﻔﻴﻑ‪.‬‬ ‫… ﻜﻠﻭﺭﻫﻴﻜﺴﻴﺩﻴﻥ‬
‫ﻤﺤﻠﻭل‪) ٪٧٠ :‬ﻤﺘﻤﺴﺦ(‪.‬‬ ‫… ﺇﻴﺜﺎﻨﻭل‬
‫ﻤﺤﻠﻭل‪.٪١٠ :‬‬ ‫… ﺒﻭﻟﻴﻔﻴﺩﻭﻥ ﺍﻟﻴﻭﺩ‬
‫‪ ٢-١٥‬ﺍﻟﻤﻁﻬﺭﺍﺕ ﺍﻟﻤﺒﻴﺩﺓ ﻟﻠﺠﺭﺍﺜﻴﻡ‬
‫ﻤﺴﺤﻭﻕ‪ ٪٠‚١) :‬ﻤﻥ ﺃﻱ ﻜﻠﻭﺭ ﻤﺘﻭﺍﻓﺭ( ﻹﻋﺩﺍﺩ ﻤﺤﻠﻭل‪.‬‬ ‫… ﻤﺭﻜﺏ ﻗﺎﺌﻡ ﻋﻠﻰ ﺍﻟﻜﻠﻭﺭ‬

‫‪EML 15‬‬ ‫‪page - 22‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺤﻠﻭل‪.٪٤‚٨ :‬‬ ‫… ﻜﻠﻭﺭﻭﻜﺴﻴﻠﻴﻨﻭل‬

‫ﻤﺤﻠﻭل‪.٪٢ :‬‬ ‫ﻏﻠﻭﺘﺎﺭﺍل‬
‫‪ -١٦‬ﻤﺩﺭﺍﺕ ﺍﻟﺒﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺃﻤﻴﻠﻭﺭﻴﺩ‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫… ﻓﻭﺭﻭﺴﻴﻤﻴﺩ‬
‫ﺃﻗﺭﺍﺹ‪ ٤٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯﺓ(‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻭﺜﻴﺎﺯﻴﺩ‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪.٪٢٠ ،٪١٠ :‬‬ ‫ﻤﺎﻨﻴﺘﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺴﺒﻴﺭﻭﻨﻭﻻﻜﺘﻭﻥ‬
‫‪ -١٧‬ﺍﻷﺩﻭﻴﺔ ﺍﻟ ‪‬ﻤﻌ‪‬ﺩﻴﺔ ﺍﻟﻤﻌﻭﻴﺔ‬
‫‪ ١-١٧‬ﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻤﻭﻀﺔ ﻭﺍﻷﺩﻭﻴﺔ ﺍﻷﺨﺭﻯ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻘﺭﺤﺔ‬
‫ﺸﺭﺍﺏ‪ ٣٢٠ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻫﻴﺩﺭﻭﻜﺴﻴﺩ ﺍﻷﻟﻭﻤﻴﻨﻴﻭﻡ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٥ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٧٥ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺭﺍﻨﻴﺘﻴﺩﻴﻥ‬ ‫…‬

‫ﺃﻗﺭﺍﺹ‪ ١٥٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬

‫ﺸﺭﺍﺏ‪ :‬ﻤﻜﺎﻓﺊ ﻟـ‪ ٥٥٠‬ﻤﻠﻐﻡ ﻤﻥ ﺃﻜﺴﻴﺩ ﺍﻟﻤﻐﻨﻴﺯﻴﻭﻡ‪ ١٠/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻫﻴﺩﺭﻭﻜﺴﻴﺩ ﺍﻟﻤﻐﻨﻴﺯﻴﻭﻡ‬
‫‪ ٢-١٧‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺘﻘﻴﺅ‬
‫ﺤﻘﻨﺔ‪ ٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﻴﺘﻭﻜﻠﻭﺒﺭﺍﻤﻴﺩ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺒﺭﻭﻤﻴﺜﺎﺯﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٢٥ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫‪ ٣-١٧‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺏ‬
‫ﺤﻘﻨﺔ ﺸﺭﺠﻴﺔ ﺍﺤﺘﺒﺎﺴﻴﺔ‪.‬‬
‫ﺘﺤﺎﻤﻴل‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺴﻠﻔﺎﺴﺎﻻﺯﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 23‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨـﺔ ﺸﺭﺠﻴـﺔ ﺍﺤﺘﺒﺎﺴﻴﺔ‪.‬‬
‫ﺘﺤﺎﻤﻴل‪ ٢٥ :‬ﻤﻠﻐﻡ )ﺃﺴﻴﺘﺎﺕ(‪.‬‬
‫… ﻫﻴﺩﺭﻭﻜﻭﺭﺘﻴﺯﻭﻥ‬
‫ﺇﻻ ﻋﻠﻰ ﺍﻟﻬﻴﺩﺭﻭﻜﻭﺭﺘﻴﺯﻭﻥ ﻓـﻲ ﺍﻟﺤﻘﻨـﺔ‬ ‫…‬ ‫)ﻻ ﻴﻨﻁﺒﻕ ﺍﻟﺭﻤﺯ ﺍﻟﻤﺭﺒﻊ‬
‫ﺍﻟﺸﺭﺠﻴﺔ ﺍﻻﺤﺘﺒﺎﺴﻴﺔ(‪.‬‬
‫‪ ٤-١٧‬ﺍﻟﻤﻠﻴ‪‬ﻨﺎﺕ‬
‫… ﺴﻨﺎ ﺴﻨﺎﻤﻜﻲ )ﺃﻭﺭﺍﻕ ﻨﺒـﺎﺕ ﺍﻟـﺴﻨﺎ ﺃﻗﺭﺍﺹ‪ ٧‚٥ :‬ﻤﻠﻐﻡ )ﺴﻴﻨﻭﺯﻴﺩ( )ﺃﻭ ﺃﺸﻜﺎل ﺍﻟﺠﺭﻋﺎﺕ ﺍﻟﺘﻘﻠﻴﺩﻴﺔ(‪.‬‬
‫ﺍﻟﺠﺎﻓﺔ(‬
‫‪ ٥-١٧‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻟﻌﻼﺝ ﻤﻥ ﺍﻹﺴﻬﺎل‬
‫‪ ١-٥-١٧‬ﺘﻌﻭﻴﺽ ﺍﻟﺴﻭﺍﺌل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ‬
‫‪ ٧٥‬ﻤﻴﻠﻲ ﻤﻜﺎﻓﺊ‬ ‫ﻏﻠﻭﻜﻭﺯ‪:‬‬
‫‪ ٧٥‬ﻤﻴﻠﻲ ﻤﻜﺎﻓﺊ ﺃﻭ ﻤﻴﻠﻴﻤﻭل‪ /‬ل‬ ‫ﺼﻭﺩﻴﻭﻡ‪:‬‬
‫‪ ٦٥‬ﻤﻴﻠﻲ ﻤﻜﺎﻓﺊ ﺃﻭ ﻤﻴﻠﻴﻤﻭل‪ /‬ل‬ ‫ﻜﻠﻭﺭﻴﺩ‪:‬‬
‫‪ ٢٠‬ﻤﻴﻠﻲ ﻤﻜﺎﻓﺊ ﺃﻭ ﻤﻴﻠﻴﻤﻭل‪ /‬ل‬ ‫ﺒﻭﺘﺎﺴﻴﻭﻡ‪:‬‬
‫‪ ١٠‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل‬ ‫ﺴﻴﺘﺭﺍﺕ‪:‬‬
‫ﺃﻤﻼﺡ ﺘﻌﻭﻴﺽ ﺍﻟﺴﻭﺍﺌل ﻋﻥ ﻁﺭﻴﻕ‬
‫‪ ٢٤٥‬ﻤﻴﻠﻲ ﺃﺴﻤﻭل‪ /‬ل‬ ‫ﺃﺴﻤﻭﻟﻴﺔ‪:‬‬
‫ﺍﻟﻔﻡ*‬
‫‪ ١٣‚٥‬ﻍ‪ /‬ل‬ ‫ﻏﻠﻭﻜﻭﺯ‪:‬‬
‫‪ ٢‚٦‬ﻍ‪ /‬ل‬ ‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ‪:‬‬
‫‪ ١‚٥‬ﻍ‪ /‬ل‬ ‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ‪:‬‬
‫ﺜﻨﺎﺌﻲ ﻫﻴﺩﺭﺍﺕ ﺍﻟﺴﻴﺘﺭﺍﺕ ﺍﻟﺜﻼﺜﻴﺔ‬
‫‪ ٢‚٩‬ﻍ‪ /‬ل‬ ‫ﺍﻟﺼﻭﺩﻴﻭﻡ ‪:+‬‬
‫‪ +‬ﻴﻤﻜﻥ ﺍﻻﺴﺘﻌﺎﻀﺔ ﻋﻥ ﺜﻨﺎﺌﻲ ﻫﻴﺩﺭﺍﺕ ﺍﻟﺴﻴﺘﺭﺍﺕ ﺍﻟﺜﻼﺜﻴﺔ ﺍﻟـﺼﻭﺩﻴﻭﻡ‬
‫ﺒﻜﺭﺒﻭﻨﺎﺕ ﻫﻴﺩﺭﻭﺠﻴﻥ ﺍﻟﺼﻭﺩﻴﻭﻡ )ﺒﻴﻜﺭﺒﻭﻨﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ( ‪ ٢‚٥‬ﻍ‪ /‬ل‪.‬‬
‫ﻏﻴﺭ ﺃﻥ ﺜﺒﺎﺕ ﻫﺫﻩ ﺍﻟﺘﺭﻜﻴﺒﺔ ﺍﻷﺨﻴﺭﺓ ﺴﻴﺊ ﺠـﺩﹰﺍ ﻓـﻲ ﻅـل ﺍﻟﻅـﺭﻭﻑ‬
‫ﺍﻟﻤﺩﺍﺭﻴﺔ‪ ،‬ﻭﻻ ﻴﻭﺼﻰ ﺒﻬﺎ ﺇﻻ ﻋﻨﺩﻤﺎ ﺘﺼﻨﻊ ﻟﻼﺴﺘﻌﻤﺎل ﺍﻟﻔﻭﺭﻱ‪.‬‬
‫* ﻓﻲ ﺤﺎﻟﺔ ﺍﻟﻜﻭﻟﻴﺭﺍ ﻗﺩ ﻴﻠﺯﻡ ﺘﺭﻜﻴﺯ ﺃﻋﻠﻰ ﻟﻠﺼﻭﺩﻴﻭﻡ‪.‬‬
‫‪ ٢-٥-١٧‬ﺃﺩﻭﻴﺔ ﺍﻟﻌﻼﺝ ﻤﻥ ﺍﻹﺴﻬﺎل ﻟﺩﻯ ﺍﻷﻁﻔﺎل‬
‫ﺸﺭﺍﺏ‪ :‬ﻓﻲ ﺸﻜل ﺠﺭﻋﺎﺕ ﻤﻘﺩﺍﺭ ﻜل ﻭﺤﺩﺓ ﻤﻨﻬﺎ ‪ ١٠‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ :‬ﻓﻲ ﺸﻜل ﺠﺭﻋﺎﺕ ﻤﻘﺩﺍﺭ ﻜل ﻭﺤﺩﺓ ﻤﻨﻬﺎ ‪ ١٠‬ﻤﻠﻐﻡ‪.‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺯﻨﻙ*‬
‫* ﻓﻲ ﺤﺎﻟﺔ ﺍﻹﺴﻬﺎل ﺍﻟﺤﺎﺩ ﻴﻨﺒﻐﻲ ﺍﺴﺘﻌﻤﺎل ﻜﺒﺭﻴﺘـﺎﺕ ﺍﻟﺯﻨـﻙ ﻜـﺩﻭﺍﺀ‬
‫ﻤﺴﺎﻋﺩ ﻷﻤﻼﺡ ﺘﻌﻭﻴﺽ ﺍﻟﺴﻭﺍﺌل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ‪.‬‬

‫‪EML 15‬‬ ‫‪page - 24‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٣-٥-١٧‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻺﺴﻬﺎل )ﺍﻟﻤﺼﺤﻭﺏ ﺒﺄﻋﺭﺍﺽ( ﻟﺩﻯ ﺍﻟﺒﺎﻟﻐﻴﻥ‬

‫ﺃﻗﺭﺍﺹ‪ ٣٠ :‬ﻤﻠﻐﻡ )ﻓﻭﺴﻔﺎﺕ(‪.‬‬
‫* ﺇﻥ ﺘﺄﺜﻴﺭ ﻫﺫﺍ ﺍﻟﺒﻨﺩ ﻤﻭﻀﻊ ﺠﺩل‪ ،‬ﻭﺴـﻴﺠﺭﻱ ﺍﺴـﺘﻌﺭﺍﺽ ﺇﺩﺭﺍﺠـﻪ‬ ‫ﻜﻭﺩﻴﻴﻥ*‬
‫ﺍﻟﻤﺴﺘﻤﺭ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻓﻲ ﺍﻻﺠﺘﻤﺎﻉ ﺍﻟﻘﺎﺩﻡ ﻟﻠﺠﻨﺔ ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫‪ -١٨‬ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﻭﺃﺩﻭﻴﺔ ﺍﻟﻐﺩﺩ ﺍﻟﺼﻤﺎﺀ ﺍﻷﺨﺭﻯ ﻭﻤﻭﺍﻨﻊ ﺍﻟﺤﻤل‬
‫‪ ١-١٨‬ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﺍﻟﻜﻅﺭﻴﺔ ﻭﺍﻷﺒﺩﺍل ﺍﻟﻤﺨﻠﻘﺔ‬
‫ﺇﻥ ﺩﺍﺀ ﺃﺩﻴﺴﻭﻥ ﻤﺭﺽ ﻨﺎﺩﺭ؛ ﻭﻗﺩ ُﺃﺩﺭﺠﺕ ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﺍﻟﻜﻅﺭﻴﺔ ﺒﺎﻟﻔﻌل ﻓﻲ ﺍﻟﻔﺭﻉ ‪.٣‬‬
‫‪ ٢-١٨‬ﺍﻷﻨﺩﺭﻭﺠﻴﻨﺎﺕ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٢٠٠ :‬ﻤﻠﻐﻡ )ﺇﻨﺎﻨﺘﺎﺕ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺘﺴﺘﻭﺴﺘﻴﺭﻭﻥ‬
‫‪ ٣-١٨‬ﻤﻭﺍﻨﻊ ﺍﻟﺤﻤل‬
‫‪ ١-٣-١٨‬ﻤﻭﺍﻨﻊ ﺍﻟﺤﻤل ﺍﻟﻬﺭﻤﻭﻨﻴﺔ ﺍﻟﺘﻲ ﺘﺅﺨﺫ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ‬
‫… ﺇﺜﻴﻨﻴل ﺇﺴﺘﺭﺍﺩﻴﻭل ‪ … +‬ﻟﻴﻔﻭﻨﻭﺭﺠﺴﺘﺭﻴل ﺃﻗﺭﺍﺹ‪ ٣٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ ‪ ١٥٠ +‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬
‫… ﺇﺜﻴﻨﻴل ﺇﺴﺘﺭﺍﺩﻴﻭل ‪ … +‬ﻨﻭﺭﻴﺜﻴﺴﺘﻴﺭﻭﻥ ﺃﻗﺭﺍﺹ‪ ٣٥ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ ‪ ١‚٠+‬ﻤﻠﻐﻡ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٣٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ ٧٥٠،‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﻋﻠﺒﺔ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﺍﺜﻨﻴﻥ(‪،‬‬
‫ﻟﻴﻔﻭﻨﻭﺭﺠﺴﺘﺭﻴل‬
‫‪ ١‚٥‬ﻤﻠﻐﻡ‪.‬‬
‫‪ ٢-٣-١٨‬ﻤﻭﺍﻨﻊ ﺍﻟﺤﻤل ﺍﻟﻬﺭﻤﻭﻨﻴﺔ ﺍﻟﺘﻲ ﺘﺅﺨﺫ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﺤﻘﻥ‬
‫ﺤﻘﻨﺔ ﻤﺩﺨﺭﻴﺔ‪ ١٥٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺃﺴﻴﺘﺎﺕ ﻤﻴﺩﺭﻭﻜﺴﻲ ﺒﺭﻭﺠﺴﺘﻴﺭﻭﻥ‬
‫ﺃﺴﻴﺘﺎﺕ ﻤﻴﺩﺭﻭﻜﺴﻲ ﺒﺭﻭﺠـﺴﺘﻴﺭﻭﻥ ‪+‬‬
‫ﺤﻘﻨﺔ‪ ٢٥ :‬ﻤﻠﻐﻡ ‪ ٥ +‬ﻤﻠﻐﻡ‪.‬‬
‫ﺴﻴﺒﻴﻭﻨﺎﺕ ﺇﺴﺘﺭﺍﺩﻴﻭل‬
‫ﻤﺤﻠﻭل ﺯﻴﺘﻲ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺇﻨﺎﻨﺘﺎﺕ ﺍﻟﻨﻭﺭﻴﺜﻴﺴﺘﻴﺭﻭﻥ‬
‫‪ ٣-٣-١٨‬ﺠﻬﺎﺌﺯ ﺩﺍﺨل ﺍﻟﺭﺤﻡ‬
‫ﺠﻬﻴﺯﺓ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﺍﻟﻨﺤﺎﺱ‬
‫‪ ٤-٣-١٨‬ﺍﻟﻁﺭﺍﺌﻕ ﺍﻟﻘﺎﺌﻤﺔ ﻋﻠﻰ ﺍﻟﺤﻭﺍﺌل‬
‫ﺍﻟﻌﻭﺍﺯل ﺍﻟﺫﻜﺭﻴﺔ‬
‫ﺍﻟﻌﻭﺍﺯل ﺍﻷﻨﺜﻭﻴﺔ‬
‫‪ ٥-٣-١٨‬ﻤﻭﺍﻨﻊ ﺍﻟﺤﻤل ﺍﻟﺘﻲ ﺘﹸﻐﺭﺱ ﺘﺤﺕ ﺍﻟﺠﻠﺩ‬
‫ﻏﺭﻴﺴﺔ ﺫﺍﺕ ﻋﻭﺩﻴﻥ ﻴ‪‬ﻁﻠﻘﺎﻥ ﻟﻴﻔﻭﻨﻭﺭﺠﺴﺘﺭﻴل‪ ،‬ﻭﻴﺤﺘﻭﻱ ﻜل ﻤﻨﻬﻤﺎ ﻋﻠﻰ‬ ‫ﻏﺭﻴﺴﺔ ﻤﻁﻠﻘﺔ ﻟﻠﻴﻔﻭﻨﻭﺭ ﺠﺴﺘﺭﻴل‬
‫‪ ٧٥‬ﻤﻠﻐﻡ ﻤﻥ ﻟﻴﻔﻭﻨﻭﺭﺠﺴﺘﺭﻴل )ﺍﻟﻤﺠﻤﻭﻉ ‪ ١٥٠‬ﻤﻠﻐﻡ(‪.‬‬

‫‪EML 15‬‬ ‫‪page - 25‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ ٤-١٨‬ﺍﻹﺴﺘﺭﻭﺠﻴﻨﺎﺕ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ ٥٠ ،‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬
‫* ﺇﻥ ﻤﺩﻯ ﻤﻼﺀﻤﺔ ﻫﺫﺍ ﺍﻟﺒﻨﺩ ﻭ‪ /‬ﺃﻭ ﻤﺩﻯ ﻨﺠﺎﻋﺘﻪ ﺍﻟﻨﺴﺒﻴﺔ ﻭ‪ /‬ﺃﻭ ﻤـﺩﻯ‬
‫ﻤﺄﻤﻭﻨﻴﺘﻪ ﻓﻴﻤﺎ ﻴﺘﻌﻠﻕ ﺒﺎﻟﺼﺤﺔ ﺍﻟﻌﻤﻭﻤﻴـﺔ ﻤﻭﻀـﻊ ﺠـﺩل‪ ،‬ﻭﺴـﻴﺠﺭﻱ‬ ‫… ﺇﺜﻴﻨﻴل ﺇﺴﺘﺭﺍﺩﻴﻭل*‬
‫ﺍﺴﺘﻌﺭﺍﺽ ﺇﺩﺭﺍﺠﻪ ﺍﻟﻤﺴﺘﻤﺭ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻓﻲ ﺍﻻﺠﺘﻤـﺎﻉ ﺍﻟﻘـﺎﺩﻡ ﻟﻠﺠﻨـﺔ‬
‫ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫‪ ٥-١٨‬ﺍﻹﻨﺴﻭﻟﻴﻨﺎﺕ ﻭﺍﻟﻌﻭﺍﻤل ﺍﻷﺨﺭﻯ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﻜﺭﻱ‬
‫ﺃﻗﺭﺍﺹ‪ ٢,٥ :‬ﻤﻠﻐﻡ‪ ٥ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻏﻠﻴﺒﻨﻴﻜﻼﻤﻴﺩ‬
‫ﺤﻘﻨﺔ‪ ٤٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪ ١٠٠ ،‬ﻭﺤﺩﺓ‬
‫ﺤﻘﻥ ﺍﻹﻨﺴﻭﻟﻴﻥ )ﺫﻭﺍﺒﺔ(‬
‫ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٤٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪ ١٠٠ ،‬ﻭﺤﺩﺓ‬
‫ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ )ﻋﻠﻰ ﺸﻜل ﻤﺴﺘﻌﻠﻕ ﻤﺭﻜـﺏ‬ ‫ﺍﻹﻨﺴﻭﻟﻴﻥ ﻤﺘﻭﺴﻁ ﺍﻟﻤﻔﻌﻭل‬
‫ﻤﻥ ﺇﻨﺴﻭﻟﻴﻥ ﺍﻟﺯﻨﻙ ﺃﻭ ﺍﻹﻨﺴﻭﻟﻴﻥ ﺍﻟﻤﺘﺠﺎﻨﺱ(‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﻤﻴﺘﻔﻭﺭﻤﻴﻥ‬
‫‪ ٦-١٨‬ﻤﺤﺭ‪‬ﻀﺎﺕ ﺍﻹﺒﺎﻀﺔ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﺴﻴﺘﺭﺍﺕ(‪.‬‬ ‫ﻜﻠﻭﻤﻴﻔﻴﻥ‬
‫‪ ٧-١٨‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﺒﺭﻭﺠﺴﺘﺭﻭﻨﻴﺔ ﺍﻟﻤﻔﻌﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﺇﻥ ﻤﺩﻯ ﻤﻼﺀﻤﺔ ﻫﺫﺍ ﺍﻟﺒﻨﺩ ﻭ‪ /‬ﺃﻭ ﻤﺩﻯ ﻨﺠﺎﻋﺘﻪ ﺍﻟﻨﺴﺒﻴﺔ ﻭ‪ /‬ﺃﻭ ﻤـﺩﻯ‬
‫ﻤﺄﻤﻭﻨﻴﺘﻪ ﻓﻴﻤﺎ ﻴﺘﻌﻠﻕ ﺒﺎﻟﺼﺤﺔ ﺍﻟﻌﻤﻭﻤﻴـﺔ ﻤﻭﻀـﻊ ﺠـﺩل‪ ،‬ﻭﺴـﻴﺠﺭﻱ‬ ‫ﻨﻭﺭﻴﺜﻴﺴﺘﻴﺭﻭﻥ*‬
‫ﺍﺴﺘﻌﺭﺍﺽ ﺇﺩﺭﺍﺠﻪ ﺍﻟﻤﺴﺘﻤﺭ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻓﻲ ﺍﻻﺠﺘﻤـﺎﻉ ﺍﻟﻘـﺎﺩﻡ ﻟﻠﺠﻨـﺔ‬
‫ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺃﺴـــﻴﺘﺎﺕ ﻤﻴﺩﺭﻭﻜـــﺴﻲ ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪.‬‬
‫* ﺇﻥ ﻤﺩﻯ ﻤﻼﺀﻤﺔ ﻫﺫﺍ ﺍﻟﺒﻨﺩ ﻭ‪ /‬ﺃﻭ ﻤﺩﻯ ﻨﺠﺎﻋﺘﻪ ﺍﻟﻨﺴﺒﻴﺔ ﻭ‪ /‬ﺃﻭ ﻤـﺩﻯ‬ ‫ﺒﺭﻭﺠﺴﺘﻴﺭﻭﻥ*‬
‫ﻤﺄﻤﻭﻨﻴﺘﻪ ﻓﻴﻤﺎ ﻴﺘﻌﻠﻕ ﺒﺎﻟﺼﺤﺔ ﺍﻟﻌﻤﻭﻤﻴـﺔ ﻤﻭﻀـﻊ ﺠـﺩل‪ ،‬ﻭﺴـﻴﺠﺭﻱ‬
‫ﺍﺴﺘﻌﺭﺍﺽ ﺇﺩﺭﺍﺠﻪ ﺍﻟﻤﺴﺘﻤﺭ ﻓﻲ ﺍﻟﻘﺎﺌﻤﺔ ﻓﻲ ﺍﻻﺠﺘﻤـﺎﻉ ﺍﻟﻘـﺎﺩﻡ ﻟﻠﺠﻨـﺔ‬
‫ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫‪ ٨-١٨‬ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﺍﻟﺩﺭﻗﻴﺔ ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺩﺭﻗﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ ١٠٠ ،‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﻤﻠﺢ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬ ‫ﻟﻴﻔﻭﺜﻴﺭﻭﻜﺴﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٦٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻴﻭﺩﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ‬

‫‪EML 15‬‬ ‫‪page - 26‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺒﺭﻭﺒﻴل ﺜﻴﻭﺭﺍﺴﻴل‬

‫‪ -١٩‬ﺍﻟﻤﻨﺎﻋﻴﺎﺕ‬
‫‪ ١-١٩‬ﺍﻟﻌﻭﺍﻤل ﺍﻟﺘﺸﺨﻴﺼﻴﺔ‬
‫ﻴﻨﺒﻐﻲ ﺃﻥ ﺘﻔﻲ ﻜل ﺍﻟﺘﻭﺒﺭﻜﻭﻟﻴﻨﺎﺕ ﺒﺎﺸﺘﺭﺍﻁﺎﺕ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺒﺸﺄﻥ ﺍﻟﺘﻭﺒﺭﻜﻭﻟﻴﻨﺎﺕ )ﺍﻟﻤﻨﻘﺤﺔ ﻋﺎﻡ ‪.(١٩٨٥‬‬
‫ﺍﻟﺘﻘﺭﻴﺭ ﺍﻟﺴﺎﺩﺱ ﻭﺍﻟﺜﻼﺜﻭﻥ ﻟﻠﺠﻨﺔ ﺨﺒﺭﺍﺀ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻤﻌﻨﻴﺔ ﺒﺎﻟﻤﻌﺎﻴﺭﺓ ﺍﻟﺒﻴﻭﻟﻭﺠﻴﺔ )ﺴﻠﺴﻠﺔ ﺍﻟﺘﻘﺎﺭﻴﺭ ﺍﻟﺘﻘﻨﻴﺔ‬
‫ﻟﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ‪ ،‬ﺭﻗﻡ ‪ ،١٩٨٧ ،٧٤٥‬ﺍﻟﻤﻠﺤﻕ ‪.(١‬‬
‫ﺘﻭﺒﺭﻜﻭﻟﻴﻥ‪ ،‬ﺃﺤﺩ ﻤﺸﺘﻘﺎﺕ ﺍﻟﺒﺭﻭﺘﻴﻥ ﺍﻟﻤﻨﻘﺎﺓ ﺤﻘﻨﺔ‪.‬‬
‫)‪(PPD‬‬

‫‪ ٢-١٩‬ﺍﻷﻤﺼﺎل ﻭﺍﻟﻐﻠﻭﺒﻭﻟﻴﻨﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ‬

‫ﻴﻨﺒﻐﻲ ﺃﻥ ﺘﻔﻲ ﻜل ﺃﺠﺯﺍﺀ ﺍﻟﺒﻼﺯﻤﺎ ﺒﺎﺸﺘﺭﺍﻁﺎﺕ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﻟﺘﺠﻤﻴﻊ ﻭﺘﺠﻬﻴـﺯ ﻭﻤﺭﺍﻗﺒـﺔ ﺠـﻭﺩﺓ ﺍﻟـﺩﻡ‪،‬‬
‫ﻭﻤﻜﻭﻨﺎﺕ ﺍﻟﺩﻡ ﻭﻤﺸﺘﻘﺎﺕ ﺍﻟﺒﻼﺯﻤﺎ )ﺍﻟﻤﻨﻘﺤﺔ ﻋﺎﻡ ‪ .(١٩٩٢‬ﺍﻟﺘﻘﺭﻴﺭ ﺍﻟﺜﺎﻟﺙ ﻭﺍﻷﺭﺒﻌﻭﻥ ﻟﻠﺠﻨﺔ ﺨﺒﺭﺍﺀ ﻤﻨﻅﻤﺔ ﺍﻟـﺼﺤﺔ‬
‫ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻤﻌﻨﻴﺔ ﺒﺎﻟﻤﻌﺎﻴﺭﺓ ﺍﻟﺒﻴﻭﻟﻭﺠﻴﺔ )ﺴﻠﺴﻠﺔ ﺍﻟﺘﻘﺎﺭﻴﺭ ﺍﻟﺘﻘﻨﻴﺔ ﻟﻤﻨﻅﻤـﺔ ﺍﻟـﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴـﺔ‪ ،‬ﺭﻗـﻡ ‪،١٩٩٤ ،٨٤٠‬‬
‫ﺍﻟﻤﻠﺤﻕ ‪.(٢‬‬
‫ﺍﻟﻐﻠﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻤﺴﺘﻀﺩ ‪ D‬ﺤﻘﻨﺔ‪ ٢٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ ﻓﻲ ﻗﻨﻴﻨﺔ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﺠﺭﻋﺔ ﻭﺍﺤﺩﺓ‪.‬‬
‫)ﺒﺸﺭﻱ(‬
‫ﺍﻟﻐﻠﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨـﺎﻋﻲ ﺍﻟﻤـﻀﺎﺩ ﻟﻠﻜـﺯﺍﺯ ﺤﻘﻨﺔ‪ ٥٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫)ﺒﺸﺭﻱ(‬
‫ﺤﻘﻨﺔ‪.‬‬
‫ﺍﻟﻐﻭﻟﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﺯﻋﺎﻑ*‬
‫* ﻴﺤﺩﺩ ﺍﻟﻨﻭﻉ ﺒﺎﻟﻀﺒﻁ ﻤﺤﻠﻴﹰﺎ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ ٢٠ ٠٠٠ ،‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫ﺘﺭﻴﺎﻕ ﺍﻟﺨﻨﺎﻕ‬
‫ﺤﻘﻨﺔ‪ ١٥٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫… ﺍﻟﻐﻠﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﻟﺩﺍﺀ ﺍﻟﻜﻠﺏ‬
‫‪ ٣-١٩‬ﺍﻟﻠﻘﺎﺤﺎﺕ‬
‫ﺴﻴﻠﺯﻡ ﺃﻥ ﻴﻘﻭﻡ ﻜل ﺒﻠﺩ ﺒﺎﻨﺘﻘﺎﺀ ﺍﻟﻠﻘﺎﺤﺎﺕ ﻤﻥ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ ﺒﻌﺩ ﻭﻀﻊ ﺍﻟﺘﻭﺼﻴﺎﺕ ﺍﻟﺩﻭﻟﻴﺔ ﻭﺍﻷﻭﻟﻭﻴـﺎﺕ ﺍﻟﻭﺒﺎﺌﻴـﺔ‬
‫ﻭﺍﻟﻭﻁﻨﻴﺔ ﻓﻲ ﺍﻻﻋﺘﺒﺎﺭ‪ .‬ﻭﺘﻌﺭﺽ ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﻭﺍﺭﺩﺓ ﺃﺩﻨﺎﻩ ﺍﻟﻠﻘﺎﺤﺎﺕ ﺍﻟﺘﻲ ﺼﺩﺭﺕ ﺒﺸﺄﻨﻬﺎ ﺘﻭﺼﻴﺔ ﻤﻥ ﻓﺭﻴـﻕ ﺍﻟﺨﺒـﺭﺍﺀ‬
‫ﺍﻻﺴﺘﺸﺎﺭﻱ ﺍﻻﺴﺘﺭﺍﺘﻴﺠﻲ ﺍﻟﻤﻌﻨﻲ ﺒـﺎﻟﺘﻤﻨﻴﻊ )‪ (http://www.who.int/immunization/sage_conclusions/en/index.html‬ﻭ‪/‬ﺃﻭ‬
‫ﻭﺭﻗﺔ ﻤﻭﻗﻑ ﻤﻥ ﻤﻨﻅﻤﺔ ﺍﻟـﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴـﺔ )‪.(http://www.who.immunization/documents/positionpapers/en/index.html‬‬
‫ﻭﺴﻴﺠﺭﻱ ﺘﺤﺩﻴﺙ ﻤﻭﻗﻊ ﺍﻹﻨﺘﺭﻨﺕ ﻫﺫﺍ ﻜﻠﻤﺎ ﻨﹸﺸﺭﺕ ﻭﺭﻗﺎﺕ ﻤﻭﻗﻑ ﺠﺩﻴﺩﺓ ﻭﺴـﻴﺤﺘﻭﻱ ﻋﻠـﻰ ﺃﺤـﺩﺙ ﺍﻟﻤﻌﻠﻭﻤـﺎﺕ‬
‫ﻭﺍﻟﺘﻭﺼﻴﺎﺕ‪.‬‬
‫ﻭﻴﻨﺒﻐﻲ ﺃﻥ ﺘﻔﻲ ﻜل ﺍﻟﻠﻘﺎﺤﺎﺕ ﺒﺎﺸﺘﺭﺍﻁﺎﺕ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺒﺨﺼﻭﺹ ﺍﻟﻤﻭﺍﺩ ﺍﻟﺒﻴﻭﻟﻭﺠﻴﺔ‪.‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺒﻲ ﺴﻲ ﺠﻲ )‪(BCG‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻜﻭﻟﻴﺭﺍ‬

‫‪EML 15‬‬ ‫‪page - 27‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻟﻘﺎﺡ ﺍﻟﺨﻨﺎﻕ‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ‪A‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ‪B‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻤﺴﺘﺩﻤﻴﺔ ﺍﻟﻨﺯﻟﻴﺔ ﻤﻥ ﺍﻟﻨﻤﻁ ﺒﺎﺀ‬
‫ﻟﻘﺎﺡ ﺍﻷﻨﻔﻠﻭﻨﺯﺍ‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﺩﻤﺎﻍ ﺍﻟﻴﺎﺒﺎﻨﻲ‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﺼﺒﺔ‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬـﺎﺏ ﺍﻟـﺴﺤﺎﻴﺎ ﺒـﺎﻟﻤﻜﻭﺭﺍﺕ‬
‫ﺍﻟﺴﺤﺎﺌﻴﺔ‬
‫ﻟﻘﺎﺡ ﺍﻟﻨﻜﺎﻑ‬
‫ﻟﻘﺎﺡ ﺍﻟﺸﺎﻫﻭﻕ )ﺍﻟﺴﻌﺎل ﺍﻟﺩﻴﻜﻲ(‬
‫ﻟﻘﺎﺡ ﺍﻟﻤﻜﻭﺭﺍﺕ ﺍﻟﺭﺌﻭﻴﺔ‬
‫ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل‬
‫ﻟﻘﺎﺡ ﺩﺍﺀ ﺍﻟﻜﻠﺏ‬
‫ﻟﻘﺎﺡ ﺍﻟﻔﻴﺭﻭﺱ ﺍﻟﻌﺠﻠﻲ‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﺼﺒﺔ ﺍﻷﻟﻤﺎﻨﻴﺔ‬
‫ﻟﻘﺎﺡ ﺍﻟﻜﺯﺍﺯ‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻴﻔﻭﺩ‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﻤﺎﻕ‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﻤﻰ ﺍﻟﺼﻔﺭﺍﺀ‬
‫‪ -٢٠‬ﻤﺭﺨ ‪‬ﻴﺎﺕ ﺍﻟﻌﻀﻼﺕ )ﺍﻟﻁﺭﻓﻴﺔ ﺍﻟﻤﻔﻌﻭل( ﻭﻤﺜﺒﻁﺎﺕ ﺍﻟﻜﻭﻟﻴﻨﺴﺘﺭﺍﺯ‬
‫ﺤﻘﻨﺔ‪ ٥ :‬ﻤﻠﻐﻡ )ﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﺃﻟﻜﻭﺭﻭﻨﻴﻭﻡ‬
‫ﺤﻘﻨﺔ‪ ٥٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ ﻓﻲ ﺃﻤﺒﻭﻟـﺔ ﺴـﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘـﺭ‪ ٢‚٥ ،‬ﻤﻠﻐـﻡ‬
‫)ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻤﻴﺘﻴل( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻨﻴﻭﺴﺘﻴﻐﻤﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٥ :‬ﻤﻠﻐﻡ )ﺒﺭﻭﻤﻴﺩ(‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺴﻭﻜﺴﺎﻤﻴﺜﻭﻨﻴﻭﻡ‬
‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪) :‬ﻜﻠﻭﺭﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ١ :‬ﻤﻠﻐﻡ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺒﻴﺭﻴﺩﻭﺴﺘﻴﻐﻤﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٦٠ :‬ﻤﻠﻐﻡ )ﺒﺭﻭﻤﻴﺩ(‪.‬‬

‫‪EML 15‬‬ ‫‪page - 28‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﻤﺴﺤﻭﻕ ﻟﻠﺤﻘﻥ‪ ١٠ :‬ﻤﻠﻐﻡ )ﺒﺭﻭﻤﻴﺩ( ﻓﻲ ﻗﻨﻴﻨﺔ‪.‬‬ ‫… ﻓﻴﻜﻭﺭﻭﻨﻴﻭﻡ‬

‫‪ -٢١‬ﻤﺴﺘﺤﻀﺭﺍﺕ ﻤﺩﺍﻭﺍﺓ ﺍﻟﻌﻴﻥ‬
‫ﺴﻴﺠﺭﻱ ﺍﺴﺘﻌﺭﺍﺽ ﻫﺫﺍ ﺍﻟﻔﺭﻉ ﻓﻲ ﺍﻻﺠﺘﻤﺎﻉ ﺍﻟﻘﺎﺩﻡ ﻟﻠﺠﻨﺔ ﺍﻟﺨﺒﺭﺍﺀ‪.‬‬
‫‪ ١-٢١‬ﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻌﺩﻭﻯ‬
‫ﻤﺭﻫﻡ‪.w/w ٪٣ :‬‬ ‫ﺃﺴﻴﻜﻠﻭﻓﻴﺭ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪٠,٣ :‬ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬
‫… ﺠﻨﺘﺎﻤﻴﺴﻴﻥ*‬
‫* ﻴﻌﺘﻤﺩ ﺍﻻﻨﺘﻘﺎﺀ ﺍﻟﻨﻬﺎﺌﻲ ﻋﻠﻰ ﺩﻭﺍﻋﻲ ﺍﻻﺴﺘﻌﻤﺎل‪.‬‬
‫ﻤﺭﻫﻡ ﻟﻠﻌﻴﻥ‪) ٪١ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫… ﺘﺘﺭﺍﺴﻴﻜﻠﻴﻥ‬
‫‪ ٢-٢١‬ﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺏ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪٠‚٥ :‬ﻓﻭﺴﻔﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬ ‫… ﺒﺭﻴﺩﻨﻴﺯﻭﻟﻭﻥ‬
‫‪ ٣-٢١‬ﻤﺒﻨﺞ ﻤﻭﻀﻌﻲ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪٠‚٥ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫… ﺘﺘﺭﺍﻜﺎﻴﻴﻥ‬
‫‪ ٤-٢١‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻘﺎﺒﻀﺔ ﺍﻟﺤﺩﻗﺔ ﻭﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻐﻼﻜﻭﻤﺎ )ﺍﻟﺯﺭﻕ(‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺃﺴﻴﺘﺎﺯﻭﻻﻤﻴﺩ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪٤ ، ٪٢ :‬ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ ﺃﻭ ﻨﺘﺭﺍﺕ(‪.‬‬ ‫… ﺒﻴﻠﻭﻜﺎﺭﺒﻴﻥ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪٠‚٥ ،٪٠‚٢٥ :‬ﻋﻠﻰ ﺸﻜل ﻤﺎﻟﻴﺎﺕ(‪.‬‬ ‫… ﺘﻴﻤﻭﻟﻭل‬
‫‪ ٥-٢١‬ﻤﻭﺴﻌﺎﺕ ﺍﻟﺤﺩﻗﺔ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪١ ،٪٠‚٥ ،٪٠‚١ :‬ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬ ‫ﺃﺘﺭﻭﺒﻴﻥ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺤﻠﻭل )ﻗﻁﺭﺓ ﻟﻠﻌﻴﻥ(‪) ٪٢ :‬ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺇﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ(‬
‫‪ -٢٢‬ﻤﻌﺠﻼﺕ ﺍﻟﻭﻻﺩﺓ ﻭﻤﻀﺎﺩﺍﺕ ﻤﻌﺠﻼﺕ ﺍﻟﻭﻻﺩﺓ‬
‫‪ ١-٢٢‬ﻤﻌﺠﻼﺕ ﺍﻟﻭﻻﺩﺓ‬
‫ﺤﻘﻨﺔ‪ ٢٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﻤﺎﻟﻴﺎﺕ ﺍﻟﻬﻴـﺩﺭﻭﺠﻴﻥ( ﻓـﻲ ﺃﻤﺒﻭﻟـﺔ ﺴـﻌﺔ‬
‫… ﺇﺭﻏﻭﻤﺘﺭﻴﻥ‬
‫‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١٠ :‬ﻭﺤﺩﺍﺕ ﺩﻭﻟﻴﺔ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﺃﻭﻜﺴﻴﺘﻭﺴﻴﻥ‬

‫‪EML 15‬‬ ‫‪page - 29‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺃﻗﺭﺍﺹ ﻤﻬﺒﻠﻴﺔ‪ ٢٥ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬ ‫ﻤﻴﺯﻭﺒﺭﻭﺴﺘﻭل‬
‫ﻤﻴﻔﻴﺒﺭﻴﺴﺘﻭﻥ*‪-‬‬
‫ﻤﻴﺯﻭﺒﺭﻭﺴﺘﻭل*‬
‫ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻠﻐﻡ – ﺃﻗﺭﺍﺹ‪ ٢٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪.‬‬ ‫ﺤﻴﺜﻤﺎ ﺘﺴﻤﺢ ﺒﻪ ﺍﻟﻘﻭﺍﻨﻴﻥ‬
‫* ﻴﻘﺘﻀﻲ ﺇﺸﺭﺍﻓﹰﺎ ﻁﺒﻴﹰﺎ ﻭﺜﻴﻘﹰﺎ‪.‬‬ ‫ﻻ‬
‫ﺍﻟﻭﻁﻨﻴﺔ ﻭﺤﻴﺜﻤﺎ ﻴﻜﻭﻥ ﻤﻘﺒﻭ ﹰ‬
‫ﻤﻥ ﺍﻟﻨﺎﺤﻴﺔ ﺍﻟﺜﻘﺎﻓﻴﺔ‪.‬‬

‫‪ ٢-٢٢‬ﻤﻀﺎﺩﺍﺕ ﻤﻌﺠﻼﺕ ﺍﻟﻭﻻﺩﺓ )ﻤﻀﺎﺩﺍﺕ ﺍﻻﺒﺘﺴﺎﺭ(‬

‫ﻜﺒﺴﻭﻻﺕ ﻟﻠﺘﺴﺭﻴﺏ ﺍﻟﻔﻭﺭﻱ‪ ١٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻨﻴﻔﻴﺩﻴﺒﻴﻥ‬
‫‪ -٢٣‬ﻤﺤﻠﻭل ﺍﻟﺩﻴـﺎل ﺍﻟﺼﻔﺎﻗﻲ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﻤﺤﻠﻭل ﺍﻟﺩﻴـﺎل ﺩﺍﺨل ﺍﻟﺼﻔﺎﻕ ﻤﺤﻠﻭل ﻟﻠﺤﻘﻥ‪.‬‬
‫)ﺍﻟﻤﻨﺎﺴﺏ ﺍﻟﺘﺭﻜﻴﺏ(‬
‫‪ -٢٤‬ﺃﺩﻭﻴﺔ ﺍﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻨﻔﺴﻴﺔ‬
‫‪ ١-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﺫﻫﺎﻨﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ٢٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﻜﻠﻭﺭﺒﺭﻭﻤﺎﺯﻴﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ١٠٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺤﻘﻨﺔ‪ ٢٥ :‬ﻤﻠﻐﻡ )ﺩﻴﻜﺎﻨﻭﺍﺕ ﺃﻭ ﺇﻴﻨﺎﻨﺘﺎﺕ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﻓﻠﻭﻓﻴﻨﺎﺯﻴﻥ‬
‫ﺤﻘﻨﺔ‪ ٥ :‬ﻤﻠﻐﻡ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫… ﻫﺎﻟﻭﺒﻴﺭﻴﺩﻭل‬
‫ﺃﻗﺭﺍﺹ‪ ٢ :‬ﻤﻠﻐﻡ‪ ٥ ،‬ﻤﻠﻐﻡ‪.‬‬
‫‪ ٢-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﻤﺯﺍﺠﻴﺔ‬
‫‪ ١-٢-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻻﻜﺘﺌﺎﺒﻴﺔ‬
‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫… ﺃﻤﻴﺘﺭﻴﺒﺘﻴﻠﻴﻥ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٢٠ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﻓﻠﻭﻜﺴﻴﺘﻴﻥ‬
‫‪ ٢-٢-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﺜﻨﺎﺌﻴﺔ ﺍﻟﻘﻁﺏ‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭﺯﺓ(‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ ٢٠٠ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻜﺎﺭﺒﺎﻤﺎﺯﻴﺒﻴﻥ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ٣٠٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﻜﺎﺭﺒﻭﻨﺎﺕ ﺍﻟﻠﻴﺜﻴﻭﻡ‬

‫‪EML 15‬‬ ‫‪page - 30‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺃﻗﺭﺍﺹ )ﻤﻐﻠﻔـﺔ ﻤﻌﻭﻴـﺔ(‪ ٢٠٠ :‬ﻤﻠﻐـﻡ‪ ٥٠٠ ،‬ﻤﻠﻐـﻡ )ﻓـﺎﻟﺒﺭﻭﺍﺕ‬ ‫ﺤﻤﺽ ﺍﻟﻔﺎﻟﺒﺭﻭﻴﻙ‬
‫ﺍﻟﺼﻭﺩﻴﻭﻡ(‪.‬‬
‫‪ ٣-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﻘﻠﻕ ﻭﺍﻟﻨﻭﻡ ﺍﻟﻤﻌﻤﻤﺔ‬
‫ﺃﻗﺭﺍﺹ )ﻤﺤﺭ‪‬ﺯﺓ(‪ ٢ :‬ﻤﻠﻐﻡ‪ ٥ ،‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﺩﻴﺎﺯﻴﺒﺎﻡ‬
‫‪ ٤-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﻭﺴﻭﺍﺴﻴﺔ ﺍﻟﻘﻬﺭﻴﺔ ﻭﻨﻭﺒﺎﺕ ﺍﻟﻬﻠﻊ‬
‫ﻜﺒﺴﻭﻻﺕ‪ ١٠ :‬ﻤﻠﻐﻡ‪ ٢٥ ،‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﻜﻠﻭﻤﻴﺒﺭﺍﻤﻴﻥ‬
‫‪ ٥-٢٤‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ ﻓﻲ ﺒﺭﺍﻤﺞ ﺍﻟﻌﻼﺝ ﻤﻥ ﺍﻻﻋﺘﻤﺎﺩ ﻋﻠﻰ ﺍﻟﻤﻭﺍﺩ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺭﻜﺎﺯﺓ ﻟﺸﺭﺍﺏ‪ ٥ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪ ١٠ ،‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬
‫ﺸﺭﺍﺏ‪ ٥ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪ ١٠ ،‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﻴﺜﺎﺩﻭﻥ*‬ ‫…‬

‫* ﺍﻟﻤﺭﺒﻊ ﻤﻀﺎﻑ ﻤﻥ ﺃﺠـل ﺇﺩﺭﺍﺝ ﺩﻭﺍﺀ ﺒﻭﺒﺭﻴﻨـﻭﺭﻓﻴﻥ‪ .‬ﻭﻻ ﻴﻨﺒﻐـﻲ‬

‫ﺍﺴﺘﻌﻤﺎل ﺍﻟﺩﻭﺍﺀﻴﻥ ﺇﻻ ﻓﻲ ﺇﻁﺎﺭ ﺒﺭﻨﺎﻤﺞ ﺩﻋﻡ ﺭﺍﺴﺦ‪.‬‬
‫‪ -٢٥‬ﺍﻷﺩﻭﻴﺔ ﺫﺍﺕ ﺍﻟﻤﻔﻌﻭل ﻓﻲ ﺍﻟﺴﺒﻴل ﺍﻟﺘﻨﻔﺴﻲ‬
‫‪ ١-٢٥‬ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺭﺒﻭ ﻓﻲ ﻤﺭﺽ ﺍﻟﺭﺌﺔ ﺍﻻﻨﺴﺩﺍﺩﻱ ﺍﻟﻤﺯﻤﻥ‬
‫ـﺩﺓ‬
‫ـﺔ ﺍﻟﻭﺍﺤـ‬‫ـﻲ ﺍﻟﺠﺭﻋـ‬‫ـﺭﺍﻡ ﻓـ‬‫ـﺒﻭﺏ(‪ ٥٠ :‬ﻤﻴﻜﺭﻭﻏـ‬ ‫ـﺸﺎﻕ )ﻀـ‬ ‫ﺍﺴﺘﻨـ‬
‫… ﺒﻴﻜﻠﻭﻤﻴﺘﺎﺯﻭﻥ‬
‫)ﺩﻴﺒﺭﻭﺒﻴﻭﻨﺎﺕ(؛ ‪ ٢٥٠‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﺩﻴﺒﺭﻭﺒﻴﻭﻨﺎﺕ( ﻓﻲ ﺍﻟﺠﺭﻋﺔ ﺍﻟﻭﺍﺤﺩﺓ‪.‬‬
‫ﺤﻘﻨﺔ‪ ١ :‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ ﺃﻭ ﻁﺭﻁﺭﺍﺕ ﺍﻟﻬﻴـﺩﺭﻭﺠﻴﻥ(‬
‫ﺇﻴﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ(‬
‫ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺍﺴﺘﻨﺸﺎﻕ )ﻀﺒﻭﺏ(‪ ٢٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﺠﺭﻋﺔ ﻤﻭﺴﻭﻤﺔ‪.‬‬ ‫ﺒﺭﻭﻤﻴﺩ ﺍﻹﺒﺭﺍﺘﺭﻭﺒﻴﻭﻡ‬
‫ﺍﺴﺘﻨﺸﺎﻕ )ﻀﺒﻭﺏ(‪ ١٠٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘـﺎﺕ( ﻓـﻲ‬
‫ﺍﻟﺠﺭﻋﺔ ﺍﻟﻭﺍﺤﺩﺓ‪.‬‬
‫ﺤﻘﻨﺔ‪ ٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ‬
‫‪ ٥‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫… ﺴﺎﻟﺒﻭﺘﺎﻤﻭل‬
‫ﺸﺭﺍﺏ‪ ٢ :‬ﻤﻠﻐﻡ‪ ٥/‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﻤﺤﻠﻭل ﻟﻠﻤﻨﻔﺎﺱ ﻴﺴﺘﻌﻤل ﻓـﻲ ﺍﻟـﺭ‪‬ﺫﺍﺫﺍﺕ‪ ٥ :‬ﻤﻠﻐـﻡ )ﻋﻠـﻰ ﺸـﻜل‬
‫ﻜﺒﺭﻴﺘﺎﺕ(‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٢ :‬ﻤﻠﻐﻡ‪ ٤ ،‬ﻤﻠﻐﻡ )ﻋﻠﻰ ﺸﻜل ﻜﺒﺭﻴﺘﺎﺕ(‪.‬‬
‫‪ ٢-٢٥‬ﺍﻷﺩﻭﻴﺔ ﺍﻷﺨﺭﻯ ﺫﺍﺕ ﺍﻟﻤﻔﻌﻭل ﻓﻲ ﺍﻟﺴﺒﻴل ﺍﻟﺘﻨﻔﺴﻲ‬
‫ﺤﻘﻨﺔ‪ ٢٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ )ﻴﻜﺎﻓﺊ ‪ ١٠‬ﻤﻠﻐﻡ ﻤﻥ ﻗﺎﻋﺩﺓ ﺍﻟﻜﺎﻓﻴﻴﻥ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ(‪.‬‬
‫ﺸﺭﺍﺏ‪ ٢٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ )ﻴﻜﺎﻓﺊ ‪ ١٠‬ﻤﻠﻐـﻡ ﻤـﻥ ﻗﺎﻋـﺩﺓ ﺍﻟﻜـﺎﻓﻴﻴﻥ‪/‬‬ ‫ﺴﻴﺘﺭﺍﺕ ﺍﻟﻜﺎﻓﻴﻴﻥ‬
‫ﻤﻴﻠﻴﻠﺘﺭ(‪.‬‬

‫‪EML 15‬‬ ‫‪page - 31‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫‪ -٢٦‬ﻤﻴﺎﻩ ﺘﺼﺤﻴﺢ ﺍﻟﻤﺤﺎﻟﻴل‪ ،‬ﻭﺍﻟﻜﻬﺭل‪ ،‬ﻭﺍﻻﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﺤﻤﻀﻴﺔ ﺍﻟﻘﺎﻋﺩﻴﺔ‬

‫‪ ١-٢٦‬ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ‬
‫ﺍﻨﻅﺭ ﺍﻟﻔﺭﻉ ‪.١-٥-١٧‬‬ ‫ﺃﻤﻼﺡ ﺘﻌﻭﻴﺽ ﺍﻟﺴﻭﺍﺌل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ‬
‫ﻤﺴﺤﻭﻕ ﻟﻤﺤﻠﻭل‪.‬‬ ‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ‬
‫‪ ٢-٢٦‬ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﺤﻘﻥ‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪ ٪١٠ ،٪٥ :‬ﻤﺘﺴﺎﻭﻱ ﺍﻟﺘﻭﺘﺭ‪ ٪٥٠ ،‬ﻤﻔﺭﻁ ﺍﻟﺘﻭﺘﺭ‪.‬‬ ‫ﻏﻠﻭﻜﻭﺯ‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪ ٪٤ :‬ﻏﻠﻭﻜﻭﺯ‪ ٪٠,١٨ ،‬ﻜﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﻏﻠﻭﻜﻭﺯ ﻤﻊ ﻜﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫)ﻴﻜﺎﻓﺊ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪ ٣٠ +‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل‪ ،‬ﺍﻟﻜﻠﻭﺭ – ‪ ٣٠‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل(‪.‬‬
‫ﻤﺤﻠﻭل‪ ٪١١,٢ :‬ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢٠‬ﻤﻴﻠﻴﻠﺘﺭ )ﻴﻜـﺎﻓﺊ ﺍﻟﺒﻭﺘﺎﺴـﻴﻭﻡ ‪+‬‬
‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ‬
‫‪ ٪١,٥‬ﻤﻴﻠﻴﻤﻭل‪ /‬ﻤﻴﻠﻴﻠﺘﺭ‪ ،‬ﺍﻟﻜﻠﻭﺭ – ‪ ١‚٥‬ﻤﻴﻠﻴﻤﻭل‪ /‬ﻤﻴﻠﻴﻠﺘﺭ(‪.‬‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪ ٪٠,٩ :‬ﻤﺘﺴﺎﻭﻱ ﺍﻟﺘﻭﺘﺭ )ﻴﻜﺎﻓﺊ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪١٥٤ +‬‬
‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﻤﻴﻠﻴﻤﻭل‪ /‬ل‪ ،‬ﺍﻟﻜﻠﻭﺭ – ‪ ١٥٤‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل(‪.‬‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪ ٪١‚٤ :‬ﻤﺘﺴﺎﻭﻱ ﺍﻟﺘﻭﺘﺭ )ﻴﻜﺎﻓﺊ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪١٦٧ +‬‬
‫ﻤﻴﻠﻴﻤﻭل‪ /‬ل‪ ،‬ﺍﻟﺒﻴﻜﺭﺒﻭﻨﺎﺕ – ‪ ١٦٧‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل(‪.‬‬
‫ﻜﺭﺒﻭﻨﺎﺕ ﻫﻴﺩﺭﻭﺠﻴﻥ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﻤﺤﻠﻭل‪ ٪٨,٤ :‬ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ )ﻴﻜـﺎﻓﺊ ﺍﻟـﺼﻭﺩﻴﻭﻡ ‪+‬‬
‫‪ ١٠٠٠‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل‪ ،‬ﺍﻟﺒﻴﻜﺭﺒﻭﻨﺎﺕ – ‪ ١٠٠٠‬ﻤﻴﻠﻴﻤﻭل‪ /‬ل(‪.‬‬
‫ﻤﺤﻠﻭل ﻗﺎﺒل ﻟﻠﺤﻘﻥ‪.‬‬ ‫… ﻻﻜﺘﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ‪ ،‬ﻤﺤﻠﻭل ﻤﺭﻜﺏ‬
‫‪ ٣-٢٦‬ﻤﺘﻨﻭﻋﺎﺕ‬
‫ﺃﻤﺒﻭﻻﺕ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪ ٥ ،‬ﻤﻴﻠﻴﻠﺘﺭ‪ ١٠ ،‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻤﺎﺀ ﻤﻌﺩ ﻟﻠﺤﻘﻥ‬
‫‪ -٢٧‬ﻓﻴﺘﺎﻤﻴﻨﺎﺕ ﻭﻤﻌﺎﺩﻥ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺤﻤﺽ ﺍﻷﺴﻜﻭﺭﺒﻴﻙ‬
‫ﻜﺒﺴﻭﻻﺕ ﺃﻭ ﺃﻗﺭﺍﺹ‪ ١‚٢٥ :‬ﻤﻠﻐﻡ )‪ ٥٠ ٠٠٠‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ(‪.‬‬
‫… ﺇﺭﻏﻭﻜﺎﻟﺴﻴﻔﻴﺭﻭل‬
‫ﺸﺭﺍﺏ‪ ٢٥٠ :‬ﻤﻴﻜﺭﻭﻏﺭﺍﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ )‪ ١٠ ٠٠٠‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ(‪.‬‬
‫ﻜﺒﺴﻭﻻﺕ‪ ٢٠٠ :‬ﻤﻠﻐﻡ‪.‬‬
‫ﺯﻴﺕ ﻤﻴﻭﺩﻥ‪ ١ :‬ﻤﻴﻠﻴﻠﺘﺭ )‪ ٤٨٠‬ﻤﻠﻐﻡ ﻴﻭﺩ(‪ ٠‚٥ ،‬ﻤﻴﻠﻴﻠﺘﺭ )‪ ٢٤٠‬ﻤﻠﻐـﻡ‬ ‫ﺍﻟﻴﻭﺩ‬
‫ﻴﻭﺩ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ )ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ﺃﻭ ﺤﻘﻨﺎﹰ(‪ ٠‚٥٧ ،‬ﻤﻴﻠﻴﻠﺘﺭ )‪ ٣٠٨‬ﻤﻠﻐﻡ‬
‫ﻴﻭﺩ( ﻓﻲ ﻗﺎﺭﻭﺭﺓ ﻤﻭﺯ‪‬ﻋﺔ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ‪.‬‬ ‫… ﻨﻴﻜﻭﺘﻴﻨﺎﻤﻴﺩ‬

‫‪EML 15‬‬ ‫‪page - 32‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬ ‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬

‫ﺃﻗﺭﺍﺹ‪ ٢٥ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺒﻴﺭﻴﺩﻭﻜﺴﻴﻥ‬

‫ـﺔ‪،‬‬
‫ـﺩﺓ ﺩﻭﻟﻴـ‬
‫ـﺔ‪ ١٠٠ ٠٠٠ ،‬ﻭﺤـ‬ ‫ـﺩﺓ ﺩﻭﻟﻴـ‬
‫ـﺴﻭﻻﺕ‪ ٥٠ ٠٠٠ :‬ﻭﺤـ‬ ‫ﻜﺒـ‬
‫‪ ٢٠٠ ٠٠٠‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ )ﻋﻠﻰ ﺸﻜل ﺒﺎﻟﻤﻴﺘﺎﺕ(‪.‬‬
‫ﻤﺤﻠﻭل ﺯﻴﺘﻲ ﻟﻠﺸﺭﺏ‪ ١٠٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ )ﻋﻠﻰ ﺸﻜل ﺒﺎﻟﻤﻴﺘﺎﺕ(‪/‬‬
‫ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﻤﻭﺯﻉ ﻤﺘﻌﺩﺩ ﺍﻟﺠﺭﻋﺎﺕ‪.‬‬ ‫ﺭﻴﺘﻴﻨﻭل‬
‫ﺃﻗﺭﺍﺹ )ﻤﻐﻠﻔﺔ ﺒﺎﻟﺴﻜﺭ(‪ ١٠ ٠٠٠ :‬ﻭﺤﺩﺓ ﺩﻭﻟﻴﺔ )ﻋﻠﻰ ﺸﻜل ﺒﺎﻟﻤﻴﺘﺎﺕ(‪.‬‬
‫ﺤﻘﻨﺔ ﻗﺎﺒﻠﺔ ﻟﻠﻤﺯﺝ ﺒﺎﻟﻤﺎﺀ‪ ١٠٠ ٠٠٠ :‬ﻭﺤـﺩﺓ ﺩﻭﻟﻴـﺔ )ﻋﻠـﻰ ﺸـﻜل‬
‫ﺒﺎﻟﻤﻴﺘﺎﺕ( ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ٢‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬
‫ﺃﻗﺭﺍﺹ‪ ٥ :‬ﻤﻠﻐﻡ‪.‬‬ ‫ﺭﻴﺒﻭﻓﻼﻓﻴﻥ‬
‫ﺒﺄﻴﺔ ﺘﺭﻜﻴﺒﺔ ﻤﻭﻀﻌﻴﺔ ﻤﻨﺎﺴﺒﺔ‪.‬‬ ‫ﻓﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ‬
‫ﺃﻗﺭﺍﺹ‪ ٥٠ :‬ﻤﻠﻐﻡ )ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻴﺩ(‪.‬‬ ‫ﺜﻴﺎﻤﻴﻥ‬
‫ﺍﻟﻘﺎﺌﻤﺔ ﺍﻟﺘﻜﻤﻴﻠﻴﺔ‬
‫ﺤﻘﻨﺔ‪ ١٠٠ :‬ﻤﻠﻐﻡ‪ /‬ﻤﻴﻠﻴﻠﺘﺭ ﻓﻲ ﺃﻤﺒﻭﻟﺔ ﺴﻌﺔ ‪ ١٠‬ﻤﻴﻠﻴﻠﺘﺭ‪.‬‬ ‫ﻏﻠﻭﻜﻭﻨﺎﺕ ﺍﻟﻜﺎﻟﺴﻴﻭﻡ‬

‫‪EML 15‬‬ ‫‪page - 33‬‬

‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬
‫ﺍﻟﻔﻬﺭﺱ‬
‫ﺇﻨﺩﻴﻨﺎﻓﻴﺭ )‪١٢ ......................................... (IDV‬‬
‫ﺍﻹﻨﺴﻭﻟﻴﻥ ﻤﺘﻭﺴﻁ ﺍﻟﻤﻔﻌﻭل ‪٢٦ ...............................‬‬
‫ﺃﻭﻓﻠﻭﻜﺴﺎﺴﻴﻥ ‪٩ ............................................‬‬
‫ﺃﻭﻜﺴﺎﻤﻨﻴﻜﻴﻥ ‪٥ ............................................‬‬
‫ﺃﻭﻜﺴﺠﻴﻥ ‪١ ...............................................‬‬
‫ﺃﻭﻜﺴﻴﺘﻭﺴﻴﻥ ‪٢٩ ............................................‬‬
‫ﺇﻴﺒﻭﺒﺭﻭﻓﻴﻥ ‪٢ ..............................................‬‬
‫ﺇﻴﺘﻭﺒﻭﺴﻴﺩ ‪١٧ ...............................................‬‬
‫ﺇﻴﺜﺎﻨﻭل ‪٢٢ ..................................................‬‬
‫ﺇﻴﺜﻭﺴﻭﻜﺴﻴﻤﻴﺩ ‪٤ ...........................................‬‬
‫ﺇﻴﺩﻴﺘﺎﺕ ﻜﺎﻟﺴﻴﻭﻡ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٣ ..............................‬‬
‫ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺇﺜﺎﻤﺒﻭﺘﻭل ‪٨ .................................‬‬
‫ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪٩ ،٨ ..........................................‬‬
‫ﺇﻴﻔﺭﻤﻜﺘﻴﻥ ‪٥ ...............................................‬‬
‫ﺇﻴﻔﻴﺩﺭﻴﻥ ‪١ ................................................‬‬
‫ﺇﻴﻤﻴﺒﻴﻨﻴﻡ ‪ +‬ﺴﻴﻼﺴﺘﺎﺘﻴﻥ ‪٧ ..................................‬‬
‫ﺇﻴﻤﻴﺒﻴﻨﻴﻡ ‪٧ .................................................‬‬
‫ﺇﻴﻨﺎﻻﺒﺭﻴل ‪٢٠ ،١٩ ..........................................‬‬
‫ﺃﻴﻭﺘﺭﻭﻜﺴﺎﺕ ﺍﻟﻤﻴﻐﻠﻭﻤﻴﻥ ‪٢٢ .................................‬‬
‫ﺃﻴﻭﻫﻴﻜﺴﻭل ‪٢٢ .............................................‬‬
‫ﺒﺎﺭﺍﺴﻴﺘﺎﻤﻭل‪١٥ ،٢ .........................................‬‬
‫ﺒﺎﺭﻭﻤﻭﻤﻴﺴﻴﻥ ‪١٣ ...........................................‬‬
‫ﺒﺎﺴﻴﺘﺭﺍﺴﻴﻥ ‪٢١ .............................................‬‬
‫ﺒﺭﺍﺯﻴﻜﻭﺍﻨﺘﻴل ‪٥ ............................................‬‬
‫ﺒﺭﻤﻨﻐﻨﺎﺕ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ ‪٢١ ....................................‬‬
‫ﺒﺭﻭﺒﺭﺍﻨﻭﻟﻭل ‪١٦ ............................................‬‬
‫ﺒﺭﻭﺒﻴل ﺜﻴﻭﺭﺍﺴﻴل ‪٢٧ .......................................‬‬
‫ﺒﺭﻭﻏﺎﻨﻴل ‪١٥ ...............................................‬‬
‫ﺒﺭﻭﻜﺎﺭﺒﺎﺯﻴﻥ ‪١٧ ............................................‬‬
‫ﺒﺭﻭﻜﺎﻴﻨﺎﻤﻴﺩ ‪١٩ .............................................‬‬
‫ﺒﺭﻭﻜﺎﻴﻴﻥ ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ ‪٦ ................................‬‬
‫ﺒﺭﻭﻤﻴﺜﺎﺯﻴﻥ ‪٢٣ ،١ .........................................‬‬
‫ﺒﺭﻭﻤﻴﺩ ﺍﻹﺒﺭﺍﺘﺭﻭﺒﻴﻭﻡ‪٣١ ....................................‬‬
‫ﺒﺭﻴﺩﻨﻴﺯﻭﻟﻭﻥ ‪٢٩ ،١٧ ،٣ ...................................‬‬
‫ﺒﺭﻴﻤﺎﻜﻴﻥ ‪١٤ ................................................‬‬
‫ﺒﻠﻴﻭﻤﻴﺴﻴﻥ ‪١٦ ...............................................‬‬
‫ﺒﻨﺘﺎﻤﻴﺩﻴﻥ ‪١٥ ،١٣ ...........................................‬‬
‫ﺒﻨﺯﻨﻴﺩﺍﺯﻭل ‪١٥ .............................................‬‬
‫ﺒﻨﺯﻭﺍﺕ ﺍﻟﺒﻨﺯﻴل ‪٢٢ .........................................‬‬
‫ﺒﻨﺯﻭﻴل ﺒﺭﻭﻜﺴﺎﻴﺩ ‪٢١ .......................................‬‬
‫ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ ﺍﻟﺒﻨﺯﺍﺜﻴﻥ ‪٦ .................................‬‬
‫ﺒﻨﺯﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ ‪٦ ..........................................‬‬
‫ﺒﻭﺒﻴﻔﺎﻜﺎﻴﻴﻥ ‪١ .............................................‬‬
‫ﺒﻭﻟﻴﻔﻴﺩﻭﻥ ﺍﻟﻴﻭﺩ‪٢٢ ..........................................‬‬
‫ﺒﻴﺒﻴﺭﺩﻥ ‪١٧ .................................................‬‬
‫ﺒﻴﺘﺎﻤﻴﺜﺎﺯﻭﻥ ‪٢١ .............................................‬‬
‫‪EML 15‬‬
‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﺃﺒﺎﻜﺎﻓﻴﺭ )‪١٠ ..........................................(ABC‬‬
‫ﺇﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ( ‪٣١ ،٢٩ ،١٩ ،٣ ،١ ..................‬‬
‫ﺃﺘﺭﻭﺒﻴﻥ ‪٢٩ ،٣ ،١ ..........................................‬‬
‫ﺃﺘﻴﻨﻭﻟﻭل ‪١٩ .................................................‬‬
‫ﺇﺜﺎﻤﺒﻭﺘﻭل‪٩ ،٨ ............................................‬‬
‫ﺇﺜﻴﻨﻴل ﺇﺴﺘﺭﺍﺩﻴﻭل ‪٢٦ ،٢٥ ..................................‬‬
‫ﺇﺜﻴﻨﻴل ﺇﺴﺘﺭﺍﺩﻴﻭل ‪ … +‬ﻟﻴﻔﻭﻨﻭﺭﺠﺴﺘﺭﻴل ‪٢٥ ..................‬‬
‫ﺇﺜﻴﻨﻴل ﺇﺴﺘﺭﺍﺩﻴﻭل ‪ … +‬ﻨﻭﺭﻴﺜﻴﺴﺘﺭﻭﻥ ‪٢٥ ....................‬‬
‫ﺇﺜﻴﻭﻨﺎﻤﻴﺩ ‪٩ .................................................‬‬
‫ﺃﺭﺘﻤﻴﺜﺭ ‪ +‬ﻟﻭﻤﻴﻔﺎﻨﺘﺭﻴﻥ ‪١٣ ...................................‬‬
‫ﺃﺭﺘﻤﻴﺜﺭ‪١٣ ..................................................‬‬
‫ﺃﺭﺘﻴﺴﻭﻨﺎﺕ ‪١٤ ..............................................‬‬
‫ﺇﺭﻏﻭﻜﺎﻟﺴﻴﻔﻴﺭﻭل ‪٣٢ ........................................‬‬
‫ﺇﺭﻏﻭﻤﺘﺭﻴﻥ ‪٢٩ ..............................................‬‬
‫ﺇﺭﻴﺜﺭﻭﻤﻴﺴﻴﻥ ‪٧ ............................................‬‬
‫ﺃﺯﺍﺜﻴﻭﺒﺭﻴﻥ ‪١٦ ،٢ ..........................................‬‬
‫ﺃﺯﻴﺜﺭﻭﻤﻴﺴﻴﻥ ‪٧ ............................................‬‬
‫ﺃﺴﺒﺎﺭﺍﺠﻴﻨﺎﺯ ‪١٦ .............................................‬‬
‫ﺃﺴﻴﺘـﺎﺕ ﻤﻴﺩﺭﻭﻜﺴـﻲ ﺒﺭﻭﺠﺴﺘﻴـﺭﻭﻥ ‪ +‬ﺴﻴﺒﻴﻭﻨـﺎﺕ‬
‫ﺇﺴﺘﺭﺍﺩﻴﻭل ‪٢٥ ...........................................‬‬
‫ﺃﺴﻴﺘﺎﺕ ﻤﻴﺩﺭﻭﻜﺴﻲ ﺒﺭﻭﺠﺴﺘﻴﺭﻭﻥ ‪٢٦ ،٢٥ ..................‬‬
‫ﺃﺴﻴﺘﺎﺯﻭﻻﻤﻴﺩ‪٢٩ .............................................‬‬
‫ﺃﺴﻴﺘﻴل ﺴﻴﺴﺘﻴﻥ ‪٣ ..........................................‬‬
‫ﺃﺴﻴﻜﻠﻭﻓﻴﺭ ‪٢٩ ،١٠ .........................................‬‬
‫ﺇﻓﺎﻓﻴﺭﻨﺯ ‪١٢ ،١١ ...........................................‬‬
‫ﺇﻓﺎﻓﻴﺭﻨﺯ )‪ EFV‬ﺃﻭ ‪١١ ................................. (EFZ‬‬
‫ﺇﻓﺎﻓﻴﺭﻨﺯ ‪ +‬ﺇﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ‪ +‬ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ‪١٢ ......................‬‬
‫ﺇﻓﻠﻭﺭﻨﻴﺜﻴﻥ ‪١٥ ...............................................‬‬
‫ﺃﻜﺴﻴﺩ ﺍﻟﻨﺘﺭﻭﺯ ‪١ ...........................................‬‬
‫ﺃﻟﺒﻴﻨﺩﺍﺯﻭل ‪٥ ...............................................‬‬
‫ﺃﻟﻜﻭﺭﻭﻨﻴﻭﻡ ‪٢٨ ..............................................‬‬
‫ﺃﻟﻭﺒﻭﺭﻴﻨﻭل ‪٢ ..............................................‬‬
‫ﺃﻤﺒﻴﺴﻴﻠﻴﻥ ‪٦ ................................................‬‬
‫ﺇﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ )‪١٢ ،١١ ............................... (FTC‬‬
‫ﺇﻤﺘﺭﻴﺴﻴﺘﺎﺒﻴﻥ‪ +‬ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ‪١٢ .................................‬‬
‫ﺃﻤﻔﻭﺘﻴﺭﻴﺴﻴﻥ ﺒﺎﺀ ‪١٣ ،١٠ ...................................‬‬
‫ﺃﻤﻼﺡ ﺘﻌﻭﻴﺽ ﺍﻟﺴﻭﺍﺌل ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﻡ ‪٣٢ ،٢٤ .............‬‬
‫ﺃﻤﻠﻭﺩﻴﺒﻴﻥ ‪١٩ ................................................‬‬
‫ﺃﻤﻭﺩﻴﺎﻜﻴﻥ ‪١٣ ...............................................‬‬
‫ﺃﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ ‪ +‬ﺤﻤﺽ ﺍﻟﻜﻼﻓﻭﻻﻨﻴﻙ ‪٦ .....................‬‬
‫ﺃﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ ‪٦ ............................................‬‬
‫ﺃﻤﻴﺘﺭﻴﺒﺘﻴﻠﻴﻥ ‪٣٠ ..............................................‬‬
‫ﺃﻤﻴﺩﻭﺘﺭﻴﺯﻭﺍﺕ ‪٢٢ ...........................................‬‬
‫ﺃﻤﻴﻜﺎﺴﻴﻥ ‪٩ ................................................‬‬
‫ﺃﻤﻴﻠﻭﺭﻴﺩ ‪٢٣ .................................................‬‬
‫ﺇﻨﺎﻨﺘﺎﺕ ﺍﻟﻨﻭﺭﻴﺜﻴﺴﺘﺭﻭﻥ ‪٢٥ ...................................‬‬
‫‪page - 34‬‬
‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬
‫ﺩﻴﺜﺭﺍﻨﻭل ‪٢٢ ................................................‬‬
‫ﺩﻴﺩﺍﻨﻭﺯﻴﻥ )‪١١ .........................................(ddI‬‬
‫ﺩﻴﻐﻭﻜﺴﻴﻥ‪٢٠ ،١٩ ..........................................‬‬
‫ﺩﻴﻔﻴﺭﻭﻜﺴﺎﻤﻴﻥ ‪٣ ...........................................‬‬
‫ﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ ‪١٧ ،٣ .......................................‬‬
‫ﺩﻴﻠﻭﻜﺴﺎﻨﻴﺩ ‪١٣ ..............................................‬‬
‫ﺩﻴﻤﻴﺭﻜﺎﺒﺭﻭل ‪٣ ............................................‬‬
‫ﺭﺍﺘﻴﻥ ﺠﺫﺭ ﺍﻟﻴﺒﺭﻭﺡ ‪٢٢ .....................................‬‬
‫ﺭﺍﻨﻴﺘﻴﺩﻴﻥ‪٢٣ ................................................‬‬
‫ﺭﻜﺎﺯﺓ ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ‪١٩ .....................................‬‬
‫ﺭﻜﺎﺯﺓ ﻤﺭﻜﺏ ﺍﻟﻌﺎﻤل ﺍﻟﺘﺎﺴـﻊ )ﻋﻭﺍﻤـل ﺍﻟﺘﺨﺜﺭ‪ ،‬ﺍﻟﺜﺎﻨﻲ‬
‫ﻭﺍﻟﺴﺎﺒﻊ ﻭﺍﻟﺘﺎﺴﻊ ﻭﺍﻟﻌﺎﺸﺭ( ‪١٩ ............................‬‬
‫ﺭﻴﺒﺎﻓﻴﺭﻴﻥ ‪١٢ ...............................................‬‬
‫ﺭﻴﺒﻭﻓﻼﻓﻴﻥ ‪٣٣ ..............................................‬‬
‫ﺭﻴﺘﻭﻨﺎﻓﻴﺭ ‪١٢ ...............................................‬‬
‫ﺭﻴﺘﻴﻨﻭل ‪٣٣ .................................................‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ‪٩ ،٨ ..........................................‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺇﺜﺎﻤﺒﻭﺘﻭل ‪٩ ...................‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺒﻴﺭﺍﺯﻴﻨﺎﻤﻴﺩ ‪ +‬ﺇﺜﺎﻤﺒﻭﺘﻭل ‪٩ .....‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪ +‬ﺒﻴﺭﺍﺯﻴﻨﺎﻤﻴﺩ ‪٩ ..................‬‬
‫ﺭﻴﻔﺎﻤﺒﻴﺴﻴﻥ ‪ +‬ﺃﻴﺯﻭﻨﻴﺎﺯﻴﺩ ‪٩ ................................‬‬
‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ ‪١٢ ،١١ .........................................‬‬
‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ )‪ ZDV‬ﺃﻭ ‪١١ .............................(AZT‬‬
‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ ‪ +‬ﻻﻤﻴﻔﻭﺩﻴﻥ ‪ +‬ﻨﻴﻔﻴﺭﺍﺒﻴﻥ ‪١٢ .....................‬‬
‫ﺯﻴﺩﻭﻓﻭﺩﻴﻥ ‪ +‬ﻻﻤﻴﻔﻭﺩﻴﻥ ‪١٢ .................................‬‬
‫ﺴﺎﻜﻭﻴﻨﺎﻓﻴﺭ )‪١٢ ...................................... (SQV‬‬
‫ﺴﺎﻟﺒﻭﺘﺎﻤﻭل ‪٣١ .............................................‬‬
‫ﺴﺒﻜﺘﻴﻨﻭﻤﻴﺴﻴﻥ ‪٨ ...........................................‬‬
‫ﺴﺒﻴﺭﻭﻨﻭﻻﻜﺘﻭﻥ ‪٢٣ .........................................‬‬
‫ﺴﺘﺎﻓﻭﺩﻴﻥ ‪١٢ ،١١ ..........................................‬‬
‫ﺴﺘﺎﻓﻭﺩﻴﻥ )‪١١ .........................................(d4T‬‬
‫ﺴﺘﺎﻓﻭﺩﻴﻥ ‪ +‬ﻻﻤﻴﻔﻭﺩﻴﻥ ‪ +‬ﻨﻴﻔﻴﺭﺍﺒﻴﻥ ‪١٢ ......................‬‬
‫ﺴﺘﺭﺒﺘﻭﻤﻴﺴﻴﻥ ‪٩ ...........................................‬‬
‫ﺴﺘﺭﻴﺒﺘﻭﻜﻴﻨﺎﺯ ‪٢١ ............................................‬‬
‫ﺴﻔﺘﺎﺯﻴﺩﻴﻡ ‪٦ ...............................................‬‬
‫ﺴﻔﺘﺭﻴﺎﻜﺴﻭﻥ ‪٦ ............................................‬‬
‫ﺴﻠﻔﺎﺩﻭﻜﺴﻴﻥ ‪ +‬ﺒﻴﺭﻴﻤﻴﺜﺎﻤﻴﻥ ‪١٤ ..............................‬‬
‫ﺴﻠﻔﺎﺩﻭﻜﺴﻴﻥ ‪١٤ .............................................‬‬
‫ﺴﻠﻔﺎﺩﻴﺎﺯﻴﻥ ﺍﻟﻔﻀﺔ ‪٢١ .......................................‬‬
‫ﺴﻠﻔﺎﺩﻴﺎﺯﻴﻥ ‪٨ ..............................................‬‬
‫ﺴﻠﻔﺎﺴﺎﻻﺯﻴﻥ ‪٢٣ ............................................‬‬
‫ﺴﻠﻔﺎﻤﻴﺜﻭﻜﺴﺎﺯﻭل ‪ +‬ﺘﺭﻴﻤﻴﺜﻭﺒﺭﻴﻡ ‪١٥ ،٨ .....................‬‬
‫ﺴﻠﻔﺎﻤﻴﺜﻭﻜﺴﺎﺯﻭل ‪١٥ ،٨ ....................................‬‬
‫ﺴﻠﻔﻴﺩ ﺍﻟﺴﻴﻠﻴﻨﻴﻭﻡ ‪٢١ .........................................‬‬
‫ﺴﻨﺎ ﺴﻨﺎﻤﻜﻲ )ﺃﻭﺭﺍﻕ ﻨﺒﺎﺕ ﺍﻟﺴﻨﺎ ﺍﻟﺠﺎﻓﺔ( ‪٢٤ ..................‬‬
‫ﺴﻭﺩﻴﻭﻡ ﺍﻟﺴﻭﺭﺍﻤﻴﻥ ‪٥ ......................................‬‬
‫ﺴﻭﻜﺴﺎﻤﻴﺜﻭﻨﻴﻭﻡ‪٢٨ ..........................................‬‬
‫ﺴﻭﻟﻔﺎﺯﺍﻻﺯﻴﻥ ‪٢ ...........................................‬‬
‫ﺴﻴﺒﺭﻭﻓﻠﻭﻜﺴﺎﻜﻴﻥ ‪٧ ........................................‬‬
‫ﺴﻴﺒﻴﻭﻨﺎﺕ ﺇﺴﺘﺭﺍﺩﻴﻭل ‪٢٥ ....................................‬‬
‫‪EML 15‬‬
‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﺒﻴﺭﺍﺯﻴﻨﺎﻤﻴﺩ ‪٩ ،٨ ..........................................‬‬
‫ﺒﻴﺭﺍﻨﺘﻴل ‪٥ .................................................‬‬
‫ﺒﻴﺭﻤﺜﺭﻴﻥ ‪٢٢ ................................................‬‬
‫ﺒﻴﺭﻴﺩﻭﺴﺘﻴﻐﻤﻴﻥ ‪٢٨ ..........................................‬‬
‫ﺒﻴﺭﻴﺩﻭﻜﺴﻴﻥ ‪٣٣ .............................................‬‬
‫ﺒﻴﺭﻴﻤﻴﺜﺎﻤﻴﻥ ‪١٥ ،١٤ ........................................‬‬
‫ﺒﻴﻜﻠﻭﻤﻴﺘﺎﺯﻭﻥ ‪٣١ ............................................‬‬
‫ﺒﻴﻠﻭﻜﺎﺭﺒﻴﻥ‪٢٩ ...............................................‬‬
‫ﺒﻴﻨﻴﺴﻴﻼﻤﻴﻥ ‪٣ ،٢ .........................................‬‬
‫ﺘﺎﻤﻭﻜﺴﻴﻔﻴﻥ ‪١٧ ..............................................‬‬
‫ﺘﺘﺭﺍﺴﻴﻜﻠﻴﻥ ‪٢٩ ..............................................‬‬
‫ﺘﺘﺭﺍﻜﺎﻴﻴﻥ ‪٢٩ ................................................‬‬
‫ﺘﺭﻭﺒﻴﻜﺎﻤﻴﺩ‪٢٢ ...............................................‬‬
‫ﺘﺭﻴﺎﻕ ﺍﻟﺨﻨﺎﻕ ‪٢٧ ............................................‬‬
‫ﺘﺭﻴﻤﻴﺜﻭﺒﺭﻴﻡ ‪١٥ ،٨ .........................................‬‬
‫ﺘﺴﺘﻭﺴﺘﻴﺭﻭﻥ ‪٢٥ ............................................‬‬
‫ﺘﻭﺒﺭﻜﻭﻟﻴﻥ‪ ،‬ﺃﺤﺩ ﻤﺸﺘﻘﺎﺕ ﺍﻟﺒﺭﻭﺘﻴﻥ ﺍﻟﻤﻨﻘﺎﺓ )‪٢٧ ......... (PPD‬‬
‫ﺘﻴﻤﻭﻟﻭل ‪٢٩ .................................................‬‬
‫ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ﺩﻴﺯﻭﺒﺭﻭﻜﺴﻴل ﻓﻴﻭﻤﻴﺭﺍﺕ )‪١١ ............... (TDF‬‬
‫ﺘﻴﻨﻭﻓﻭﻓﻴﺭ ‪١٢ ................................................‬‬
‫ﺜﺎﻨﻲ ﺃﺴﻴﺘﺎﺕ ﺍﻷﻟﻭﻤﻴﻨﻴﻭﻡ ‪٢١ .................................‬‬
‫ﺜﻼﺜﻲ ﻜﻼﺒﻨﺩﺍﺯﻭل‪٥ ........................................‬‬
‫ﺜﻼﺜﻲ ﻨﺘﺭﺍﺕ ﺍﻟﻐﻠﻴﺴﻴﺭﻴل ‪١٩ .................................‬‬
‫ﺜﻨﺎﺌﻲ ﺇﻴﺜﻴل ﻜﺎﺭﺒﺎﻤﺎﺯﻴﻥ ‪٥ ..................................‬‬
‫ﺜﻨﺎﺌﻲ ﻨﺘﺭﺍﺕ ﺍﻷﻴﺯﻭﺴﻭﺭﺒﻴﺩ ‪١٩ ...............................‬‬
‫ﺜﻴﺎﻤﻴﻥ ‪٣٣ ...................................................‬‬
‫ﺜﻴﻭﺒﻨﺘﺎل ‪١ .................................................‬‬
‫ﺜﻴﻭﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٢١ ،٣ ...............................‬‬
‫ﺠﻨﺘﺎﻤﻴﺴﻴﻥ ‪٢٩ ،٧ ..........................................‬‬
‫ﺠﻬﻴﺯﺓ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﺍﻟﻨﺤﺎﺱ ‪٢٥ ..............................‬‬
‫ﺤﻘﻥ ﺍﻹﻨﺴﻭﻟﻴﻥ )ﺫﻭﺍﺒﺔ( ‪٢٦ ..................................‬‬
‫ﺤﻤﺽ ﺃﺴﻴﺘﻴل ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ ‪٢٠ ،١٥ ،٢ .....................‬‬
‫ﺤﻤﺽ ﺍﻷﺴﻜﻭﺭﺒﻴﻙ ‪٣٢ ......................................‬‬
‫ﺤﻤﺽ ﺍﻟﺒﺎﺭﺍ‪ -‬ﺃﻤﻴﻨﻭﺴﺎﻟﻴﺴﻴﻠﻴﻙ ‪٩ ...........................‬‬
‫ﺤﻤﺽ ﺍﻟﺒﻨﺯﻭﻴﻙ ‪ +‬ﺤﻤﺽ ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ ‪٢١ ...................‬‬
‫ﺤﻤﺽ ﺍﻟﺒﻨﺯﻭﻴﻙ ‪٢١ .........................................‬‬
‫ﺤﻤﺽ ﺍﻟﺴﺎﻟﻴﺴﻴﻠﻴﻙ‪٢٢ ،٢١ .................................‬‬
‫ﺤﻤﺽ ﺍﻟﻔﺎﻟﺒﺭﻭﻴﻙ‪٣١ ،٤ ....................................‬‬
‫ﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ ‪١٨ ...........................................‬‬
‫ﺤﻤﺽ ﺍﻟﻜﻼﻓﻭﻻﻨﻴﻙ ‪٦ ......................................‬‬
‫ﺩﺍﺒﺴﻭﻥ ‪٨ ..................................................‬‬
‫ﺩﺍﻜﺎﺭﺒﺎﺯﻴﻥ ‪١٦ ..............................................‬‬
‫ﺩﺍﻜﺘﻴﻨﻭﻤﻴﺴﻴﻥ ‪١٦ ............................................‬‬
‫ﺩﺍﻭﻨﻭﺭﻭﺒﻴﺴﻴﻥ ‪١٦ ...........................................‬‬
‫ﺩﻜﺴﺘﺭﺍﻥ ‪١٨ ............................................ ٧٠‬‬
‫ﺩل – ﻤﻴﺜﻴﻭﻨﻴﻥ ‪٣ ..........................................‬‬
‫ﺩﻭﺒﺎﻤﻴﻥ ‪٢٠ .................................................‬‬
‫ﺩﻭﻜﺴﻭﺭﻭﺒﻴﺴﻴﻥ‪١٦ ..........................................‬‬
‫ﺩﻭﻜﺴﻴﺴﻴﻜﻠﻴﻥ ‪١٤ ،٧ ........................................‬‬
‫ﺩﻴﺎﺯﻴﺒﺎﻡ ‪٣١ ،٤ ،١ .........................................‬‬
‫‪page - 35‬‬
‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬
‫ﻜﺎﺭﺒﺎﻤﺎﺯﻴﺒﻴﻥ ‪٣٠ ،٤ .......................................‬‬
‫ﻜﺎﺭﺒﻭﻨﺎﺕ ﺍﻟﻠﻴﺜﻴﻭﻡ ‪٣٠ .......................................‬‬
‫ﻜﺎﺭﺒﻴﺩﻭﺒﺎ ‪١٧ ...............................................‬‬
‫ﻜﺎﻨﺎﻤﻴﺴﻴﻥ ‪٩ ...............................................‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺒﺎﺭﻴﻭﻡ ‪٢٢ ........................................‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺒﺭﻭﺘﺎﻤﻴﻥ ‪١٨ .....................................‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﺯﻨﻙ ‪٢٤ ..........................................‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻤﻐﻨﻴﺯﻴﻭﻡ ‪٤ .....................................‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻨﻴﻭﻤﻴﺴﻴﻥ ‪ … +‬ﺒﺎﺴﻴﺘﺭﺍﺴﻴﻥ ‪٢١ ...................‬‬
‫ﻜﺒﺭﻴﺘﺎﺕ ﺍﻟﻨﻴﻭﻤﻴﺴﻴﻥ ‪٢١ .....................................‬‬
‫ﻜﺭﺒﻭﻨﺎﺕ ﻫﻴﺩﺭﻭﺠﻴﻥ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٣٢ ..........................‬‬
‫ﻜﻠﻭﺘﺭﻴﻤﺎﺯﻭل‪١٠ ............................................‬‬
‫ﻜﻠﻭﺭﺍﻤﺒﻭﺴﻴل ‪١٦ ...........................................‬‬
‫ﻜﻠﻭﺭﺍﻤﻔﻴﻨﻴﻜﻭل ‪٧ ..........................................‬‬
‫ﻜﻠﻭﺭﺒﺭﻭﻤﺎﺯﻴﻥ ‪٣٠ ..........................................‬‬
‫ﻜﻠﻭﺭﻓﻴﻨﺎﻤﻴﻥ ‪٣ .............................................‬‬
‫ﻜﻠﻭﺭﻫﻴﻜﺴﻴﺩﻴﻥ ‪٢٢ ..........................................‬‬
‫ﻜﻠﻭﺭﻭﻜﺴﻴﻠﻴﻨﻭل ‪٢٣ .........................................‬‬
‫ﻜﻠﻭﺭﻭﻜﻴﻥ‪١٤ ،٢ ...........................................‬‬
‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ ‪٣٢ .......................................‬‬
‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٣٢ .......................................‬‬
‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﻤﻴﺘﻴﻠﻴﻭﻨﻴﻨﻴﻭﻡ )ﺃﺯﺭﻕ ﺍﻟﻤﻴﺘﻴل( ‪٣ ...................‬‬
‫ﻜﻠﻭﺭﻴﺩ ﺍﻟﻤﻴﺜﻴل ﺭﻭﺯﺍﻨﻴﻠﻴﻨﻴﻭﻡ )ﺒﻨﻔﺴﺠﻲ ﺍﻟﺠﻨﻁﻴﺎﻥ( ‪٢١ .........‬‬
‫ﻜﻠﻭﻓﺎﺯﻴﻤﻴﻥ‪٨ ..............................................‬‬
‫ﻜﻠﻭﻜﺴﺎﺴﻴﻠﻴﻥ ‪٦ ............................................‬‬
‫ﻜﻠﻭﻤﻴﺒﺭﺍﻤﻴﻥ ‪٣١ ............................................‬‬
‫ﻜﻠﻭﻤﻴﻔﻴﻥ ‪٢٦ ................................................‬‬
‫ﻜﻠﻴﻨﺩﺍﻤﻴﺴﻴﻥ ‪٨ .............................................‬‬
‫ﻜﻭﺩﻴﻴﻥ ‪٢٥ ،٢ .............................................‬‬
‫ﺍﻟﻜﻴﺘﺎﻤﻴﻥ ‪١ ................................................‬‬
‫ﻜﻴﻨﻴﺩﻴﻥ ‪١٩ .................................................‬‬
‫ﻜﻴﻨﻴﻥ ‪١٤ ...................................................‬‬
‫ﻻﻜﺘﺎﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ‪ ،‬ﻤﺤﻠﻭل ﻤﺭﻜﺏ ‪٣٢ .......................‬‬
‫ﻻﻤﻴﻔﻭﺩﻴﻥ )‪١١ ........................................(3TC‬‬
‫ﻻﻤﻴﻔﻭﺩﻴﻥ ‪١٢ ،١١ ..........................................‬‬
‫ﻟﻘﺎﺡ ﺍﻷﻨﻔﻠﻭﻨﺯﺍ ‪٢٨ ..........................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺒﻲ ﺴﻲ ﺠﻲ )‪٢٧ .............................. (BCG‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﺩﻤﺎﻍ ﺍﻟﻴﺎﺒﺎﻨﻲ ‪٢٨ ..............................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﺴﺤﺎﻴﺎ ﺒﺎﻟﻤﻜﻭﺭﺍﺕ ﺍﻟﺴﺤﺎﺌﻴﺔ ‪٢٨ .................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ‪٢٨ .................................... A‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ‪٢٨ ..................................... B‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺘﻴﻔﻭﺩ ‪٢٨ .............................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﺼﺒﺔ ﺍﻷﻟﻤﺎﻨﻴﺔ ‪٢٨ ...................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﺼﺒﺔ ‪٢٨ ............................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﻤﺎﻕ‪٢٨ .............................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺤﻤﻰ ﺍﻟﺼﻔﺭﺍﺀ ‪٢٨ ....................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺨﻨﺎﻕ ‪٢٨ .............................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﺸﺎﻫﻭﻕ )ﺍﻟﺴﻌﺎل ﺍﻟﺩﻴﻜﻲ( ‪٢٨ ..........................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻔﻴﺭﻭﺱ ﺍﻟﻌﺠﻠﻲ ‪٢٨ ...................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻜﺯﺍﺯ ‪٢٨ .............................................‬‬
‫‪EML 15‬‬
‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﺴﻴﺘﺎﺭﺍﺒﻴﻥ ‪١٦ ...............................................‬‬
‫ﺴﻴﺘﺭﺍﺕ ﺍﻟﻜﺎﻓﻴﻴﻥ ‪٣١ .........................................‬‬
‫ﺴﻴﺴﺒﻼﺘﻴﻥ ‪١٦ ...............................................‬‬
‫ﺴﻴﻔﺎﺯﻭﻟﻴﻥ ‪٦ ...............................................‬‬
‫ﺴﻴﻔﻴﻜﺴﻴﻡ ‪٦ ................................................‬‬
‫ﺴﻴﻜﻠﻭﺴﺒﻭﺭﻴﻥ ‪١٦ ...........................................‬‬
‫ﺴﻴﻜﻠﻭﺴﻴﺭﻴﻥ ‪٩ .............................................‬‬
‫ﺴﻴﻜﻠﻭﻓﻭﺴﻔﺎﻤﻴﺩ‪١٦ ...........................................‬‬
‫ﺴﻴﻼﺴﺘﺎﺘﻴﻥ ‪٧ ..............................................‬‬
‫ﺴﻴﻤﻔﺎﺴﺘﺎﺘﻴﻥ ‪٢١ .............................................‬‬
‫ﺼﻭﺩﻴﻭﻡ ﺍﻟﺴﻭﺭﺍﻤﻴﻥ ‪١٥ .....................................‬‬
‫ﺼﻭﺩﻴﻭﻡ ﺍﻟﻬﻴﺒﺎﺭﻴﻥ ‪١٨ .......................................‬‬
‫ﺍﻟﻌﻭﺍﺯل ﺍﻷﻨﺜﻭﻴﺔ ‪٢٥ .........................................‬‬
‫ﺍﻟﻌﻭﺍﺯل ﺍﻟﺫﻜﺭﻴﺔ ‪٢٥ .........................................‬‬
‫ﻏﺭﻴﺯﻴﻭﻓﻭﻟﻔﻴﻥ ‪١٠ ...........................................‬‬
‫ﻏﺭﻴﺴﺔ ﻤﻁﻠﻘﺔ ﻟﻠﻴﻔﻭﻨﻭﺭ ﺠﺴﺘﺭﻴل ‪٢٥ .........................‬‬
‫ﻏﺴﻭل ﺍﻟﻜﺎﻻﻤﻴﻥ ‪٢١ .........................................‬‬
‫ﺍﻟﻐﻠﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻜﺯﺍﺯ )ﺒﺸﺭﻱ( ‪٢٧ ..............‬‬
‫ﺍﻟﻐﻠﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻤﺴﺘﻀﺩ ‪) D‬ﺒﺸﺭﻱ( ‪٢٧ .........‬‬
‫ﺍﻟﻐﻠﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﻟﺩﺍﺀ ﺍﻟﻜﻠﺏ ‪٢٧ ...........................‬‬
‫ﻏﻠﻭﺒﻭﻟﻴﻥ ﻤﻨﺎﻋﻲ ﻋﺎﺩﻱ ﺒﺸﺭﻱ ‪١٨ ...........................‬‬
‫ﻏﻠﻭﺘﺎﺭﺍل ‪٢٣ ................................................‬‬
‫ﻏﻠﻭﻜﻭﺯ ﻤﻊ ﻜﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٣٢ ...........................‬‬
‫ﻏﻠﻭﻜﻭﺯ ‪٣٢ .................................................‬‬
‫ﻏﻠﻭﻜﻭﻨﺎﺕ ﺍﻟﻜﺎﻟﺴﻴﻭﻡ ‪٣٣ ،٣ .................................‬‬
‫ﻏﻠﻴﺒﻨﻴﻜﻼﻤﻴﺩ ‪٢٦ .............................................‬‬
‫ﺍﻟﻐﻭﻟﻭﺒﻭﻟﻴﻥ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﺯﻋﺎﻑ ‪٢٧ ....................‬‬
‫ﻓﺎﻨﻜﻭﻤﻴﺴﻴﻥ ‪٨ ..............................................‬‬
‫ﺍﻟﻔﺤﻡ‪ ،‬ﺍﻟﻤﻨﺸﻁ ‪٣ ...........................................‬‬
‫ﻓﺭ‪‬ﻴـﻙ ﺍﻟﺒﻭﺘﺎﺴﻴـﻭﻡ ﻫﻜﺴﺎﺴﻴﺎﻨﻭﻓﻴﺭﻴـﺕ ‪(II)-2H2O‬‬
‫)ﺃﺯﺭﻕ ﺒﺭﻭﺴﻲ( ‪٣ ......................................‬‬
‫ﻓﻠﻭﺭﻭﺭﺍﺴﻴل ‪٢٢ ،١٧ .......................................‬‬
‫ﻓﻠﻭﺭﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٣٣ ........................................‬‬
‫ﻓﻠﻭﺭﻴﺴﻴﻥ‪٢٢ ................................................‬‬
‫ﻓﻠﻭﺴﻴﺘﻭﺴﻴﻥ ‪١٠ .............................................‬‬
‫ﻓﻠﻭﻓﻴﻨﺎﺯﻴﻥ ‪٣٠ ...............................................‬‬
‫ﻓﻠﻭﻜﺴﻴﺘﻴﻥ ‪٣٠ ...............................................‬‬
‫ﻓﻠﻭﻜﻭﻨﺎﺯﻭل ‪١٠ .............................................‬‬
‫ﻓﻭﺭﻭﺴﻴﻤﻴﺩ ‪٢٣ ،٢٠ ........................................‬‬
‫ﻓﻭﻟﻴﻨﺎﺕ ﺍﻟﻜﺎﻟﺴﻴﻭﻡ ‪١٦ ........................................‬‬
‫ﻓﻴﺘﻭﻤﻴﻨﺎﺩﻴﻭﻥ ‪١٨ .............................................‬‬
‫ﻓﻴﺭﺍﺒﺎﻤﻴل ‪١٩ ...............................................‬‬
‫ﻓﻴﻜﻭﺭﻭﻨﻴﻭﻡ ‪٢٩ ..............................................‬‬
‫ﻓﻴﻨﺒﻼﺴﺘﻴﻥ ‪١٧ ...............................................‬‬
‫ﻓﻴﻨﻜﺭﻴﺴﺘﻴﻥ ‪١٧ ..............................................‬‬
‫ﻓﻴﻨﻭﺒﺎﺭﺒﻴﺘﺎل ‪٤ .............................................‬‬
‫ﻓﻴﻨﻭﻜﺴﻴﻤﻴﺜﻴل ﺒﻨﻴﺴﻴﻠﻴﻥ ‪٦ ...................................‬‬
‫ﻓﻴﻨﻴﺘﻭﻴﻥ ‪٤ .................................................‬‬
‫ﻗﻁﺭﺍﻥ ﺍﻟﻔﺤﻡ ‪٢١ ............................................‬‬
‫ﻜﺎﺒﺭﻴﻭﻤﻴﺴﻴﻥ ‪٩ ............................................‬‬
‫‪page - 36‬‬
‫ﺍﻟﻁﺒﻌﺔ ﺍﻟﺨﺎﻤﺴﺔ ﻋﺸﺭﺓ )ﺁﺫﺍﺭ‪ /‬ﻤﺎﺭﺱ ‪(٢٠٠٧‬‬
‫ﻗﺎﺌﻤﺔ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻨﻤﻭﺫﺠﻴﺔ‬
‫ﻤﻴﺜﻴل ﺩﻭﺒﺎ ‪٢٠ ..............................................‬‬
‫ﻤﻴﺭﻜﺎﺒﺘﻭﺒﻭﺭﻴﻥ ‪١٧ ..........................................‬‬
‫ﻤﻴﺯﻭﺒﺭﻭﺴﺘﻭل ‪٣٠ ..........................................‬‬
‫ﻤﻴﻔﻴﺒﺭﻴﺴﺘﻭﻥ ‪٣٠ ............................................‬‬
‫ﻤﻴﻜﻭﻨﺎﺯﻭل ‪٢١ ..............................................‬‬
‫ﻤﻴﻼﺭﺴﻭﺒﺭﻭل‪١٥ ...........................................‬‬
‫ﻨﺎﻟﻭﻜﺴﻭﻥ ‪٣ ...............................................‬‬
‫ﻨﺘﺭﻭﺒﺭﻭﺴﻴﺩ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٢٠ ..................................‬‬
‫ﻨﺘﺭﻴﺕ ﺍﻟﺼﻭﺩﻴﻭﻡ ‪٣ ........................................‬‬
‫ﻨﻠﻔﻴﻨﺎﻓﻴﺭ )‪١٢ ......................................... (NFV‬‬
‫ﻨﻭﺭﻴﺜﻴﺴﺘﻴﺭﻭﻥ‪٢٦ ،٢٥ ......................................‬‬
‫ﻨﻴﺘﺭﻭﻓﻭﺭﺍﻨﺘﻭﻴﻥ ‪٨ .........................................‬‬
‫ﻨﻴﺴﺘﺎﺘﻴﻥ ‪١٠ ................................................‬‬
‫ﻨﻴﻔﻭﺭﺘﻴﻤﻭﻜﺱ ‪١٥ ...........................................‬‬
‫ﻨﻴﻔﻴﺩﻴﺒﻴﻥ ‪٣٠ ................................................‬‬
‫ﻨﻴﻔﻴﺭﺍﺒﻴﻥ )‪١١ ........................................ (NVP‬‬
‫ﻨﻴﻔﻴﺭﺍﺒﻴﻥ ‪١٢ ................................................‬‬
‫ﻨﻴﻜﻠﻭﺯﺍﻤﻴﺩ ‪٥ ..............................................‬‬
‫ﻨﻴﻜﻭﺘﻴﻨﺎﻤﻴﺩ ‪٣٢ ..............................................‬‬
‫ﻨﻴﻭﺴﺘﻴﻐﻤﻴﻥ ‪٢٨ .............................................‬‬
‫ﻫﺎﻟﻭﺒﻴﺭﻴﺩﻭل ‪٣٠ ............................................‬‬
‫ﺍﻟﻬﺎﻟﻭﺜﺎﻥ ‪١ ................................................‬‬
‫ﻫﻴﺩﺭﺍﻻﺯﻴﻥ ‪٢٠ .............................................‬‬
‫ﻫﻴﺩﺭﻭﻜﺴﻭﻜﻭﺒﺎﻻﻤﻴﻥ ‪١٨ ....................................‬‬
‫ﻫﻴﺩﺭﻭﻜﺴﻴﺩ ﺍﻷﻟﻭﻤﻴﻨﻴﻭﻡ ‪٢٣ ..................................‬‬
‫ﻫﻴﺩﺭﻭﻜﺴﻴﺩ ﺍﻟﻤﻐﻨﻴﺯﻴﻭﻡ ‪٢٣ ..................................‬‬
‫ﻫﻴﺩﺭﻭﻜﻠﻭﺭﻭﺜﻴﺎﺯﻴﺩ ‪٢٣ ،٢٠ .................................‬‬
‫ﻫﻴﺩﺭﻭﻜﻭﺭﺘﻴﺯﻭﻥ ‪٢٤ ،٢١ ،١٧ ،٣ ..........................‬‬
‫ﻭﺍﺭﻓﺎﺭﻴﻥ ‪١٨ ...............................................‬‬
‫ﺍﻟﻴﻭﺩ ‪٣٢ ....................................................‬‬
‫ﻴﻭﺩﻴﺩ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡ ‪٢٦ ،١٠ ...................................‬‬
‫ﻴﻭﺭﻴﺎ ‪٢٢ ...................................................‬‬
‫‪EML 15‬‬
‫ﺍﻷﺩﻭﻴﺔ ﺍﻷﺴﺎﺴﻴﺔ‬
‫ﻟﻘﺎﺡ ﺍﻟﻜﻭﻟﻴﺭﺍ ‪٢٧ ............................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻤﺴﺘﺩﻤﻴﺔ ﺍﻟﻨﺯﻟﻴﺔ ﻤﻥ ﺍﻟﻨﻤﻁ ﺒﺎﺀ ‪٢٨ .....................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻤﻜﻭﺭﺍﺕ ﺍﻟﺭﺌﻭﻴﺔ ‪٢٨ ..................................‬‬
‫ﻟﻘﺎﺡ ﺍﻟﻨﻜﺎﻑ ‪٢٨ .............................................‬‬
‫ﻟﻘﺎﺡ ﺩﺍﺀ ﺍﻟﻜﻠﺏ ‪٢٨ ..........................................‬‬
‫ﻟﻘﺎﺡ ﺸﻠل ﺍﻷﻁﻔﺎل‪٢٨ ........................................‬‬
‫ﻟﻭﺒﻴﻨﺎﻓﻴﺭ ‪ +‬ﺭﻴﺘﻭﻨﺎﻓﻴﺭ )‪١٢ ........................... (LPV/r‬‬
‫ﻟﻭﺒﻴﻨﺎﻓﻴﺭ‪١٢ .................................................‬‬
‫ﻟﻭﻤﻴﻔﺎﻨﺘﺭﻴﻥ ‪١٣ ..............................................‬‬
‫ﻟﻴﺩﻭﻜﺎﻴﻴﻥ ‪ +‬ﺇﺒﻴﻨﻴﻔﺭﻴﻥ )ﺃﺩﺭﻴﻨﺎﻟﻴﻥ( ‪١ ........................‬‬
‫ﻟﻴﺩﻭﻜﺎﻴﻴﻥ ‪١٩ ،١ ............................................‬‬
‫ﻟﻴﻔﺎﻤﻴﺴﻭل ‪٥ ...............................................‬‬
‫ﻟﻴﻔﻭﺜﻴﺭﻭﻜﺴﻴﻥ ‪٢٦ ...........................................‬‬
‫ﻟﻴﻔﻭﺩﻭﺒﺎ ‪ … +‬ﻜﺎﺭﺒﻴﺩﻭﺒﺎ ‪١٧ .................................‬‬
‫ﻟﻴﻔﻭﺩﻭﺒﺎ ‪١٧ .................................................‬‬
‫ﻟﻴﻔﻭﻨﻭﺭﺠﺴﺘﺭﻴل ‪٢٥ .........................................‬‬
‫ﻤﺎﺀ ﻤﻌﺩ ﻟﻠﺤﻘﻥ‪٣٢ ...........................................‬‬
‫ﻤﺎﻨﻴﺘﻭل‪٢٣ ..................................................‬‬
‫ﻤﺘﺭﻭﻨﻴﺩﺍﺯﻭل ‪١٣ ............................................‬‬
‫ﻤﺤﻠﻭل ﺍﻟﺩﻴـﺎل ﺩﺍﺨل ﺍﻟﺼﻔﺎﻕ )ﺍﻟﻤﻨﺎﺴﺏ ﺍﻟﺘﺭﻜﻴﺏ(‪٣٠ ........‬‬
‫ﻤﺭﻜﺏ ﻗﺎﺌﻡ ﻋﻠﻰ ﺍﻟﻜﻠﻭﺭ ‪٢٢ ..................................‬‬
‫ﻤﻐﻠﻭﻤﻴﻥ ﺃﻨﺘﻴﻤﻭﻨﻴﺎﺕ‪١٣ ......................................‬‬
‫ﻤﻔﻠﻭﻜﻴﻥ ‪١٤ .................................................‬‬
‫ﻤﻠﺢ ﺍﻟﺤﺩﻴﺩﻭﺯ ‪ +‬ﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ ‪١٨ ..........................‬‬
‫ﻤﻠﺢ ﺍﻟﺤﺩﻴﺩﻭﺯ ‪١٨ ...........................................‬‬
‫ﻤﻭﺭﻓﻴﻥ ‪٢ ،١ ............................................‬‬
‫ﻤﻴﺒﻴﻨﺩﺍﺯﻭل ‪٥ ..............................................‬‬
‫ﻤﻴﺘﺭﻭﻨﻴﺩﺍﺯﻭل ‪٧ ...........................................‬‬
‫ﻤﻴﺘﻔﻭﺭﻤﻴﻥ ‪٢٦ ...............................................‬‬
‫ﻤﻴﺘﻭﻜﻠﻭﺒﺭﺍﻤﻴﺩ ‪٢٣ ...........................................‬‬
‫ﻤﻴﺜﺎﺩﻭﻥ ‪٣١ .................................................‬‬
‫ﻤﻴﺜﻭﺘﺭﻴﻜﺴﺎﺕ ‪١٧ ،٢ ........................................‬‬
‫‪page - 37‬‬